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Immunoglobulins have important functions in immunity [1, 2]. In mucosal areas like the 
gastrointestinal, urinary, and respiratory tracts, immunoglobulin A (IgA) is the predominant 
antibody present [3]. It plays a key role at these surfaces, which are continuously exposed 
to antigens, food and (commensal) microorganisms. Keeping a tight balance by tolerating 
commensals and harmless (food)antigens on the one hand and providing protection against 
harmful pathogens on the other hand is a challenging role of mucosal immunity. Mucosal 
IgA protects the host by diversifying the microbiota, neutralizing toxins and viruses, blocking 
colonization and penetration of pathogenic bacteria, clearing unwanted particles and 
promoting sampling of antigens [4]. Mucosal IgA is generally considered as a neutralizing, 
non-activating antibody. In serum, IgA is the second most abundant antibody after IgG. In 
contrast to mucosal IgA, the roles of serum IgA are relatively unexplored [5].
IgA can interact with several receptors that are present on a variety of (immune) cells. The 
polymeric immunoglobulin receptor (pIgR) is present on the basolateral side of epithelial 
cells and mediates transport of dimeric IgA (dIgA) to the mucosal lumen, where it is released 
as secretory IgA (SIgA) [6]. Retrograde transport of SIgA immune complexes back into the 
lamina propria can occur via the transferrin receptor (Tfr or CD71) on epithelial cells or 
through microfold cells (M cells), possible via interaction with Dectin-1 [7, 8]. It has been 
reported that SIgA immune complexes in the lamina propria can be taken up by sub-
epithelial dendritic cells (DCs) through interaction with Dendritic Cell-Specific Intercellular 
adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) [9]. B cells were shown to express 
the inhibitory IgA receptor Fc receptor-like 4 (FcRL4), which was suggested to contribute 
to the regulation of mucosal IgA responses [10]. In the liver, hepatocytes express the 
asialoglycoprotein receptor (ASGPR) that is involved in clearance of IgA from the circulation 
[11]. Mesangial cells in the glomeruli of the kidneys express CD71 and the recently identified 
β-1,4-galactosyltransferase as potential receptors to clear IgA [12]. Furthermore, an Fc 
alpha/mu receptor is expressed in gut, spleen and lymph nodes, although its functions 
remain to be elucidated [13]. Finally, the IgA Fc receptor FcαRI (CD89) is expressed by 
myeloid cells [14]. It was demonstrated that interaction of monomeric serum IgA with FcαRI 
induces inhibitory signals [15, 16]. As such, it is thought that IgA has an anti-inflammatory 
role during homeostatic conditions. By contrast, IgA immune complexes bind avidly to FcαRI, 
resulting in cross-linking and induction of pro-inflammatory responses, which may play an 
important role in resolving (mucosal) infections. Additionally, it was suggested that the 
presence of excessive IgA immune complexes can lead to uncontrolled and disproportionate 
immune cell activation, which leads to severe tissue damage in autoimmune diseases, 
such as IgA blistering diseases and rheumatoid arthritis (RA) [14]. The number of diverse 
IgA receptors, their differential expression on cells and the distinct IgA-induced effector 
functions support the complex roles of this antibody in maintaining homeostatic conditions, 
which go beyond the dogma of IgA as a non-inflammatory regulator of mucosal immunity. 
This is further supported by the fact that several bacteria have evolved to escape IgA-
mediated functions by for instance producing IgA1 proteases or expressing molecules that 





IgA is the most predominant antibody produced by humans with a synthesis rate of 66mg/
kg each day. IgA can be subdivided into IgA1 and IgA2 (Figure 1A). The IgA1 hinge region 
contains multiple O-linked glycans and two N-linked glycosylation sites per heavy chain. 
The truncated hinge of IgA2 lacks O-glycans and each heavy chain contains two additional 
N-glycans [20].
IgA1 comprises 80-85% of total human serum IgA (1 – 3 mg/ml) and is prevalent on many 
mucosal surfaces including the nasal, bronchial, gastric and small intestinal mucosa. IgA2 is 
predominantly present in the colon [21]. This division of IgA1 and IgA2 between the small 
and large intestine may reflect the luminal distribution of food proteins and gram-negative 
bacteria, which is supported by findings that bacterial overgrowth in the small intestine 
shifts production towards IgA2 [22]. Whereas IgA1 is susceptible to proteolytic cleavage 
due to a longer hinge region, IgA2 is resistant to bacterial proteases that are present in 
the lumen of mucosal areas [17, 23]. In the female reproductive tract approximately equal 
amounts of IgA1 and IgA2 positive cells were found [24]. Eighty percent of the produced 
IgA in the uterine is released in its polymeric form, while in the vagina approximately 45% 
is polymeric IgA [24, 25].
Serum IgA is predominantly monomeric in humans and primates (while dimeric in other 
animals) and is produced by local plasma cells in the bone marrow, spleen and lymph 
nodes. IgA at mucosal surfaces is produced by local plasma cells as dimeric molecules, 
although small amounts of monomers, trimers and tetramers or polymers can also be 
present [1, 3]. Dimeric IgA is composed of two monomers, which are linked with a J-chain 
(Figure 1B). It associates with the pIgR present at the basolateral side of epithelial cells in 
mucosal surfaces, after which dIgA is transported across the epithelium and released into 
the lumen. For every molecule of dIgA that is transported across the epithelium, one pIgR 
is needed [6, 26, 27]. At the luminal side, pIgR is cleaved and a part, referred to as secretory 
component (SC), remains attached thereby forming SIgA (Figure 1B). Secretory component is 
a hydrophilic and highly (N- and O-linked) glycosylated negatively charged molecule, which 
protects SIgA from degradation when present in luminal secretions [28]. Glycan removal 
led to reduced binding capacity of SIgA to gram-positive bacteria, indicating the essential 
role of carbohydrate structures in efficient IgA coating of (mainly commensal) bacteria [29].
Structure and expression of FcαRI
FcαRI is a member of the Fc receptor immunoglobulin superfamily [30]. It is expressed on 
cells of the myeloid lineage, including neutrophils, eosinophils, monocytes, macrophages, 
Kupffer cells, and certain DC subsets [14, 31, 32]. Additionally, FcαRI expression on human 
platelets was described [33]. Unlike for other Fc receptors, the FcαRI gene is located on 
chromosome 19 (19q13.4) within the leukocyte receptor cluster (LRC). This region also 
encodes natural killer cell inhibitory/activatory receptors and leukocyte Ig-like receptors. 
The FcαRI amino acid sequence has therefore more similarity with these receptors than 
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with other Fc receptors [15, 34]. The EC1 and EC2 exons each encode an extracellular Ig-like 
domain. These domains are folded in an angle of approximately 90°. The TM/C exon encodes 
both the transmembrane domain and a short cytoplasmic tail (Figure 1C) [34].
Surface expression of two isoforms of FcαRI has been described on human phagocytes. 
The a.1 isoform is a 32 kDa single pass transmembrane receptor, which can be extensively 
glycosylated (six N-linked sites and seven O-linked sites) [35]. The molecular weight of the 
a.1 isoform varies between 55-75 kDa on neutrophils and monocytes, while the molecule 
is heavier (70-100 kDa) on eosinophils due to more extensive glycosylation [17, 35]. The a.2 
isoform misses 66 nucleotides in the EC2 exon resulting in loss of one O-linked glycosylation 
site and has a weight of 28 kDa (without glycosylation) [36]. The a.2 isoform is solely 
expressed on alveolar macrophages [36].
The expression of FcαRI was estimated to represent 66.000 and 57.000 molecules on 
neutrophils and monocytes, respectively [31]. Expression level can be modulated by several 
mediators. On neutrophils, N-formylmethionyl-leucyl-phenylalanine (fMLP), interleukin 
(IL)-8, tumor necrosis factor-alpha (TNF-α), lipopolysaccharide (LPS) and granulocyte-
macrophage colony–stimulating factor (GM-CSF) enhanced the expression of FcαRI [38-40]. 
GM-CSF has also an important role in mobilizing neutrophils from the bone marrow [41] 
and was shown to induce high affinity binding of IgA by human neutrophils [42]. Neutrophil 
FcαRI upregulation was rapid and either induced by de novo synthesis or via transport 
from an intracellular pool to the cell surface [43]. On monocytes and monocyte-like cell 
lines FcαRI expression was enhanced by calcitriol, LPS, TNF-α, GM-CSF and IL-1β, while 
downregulation was observed in response to transforming growth factor-beta (TGF-β) or 
interferon-gamma (IFN-γ) [44, 45]. Both monomeric and, to a greater extent, polymeric 
IgA were able to downregulate FcαRI, possibly due to receptor aggregation, resulting in 
internalization [46-48].
Binding of IgA to FcαRI
FcαRI is a low affinity Fc receptor for monomeric IgA and dIgA (Ka = 10
6 M-1), while IgA 
immune complexes bind with high avidity and cross-link FcαRI [49]. Monomeric IgA binds 
to the EC1 domain of FcαRI via its Cα2 and Cα3 domains in a 2:1 stoichiometry (i.e. one IgA 
molecule binds two FcαRI molecules) (Figure 1C) [50, 51]. Presence of residues Pro440-




Figure 1. Structure of IgA isotypes and the IgA Fc receptor (FcαRI). (A) IgA consists of two heavy 
chains (blue), each composed of three constant regions and one variable region, and two light chains 
(brown) that consist of one constant and one variable region. IgA1 contains a hinge region with 
O-linked glycosylation. (B) Dimeric IgA consist of two IgA monomers that are linked with a J-chain 
(green). Secretory IgA contains an additional molecule, the secretory component (SC; red). (C) FcαRI 
consists of a transmembrane domain, a short cytoplasmic tail and two extracellular domains (EC1 & 
EC2). It is associated with the signaling FcR γ chain via an electrostatic interaction. The IgA heavy chain 
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junction of Cα2 and Cα3 binds to the EC1 domain of FcαRI in a 2:1 stoichiometry. (D) The FcαRI:IgA1-Fc 
complex (PDB 1OW0) was superimposed onto the solution structure of dIgA1 published by Bonner et 
al. [37] (PDB 2QTJ). FcαRI molecules bound to the top or bottom IgA1 antibodies are colored green or 
yellow, respectively. The C-terminal residue of each receptor is shown in orange or red to illustrate the 
membrane-proximal region. Kindly provided by Andrew B. Herr, PhD (Cincinnati Children’s Hospital).
Dimeric IgA contains four FcαRI binding sites and can therefore theoretically bind four 
FcαRI, although this is presumably not possible due to steric hindrance (Figure 1D) [37]. 
It remains to be elucidated how dIgA exactly interacts with the FcαRI. Binding of SIgA to 
FcαRI is hampered because of steric hindrance by SC. In order for SIgA to activate cells, co-
stimulation of FcαRI and the lectin Mac-1 (CD11b/CD18) was necessary [53].
Little is known about the difference between IgA1 and IgA2 binding to FcαRI (if any) or the 
influence of glycosylation on binding capacity. It was however shown that a specific mutation 
(Asn58 to Glu58) resulted in an altered glycosylation pattern of FcαRI, which increased the 
binding capacity of IgA nearly twofold [54]. Removal of sialic acids led to a nearly fourfold 
increase of IgA binding. This demonstrates the importance of glycosylation at position 58 
of FcαRI in binding affinity for IgA [54]. N-glycans located at the external surface of the IgA 
heavy chain were important for interaction with FcαRI as well [55]. It was demonstrated 
that these N-linked glycans present on IgA1 have increased sialylation compared to IgA2. 
Removal of sialic acids on IgA1 induced its pro-inflammatory capacity, similar as observed 
for IgA2 [56]. Furthermore, it was shown that alterations in IgA1 glycosylation and impaired 
sialylation of FcαRI were linked to increased binding of IgA1 to FcαRI on neutrophils of 
patients with IgA nephropathy, which may influence pro-inflammatory functions [46]. In 
transfectants, eosinophils and monocytes FcαRI binding capacity for IgA immune complexes 
was enhanced by incubation with several cytokines like GM-CSF, IL-4 and IL-5, without 
affecting the expression level of the FcαRI on the cell surface [42, 57].
Competitive binding for FcαRI has been described for pentraxins, including the acute phase 
C reactive protein and serum amyloid P component, resulting in cell activation [58]. These 
proteins are characterized by a pentameric ring-like structure containing five subunits, 
which recognize a similar site on FcαRI as IgA. However, mutations in FcαRI outside the IgA 
binding site did not affect IgA binding, but enhanced pentraxin binding two-fold, suggesting 
that pentraxins bind to a broader region on FcαRI than IgA [58].
Importantly, Staphylococcus aureus and group A and B streptococci developed evasion 
strategies for IgA-mediated elimination by FcαRI-expressing immune cells by producing 
several decoy proteins that obstruct binding of IgA to FcαRI [18, 19]. Anti-IgA proteins from 
group B streptococci include Sir22, Arp4 and an unrelated β protein, whereas Staphylococcus 
aureus produces staphylococcal superantigen-like protein 7. These proteins bind to specific 
Fc residues (amino acids Pro440-Phe443; i.e. PLAF) in the Cα2 and Cα3 domains of IgA [18, 




elimination by FcαRI-expressing immune cells [60], challenges the dogma of IgA as a non-
inflammatory and possibly redundant antibody.
Cell activation after FcαRI cross-linking
Cross-linking of FcαRI by IgA immune complexes (or IgA opsonized pathogens) induces 
a variety of processes, including phagocytosis, antibody-dependent cellular cytotoxicity, 
superoxide generation, release of inflammatory mediators and cytokines as well as antigen 
presentation [61-65]. Due to hampered binding of SIgA to FcαRI, SIgA does not induce 
efficient uptake of pathogens by neutrophils or Kupffer cells. However, respiratory burst 
in neutrophils can be triggered by SIgA, although less efficiently compared to serum IgA 
[53]. Phagocytosis of IgA-coated bacteria or yeast particles by neutrophils was enhanced 
after priming with GM-CSF or IL-8 [42, 66]. Uptake of IgA-coated particles induces increased 
reactive oxygen species production, subsequently resulting in the release of neutrophil 
extracellular traps (NETs), which are web-like structures consisting of DNA and proteins (e.g. 
elastase and myeloperoxidase) able to catch pathogens [61]. FcαRI cross-linking furthermore 
induces release of the neutrophil chemoattractant leukotriene B4 (LTB4) by neutrophils, 
thereby generating a positive migration feedback loop [64]. LTB4 was also shown to mediate 
migration of monocyte derived DCs [67]. As such, in case of mucosal infection neutrophils 
can function as potent phagocytes, which eliminate invading IgA-coated pathogens, and 
attract DCs that present antigens to T cells. It was recently shown that in vitro generated 
human mucosal CD103+ DCs (cultured with retinoic acid) express FcαRI. After stimulation with 
IgA-coated Staphylococcus aureus in the presence of Pam3CSK4 CD103+ DCs produced pro-
inflammatory cytokines including TNF-α, IL-1β, IL-6 and IL-23, which was dependent on FcαRI 
[68]. Furthermore, IgA-stimulated CD103+ DCs enhanced IL-17 production by allogeneic T cells 
and IL-22 production by intestinal type 3 innate lymphoid cells, respectively. This suggests 
that FcαRI crosslinking by IgA induces a pro-inflammatory T helper 17 response accompanied 
with IL-22 induced activation of epithelial cells, which might contribute to tissue repair [68].
Signaling via FcαRI
In order to initiate optimal effector functions after FcαRI cross-linking, FcαRI needs 
association with the FcR γ-chain, which contains an immunoreceptor tyrosine-based 
activation motif (ITAM) in its intracellular domain [69-72]. After cross-linking of FcαRI, 
the src family kinase Fyn aggregates with the receptor complex and phosphorylates the 
tyrosines in the ITAM in order to act as docking sites for signaling molecules [69, 73, 74]. 
Recruited Syk associates with the phosphorylated ITAM and plays an essential role in the 
signaling cascade. It directly activates phosphoinositide 3-kinase and phospholipase Cγ, 
which are involved in two separate signaling routes. These pathways are interconnected 
and can therefore modulate each other [69, 72, 75]. Eventually the signaling pathways 
will activate the cell, resulting in pro-inflammatory functions [14, 66]. Alternatively, it was 
demonstrated that inhibitory signals can also be transduced via the FcαRI-FcR γ-chain 
complex. Monomeric targeting of FcαRI (not leading to cross-linking) results in an inhibitory 
signal and is dependent on Lyn instead of Fyn kinase [74]. Phosphorylation of Syk, LAT and 
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ERK is hampered by “inhibisomes” that contain signaling molecules and both inhibitory 
and activating receptors. [16, 76]. Inhibisomes impair activating Fc receptor functioning 
via a process referred to as inhibitory ITAM (ITAMi) receptor signaling that initiates anti-
inflammatory responses to dampen pro-inflammatory responses induced by other Fc 
receptors [77]. Thus, Lyn and Fyn are essential molecules controlling ITAM inhibition and 
activation respectively [74]. Recently it was demonstrated that IgA2 immune complexes 
activated Syk and ERK in neutrophils while IgA1 immune complex-induced signaling was 
less stable and partially blocked by inhibitory Shp-2 signals [56] .
IgA and FcαRI mediated functions at different locations
In the lumen of mucosal sites
The functions of SIgA in the intestinal lumen have been well characterized (Figure 2A). SIgA 
and commensal microbes have important roles in maintaining balance between tolerance 
towards non-harmful commensals and food compounds versus immunity against pathogens 
[78, 79]. When SIgA is released from the epithelial layer into the lumen, it remains attached 
to the outer mucus layer [80]. This close localization to bacteria enables SIgA to disturb 
bacterial motility and to surround pathogens that have a hydrophilic shell. SIgA coating 
blocks entrance of pathogens into the intestinal epithelium (a process called immune 
exclusion). This coating leads to agglutination, because antibody-mediated crosslinking of 
surface antigens will lead to formation of bacterial clumps. Peristaltic bowel movements 
ensure removal of bacterial aggregates. Bacterial products like enzymes and toxins can be 
neutralized by SIgA and adherence to host cells, including epithelial cells, is prevented [78]. 
Thus, together with the mucus layer, SIgA forms a barrier against pathogens and commensals 
by preventing colonization and penetration of the mucosal epithelium, thereby avoiding 
infection and antigen leakage into the systemic circulation [81].
Recently the interplay between luminal microbiota and SIgA was investigated in more 
detail [4, 82] (Figure 2A). It is still unclear how SIgA and the microbiota exactly relate to 
each other, but it was described that SIgA shapes and diversifies the gut microflora on the 
one hand, while the microbiota on the other hand has an important role in regulating IgA 
levels [82-84]. During weaning up to 70% of intestinal commensals are coated with SIgA 
in mice and the majority of human fecal bacteria in healthy donors are opsonized with 
IgA, emphasizing the importance of this association in maintaining homeostasis [29, 85]. A 
wide variety of commensals can be opsonized with polyreactive IgA, although it remains 
unclear how these IgA antibodies are generated, what the relevant targets are and how 
binding affects the fitness and physiology of commensals [86]. In contrast to commensals, 
pathogens elicit highly specific T-cell dependent IgA responses [86, 87]. Genetic background 
was shown to influence the repertoire diversity and abundance of innate IgA as germ free 
(GF) naïve BALB/c mice already had substantial innate IgA levels, independent of microbiota 




Furthermore, highly glycosylated IgA was able to bind to several gram negative bacteria, which 
modulated their gene expression, leading to enhanced processing of fibers and production 
of butyrate as well as a diversified microbiota composition [82]. Moreover, it was shown 
that the disbalanced microbiota of colitogenic mice became more balanced and diversified 
after oral administration of the monoclonal IgA W27, which is a high-affinity polyreactive 
antibody [84]. Importantly, mice lacking IgA, J-chain or pIgR were unable to efficiently 
protect themselves against mucosal infections. These mice have an altered gut microbiota 
as well as increased mucosal permeability, which renders them more susceptible to develop 
colitis [80, 88-94]. Of note, lack of J-chain or pIgR also led to absence of SIgM which may have 
contributed to altered microbiota and compromised immunity [88, 91, 94]. A diversified 
microbiota can regulate the amount of SIgA present in luminal secretions by enhancing 
the level of pIgR on epithelial cells [1, 29, 95], illustrating the complex interrelationship 
between IgA (and IgM) and the microbiota in maintaining homeostatic conditions.
In epithelial layers
It was described that SIgA can be translocated back into the lamina propria (retrograde 
transport). SIgA and SIgA immune complexes can be transported across specialized epithelial 
cells, referred to as M cells, which are located in the Peyer’s patches of the intestine. Dectin-
1 that is expressed by M cells may facilitate transepithelial transport [7, 96]. Additionally, 
a role for TfR1 on epithelial cells in retrotransport of SIgA-coated gliadin was reported 
in studies investigating celiac disease [8]. Retrotransported SIgA immune complexes can 
be taken up by DCs that are present in the subepithelial dome. In vitro models support 
an essential role for DC-SIGN in recognizing SIgA immune complexes [9]. The retrograde 
transport mechanism and recognition of SIgA by DCs is thought to be essential in monitoring 
the antigenic status of the intestinal lumen.
On route through epithelial cells, dIgA has the ability to intercept and disarm viruses and 
redirect them into the lumen, after which they are removed with the feces (Figure 2B). 
Neutralization of several viruses by IgA including sendai, influenza, rota, measles and human 
immunodeficiency virus (HIV), as well as bacterial LPS was demonstrated in vitro [97-104]. 
IgA has enhanced neutralizing capacity compared to other Ig isotypes due to the N-linked 
glycosylation of position N459D in the heavy chain Cα3 [105]. This effect is independent 
of the antigen binding site as glycosylated non-specific IgA neutralized the virus as well.
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Figure 2. Roles of mucosal IgA in homeostasis. (A) Dimeric IgA (dIgA) is produced by local plasma 
cells (PC) in the lamina propria. Dimeric IgA is transported to the intestinal lumen by binding to the 
polymeric immunoglobulin receptor (pIgR) present on epithelial cells. In the lumen it is released as 
secretory IgA (SIgA) where it can coat (commensal) bacteria. (B) On route dIgA can bind, neutralize 
and eliminate viruses. (C) (1) Infiltrated antigens and pathogens are opsonized by dIgA and transported 
back into the lumen. Sub epithelial dendritic cells (DCs) can (2) sample antigens or (3) take up SIgA-
coated pathogens that enter via microfold cells (M cells). Pathogens in the lamina propria are coated 
with dIgA after which this immune complex is taken up by FcαRI- expressing (4) DCs and (5) neutrophils. 
In response neutrophils secrete leukotriene B4 (LTB4), hereby attracting more neutrophils, which will 
clear the infection. (D) Serum IgA is (1) capable of inhibiting (unwanted) pro inflammatory responses 
in the circulation via ITAMi signaling in monocytes. (2) IgA-opsonized bacteria which have leaked into 




IgA deficient mice, J-chain deficient mice (lacking dIgA, SIgA and SIgM) and pIgR deficient 
mice (lacking SIgA and SIgM) have defects in clearing viruses, are more susceptible to 
reinfection and lack protective immunity [106-108], which emphasizes the important role 
of IgA in anti-viral immune responses. By contrast, in a recent study pIgR knock-out mice 
showed a reduced acute norovirus infection rate, suggesting that pIgR and natural polymeric 
immunoglobulins may promote viral infections. It was suggested that the less diversified 
intestinal microbiota present in pIgR deficient mice was responsible for reduced infection. 
pIgR deficient mice had enhanced levels of the anti-viral cytokine IFN-γ, which might explain 
the reduced infection rates [109].
In the lamina propria
Food particles and commensal microbiota are abundantly present in the lumen and can 
continuously reach the lamina propria through diffusion (via epithelial tight junctions) or 
transcytosis (Figure 2C). These non-harmful components need to be tolerated and they 
need to be cleared from the mucosa to avoid the formation of immune complexes, which 
may trigger undesired immune responses. In the lamina propria dIgA can eliminate both 
non-harmful and harmful components from the tissue by transporting immune complexes 
back into the lumen through association with the pIgR [97, 101]. Additionally, FcαRI+ residing 
immune cells may help to clear IgA-opsonized pathogens. Under homeostatic conditions, 
only few FcαRI+ cells are found in mucosal areas (own unpublished data). However, as 
dIgA-opsonized complexes have the ability to cross-link FcαRI, leading to release of LTB4, 
neutrophils can be rapidly recruited [64] (Figure 2C). Furthermore, in vitro generated FcαRI+ 
CD103+ DCs were shown to produce pro-inflammatory cytokines after stimulation with IgA-
coated Staphylococcus aureus in the presence of Pam3CSK4, suggesting that a protective 
adaptive immune response is initiated during mucosal infections [68].
Systemic protection
It was demonstrated that a variety of commensal microbes in the gut influenced serum IgA 
levels, which protected mice against lethal sepsis when the intestinal barrier was damaged 
[110]. Serum IgA was shown to target the same epitopes and used the same V-gene 
segments as plasma cells in the gut [111], suggesting that systemic and mucosal plasma 
cells originated from the same B cell clone. Diminished serum IgA titers were found in GF 
mice compared to specific pathogen free mice, supporting the essential role for microbiota 
diversity in IgA production [110, 112]. Mice lacking pIgR and SIgA have epithelial barrier 
disruption, enhanced numbers of IgA-secreting plasma cells and systemic immune activation 
indicated by increased levels of serum IgG and IgA [113, 114]. Higher levels of albumin were 
found in the feces, suggesting leakage of serum proteins across the epithelium [113]. At 
the same time intestinal proteins and microorganisms can leak into the tissue and enter 
the bloodstream. After entering the portal circulation they will encounter Kupffer cells in 
the liver, which are specialized FcαRI+ macrophages that can eliminate IgA-coated bacteria 
from the bloodstream (Figure 2D) [32]. Kupffer cells, macrophages and monocytes produced 
increased levels of pro-inflammatory cytokines (e.g. TNF-α, IL-1β and IL-6) after cross-linking 
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of FcαRI in the presence of pathogen recognition receptor ligands (such as Pam3CSK4, LPS, 
flagellin) (reflecting IgA-opsonized pathogens) [115].
In contrast to the activating properties of complexed serum IgA, monomeric serum IgA was 
capable of downregulating cell responses and promoted powerful anti-inflammatory effects 
(Figure 2D). This is referred to as ITAMi signaling (see above) [15]. Monomeric targeting 
of the FcαRI with serum IgA may protect against enhanced receptor activation, which is 
beneficial in inflammatory diseases characterized by the presence of IgG immune complexes 
or enhanced FcεRI signaling.
Concluding remarks
IgA is an important antibody in maintaining mucosal immune homeostasis. SIgA regulates 
immune exclusion by neutralizing pathogens and more recently the role of SIgA in diversifying 
the intestinal microbiota has been investigated more extensively. The mechanisms involved 
in IgA-mediated regulation of microbiota diversity and reciprocal regulation of IgA levels 
by microbes are incompletely understood. Unlike SIgA, dIgA and mIgA have the ability to 
potently activate the FcαRI. This process ensures efficient elimination of IgA-opsonized 
pathogens and eventually restoration of immune homeostasis after infection. Unfortunately 
to date little is known about the role of IgA in the circulation.
Thesis outline
Although the exact biology of IgA remains to be defined, it is widely accepted that IgA plays 
an important role in mucosal immunity. In this thesis I investigated the role of IgA at different 
sites in the human body to gain better understanding in its pivotal role in maintaining 
immune homeostasis at mucosal surfaces and in the circulation, and its pathological role 
in auto-immunity.
Tolerating non-harmful commensals and food particles and generating an effective immune 
response towards harmful pathogens is essential to maintain balance. Most knowledge 
regarding host-microbe interactions resides from the intestinal tract. On the one hand IgA 
is thought to play an important role in regulating the maintenance of a healthy intestinal 
microbiota composition, while on the other hand bacteria are thought to regulate IgA 
levels in turn. Little is known about the interactions between vaginal microbiota and IgA. 
In chapter 2 we characterized the vaginal microbiota and its coating with IgA during the 
menstrual cycle. We showed that IgA coating of the vaginal microbiota is significantly 
increased during menstrual bleeding. Furthermore, Lactobacillus crispatus dominant 
flora had significantly increased coated with IgA compared to non-Lactobacillus crispatus 
dominant flora. I hypothesize that IgA has a beneficial role in regulating the maintenance 
of a healthy microbiota composition, similar as in the intestinal tract. In chapter 3 we 
further investigated the role of IgA in the vaginal mucosa during early pregnancy in different 
ethnic groups. We showed that local unbound and bacteria bound immunoglobulin levels 




bound IgA levels in White European women compared to non-White European women. 
As the vaginal microbiota composition of these women is unknown to date we cannot 
draw any conclusions whether this increased bacteria bound IgA is related to more L. 
crispatus which we demonstrated in chapter 2. The inflammatory protein S100A8/A9 was 
negatively associated with IgA levels in women with term birth, but not with preterm birth. 
I hypothesize that IgA is important in down regulating inflammatory S100A8/A9 thereby 
potentially delaying inflammation induced preterm birth. Moreover, this explorative study 
underlines the importance of reporting ethnic background when investigating factors 
associated with the vaginal microbiota composition.
During infection, neutrophils are the first cells to be recruited towards sites of infection. 
In order to maintain homeostatic conditions IgA can opsonize pathogens and facilitate 
elimination by FcαRI-expressing immune cells. In chapter 4 we reviewed the current 
literature on how neutrophils interact with dendritic cells and in chapter 5 we elaborated 
on the specific roles of IgA in cellular interactions. We demonstrated that tissue-resident 
tolerogenic CD103+ DC were not affected by IgA-activated neutrophils. IgA-activated 
neutrophils enhanced recruitment of monocytes through the release of LTB4. Monocyte-
derived dendritic cell maturation and cytokine production was enhanced by IgA-activated 
neutrophils underlining the importance of IgA in the establishment of an effective immune 
response against pathogens.
In contrast to the mucosa, the pivotal function of systemic IgA is poorly studied and often 
overlooked. In chapter 6 we investigated the inflammatory potential of serum IgA in depth 
using RNA sequencing, proteomics and lipidomics. Specific IgA was found in serum of 
Lyme’s disease patients and individuals vaccinated with a typhoid fever vaccine. Increased 
opsonization of the Lyme’s disease Borrelia bacteria with IgA compared to IgG underlines the 
superior potential of IgA in pathogen neutralization compared to IgG. We demonstrated that 
IgA enhanced the gene expression of many pro-inflammatory proteins in monocytes and 
also induced pro-inflammatory protein and lipid secretion by monocytes and neutrophils 
towards a higher extend than IgG. Enhancing IgA production through active immunization 
might be an effective strategy to combat infections.
Prolonged activation of IgA-FcαRI interactions can result in tissue damage, and in case IgA 
is directed towards self-antigens this can result in tissue damage resulting in autoimmune 
diseases. In chapter 7 we demonstrated that rheumatoid arthritis patients have a unique 
profile of different IgA autoantibodies in their synovial fluid. Immune complexes isolated 
from synovial fluid can activate monocytes and osteoclasts. IgA-activated monocytes 
indirectly enhanced bone resorption by osteoclasts through the release of soluble factors. 
IgA also enhanced bone resorption directly by activating FcαRI-expressing osteoclasts. 




In chapter 8 the content of the previous chapters are summarized and discussed in relation to the 
current literature. Suggestions for future research and potential therapeutic strategies are given.
Depending on the location in the body and the immune environment, IgA can either 
maintain homeostasis, restore homeostasis in case of infection or induce pathology when 
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CHAPTER 2
Enhanced IgA coating of Lactobacillus  




Immunoglobulin (Ig) A plays an important role in maintaining a healthy intestinal 
microbiome, but little is known about the interaction between local immunoglobulins and 
the vaginal microbiome. We therefore assessed immunoglobulins (unbound and bound to 
bacteria), the influence of vaginal microbiota composition on immunoglobulins and the 
changes over time in 25 healthy women of reproductive age.
In both Lactobacillus crispatus dominant and non-L. crispatus dominant microbiota, IgA 
(unbound and bound to bacteria) was higher during menses (T=1) compared to day 7-11 
(T=2) and day 17-25 (T=3) after menses onset. IgA coating of vaginal microbiota was however 
significantly higher in women with L. crispatus dominant microbiota. Presence of an IgA 
coated population at T=2 and/or T=3 was also strongly associated with L. crispatus dominant 
microbiota.
We propose that IgA is involved in maintaining a L. crispatus dominant microbiota, which 
may play a role in L. crispatus associated health benefits.
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2
Background
A healthy vaginal mucosa is populated by a low diversity of species, generally dominated 
by either Lactobacillus species or diverse anaerobic bacteria. Of the Lactobacillus spp, L. 
crispatus and L. iners are the most prevalent in the vagina. Especially L. crispatus dominated 
vaginal microbiota is considered more beneficial compared to L. iners dominated or diverse 
vaginal microbiota since L. crispatus is associated with protection from pathogens and 
the regulation of anti-inflammatory responses [1-4]. A diverse vaginal microbiome is 
associated with bacterial vaginosis, the most common gynecological condition in women 
of reproductive age, and an increased risk of HIV, other sexually transmitted infections and 
preterm birth [5-7]. Furthermore, L. crispatus dominant microbiota are less likely to shift 
to a diverse microbiome than L. iners dominant vaginal microbiota [8-10]. L. iners is often 
found in diversified vaginal microbiota and therefore its potential beneficial role has been 
debated. The etiology of the different phenotypes of the distinct vaginal microbiota profiles 
is largely unknown.
In the intestinal tract, the interaction between microbiota and local immunoglobulins is 
important in maintaining mucosal homeostasis [11]. Immunoglobulin A (IgA) is the most 
abundant antibody present in the intestinal tract. It can be subdivided into IgA1 and IgA2, 
of which the latter is resistant to proteolytic cleavage induced by bacterial proteases and is 
the most commonly found subtype in the intestinal tract [12]. IgA can coat and contain the 
resident intestinal commensal microbiota and provide protection against enteric pathogens 
by inhibiting their entrance into the intestinal epithelium. As such, IgA contributes to the 
maintenance of a healthy and diversified microbiota composition [13, 14]. Vice versa, 
the microbiota also plays a significant role in regulating IgA levels [14-17]. Changes in 
immunoglobulin coating of intestinal bacteria have been associated with inflammatory 
bowel diseases [18, 19].
Unlike other mucosal tissues, IgG dominates IgA in the vaginal mucosa. Levels of both IgA 
and IgG vary during the menstrual cycle [20]. Little is known about the role of IgA and IgG in 
the female genital tract and knowledge regarding cross-talk between local immunoglobulins 
and vaginal microbiota is currently lacking. In this study we investigated immunoglobulins 
(unbound and bound to bacteria) in relation to the vaginal microbiota composition and the 





For this investigation we made use of the microbiota data, meta data and samples from a 
previous study about the influence of vaginal douching on vaginal microbiota composition 
[21]. The study protocol and methods are extensively described in the publication by van 
der Veer et al. [21]. In short, women without sexually transmitted infections were recruited. 
Both hormonal contraceptive users and non-users were eligible. Participants were asked 
to take vaginal swabs (155C Rayon dry swabs, Copan Diagnostics Inc., Murietta, CA) for the 
duration of the study. For the current study, only samples collected during the first month, 
when no vaginal douching was performed, were used. Participants collected a swab every 
other day. Swabs were stored at -20⁰C at the Public Health Laboratory of Amsterdam. 
On average, eight swabs evenly distributed over the menstrual cycle were selected per 
participant for microbiota composition analysis. For the current study, three swabs were 
selected for additional immunologic analysis. The first swab was taken on day three after 
onset of menses, the second between day seven and eleven after onset of menses and 
the third between day seventeen and 25 after onset of menses. These specimens will be 
referred to as collected during menses or first time point (T=1), second time point (T=2) and 
third time point (T=3) for all women.
Profiling of immunoglobulins that were bound to bacteria
Vaginal swabs were washed in sterile PBS and vortexed for at least 10 seconds to extract 
bacteria from the rayon swabs. Samples were transferred to a 96-well v-bottom plate, 
centrifuged for 5 min (4000 rpm, 4°C), and blocked with 5% endotoxin free bovine serum 
albumin (BSA) (Akron Biotech, Boca Raton, FL) for 20 min on ice. Bacteria were stained 
with F(ab’)2 anti-human IgA-AF647 (1:200) and F(ab’)2 anti-human IgG-AF488 (1:200) (both 
Jackson ImmunoResearch, West Grove, PA) for 30 min on ice. Samples were washed in PBS 
before flow cytometric analysis (Sony SH800S, Sony Biotechnology, San Jose, CA). For each 
sample approximately 20.000 events were recorded.
FlowJo (version 10.6.2) was used for the analysis of the flow cytometry data. The coating 
index was calculated by multiplying the percentage of bacteria with bound immunoglobulin 
with the median fluorescence intensity (MFI). Contour plotting was used for cluster analysis 
of the flow cytometry data. The populations were defined by the appearance of a separate 
population in a contour plot and gates were manually set on the defined populations.
Quantification of unbound immunoglobulins
Total IgA, IgA1, IgA2, secretory IgA (SIgA) and IgG concentrations in vaginal swabs were 
determined by capture enzyme-linked immunosorbent assay (ELISA). Briefly, 96-well plates 
(Maxisorb Nalge Nunc International, Rochester, NY) were coated with 100 μL of the capture 
antibodies goat anti-human serum IgA (2 μg/ml, Jackson ImmunoResearch, West Grove, PA), 
mouse anti-human Secretory Component (1:10.000, Sigma-Aldrich Corporation, St. Louis, 
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MO) or goat anti-human IgG (2 μg/ml, Invitrogen, Waltham, MA) in sodium carbonate buffer 
(15 mM NaCO3, pH 9,6) and incubated overnight at 4°C. Nonspecific-binding free sites were 
blocked with 200 μl of blocking buffer (0.5% BSA in PBS containing 0.05% Tween20) for 60 
min at 37°C. Samples were thawed and bacterial content was spun (10.000 rpm, 7 min at 
4°C) after which the supernatant was diluted 1:20, 1:100 and 1:1000 in blocking buffer and 
100 μl was incubated in duplicate for 60 min at 37°C. Wells were incubated with 100 μl of 
detecting antibodies F(ab’)2 goat anti-human IgA-HRP (1:2000, Invitrogen, Waltham, MA), 
mouse anti-human IgA1-biotin (1:1000, Abcam, Cambridge, United Kingdom), mouse anti-
human IgA2-biotin (1:1000, Abcam, Cambridge, United Kingdom) or F(ab’)2 goat anti-human 
IgG-HRP (1:2000, Invitrogen, Waltham, MA) and incubated for 60 min at 37°C. For IgA1 
and IgA2 detection, 100 μl of streptavidin poly-HRP (100 ng/ml, Sanquin, Amsterdam, The 
Netherlands) was added for 30 min at 37°C. Presence of immunoglobulins was detected with 
100 μl/well of 12ml of 0,1M sodium acetate (NaAc pH 4) with 3 μl of 30% hydrogen peroxide 
and 200 μl of 6 mg/ml 3,3’,5,5’-Tetramethylbenzidine (TMB). The reaction was stopped with 
100 μl of sulfuric acid (10% H2SO4) and absorbance was measured with a microplate reader 
(Bio-Rad, Berkeley, CA) at 450nm.
Total protein concentration vaginal fluid
Total protein concentration of every vaginal sample was determined using PierceTM BCA 
Protein Assay Kits (ThermoFisher, Waltham, MA). In brief, 10 μL of vaginal fluid was added 
to a 96-well flat bottom plate, mixed with 200 μL of BCA working reagent and incubated 
for 30 min at 37°C. Absorbance was measured with a microplate reader (Bio-Rad) at 562 
nm when the plate was cooled to room temperature.
To correct for inter- and intra-participant variation, unbound immunoglobulin levels 
(defined with ELISA) were corrected for total protein content by dividing the measured 
immunoglobulin levels by total protein level and multiplied by a thousand (ng/1 mg protein). 
Immunoglobulin levels below detection limit (determined per 96-wells plate) were imputed 
ten times and the average of the imputed levels were corrected for total protein content.
Statistical analysis
Data were log-transformed to reach normality. We used repeated measures analyses (linear 
mixed models) with an unstructured variance-covariance matrix, to analyze the differences 
between time points with post-hoc Bonferroni correction for individual comparisons. To 
analyze the effect of microbiota composition and hormonal contraceptive usage on the 
measured outcomes, these variables were added as fixed parameters to the model. The 
Pearson Chi-Square test was used for categorical data.
Spotfire (version 7.13.0) was used for creating heat maps and performing complete 
linkage hierarchical clustering. The linear discriminant analysis effect size (LEfSe) algorithm 
was used to identify bacterial taxa associated with changes in immunoglobulin coated 
populations [22]. The median relative abundance of taxa at all available measurements 
32
Chapter 2
was calculated and compared between participants with an IgA dominant population at 
time point two or three and participants who do not have a third population at any time 
point. LEfSe uses factorial Kruskal-Wallis rank-sum test to detect differential abundances 
of bacterial taxa between specified groups. The estimated effect size of the differentially 
abundant taxa was measured using linear discriminant analysis. An alpha-value of 0.01 for 
factorial Kruskal-Wallis test was considered significantly different between different classes. 
A minimum threshold of 2.0 was used for logarithmic latent discriminatory analysis score 
for discriminative features. Statistical analyses were performed using IBM SPSS statistics 
(version 26). Data of the immunoglobulin measurements were visualized using GraphPad 
Prism (version 8.2.1.).
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Vaginal swabs of twenty-five women were included in the current study. Participant 
characteristics are shown in table 1. For extensive characteristics see the original research 
paper [21]. The median age was 24 year (interquartile range (IQR): 22-29). The majority of 
participants were of Dutch descent (n = 22, 88%). The other women had Eastern-European, 
Middle-Eastern or European/African mixed heritage (n = 3, 12%). Smoking was reported by 
five women (20%). Fifteen women (60%) used oral hormonal contraceptives.
Table 1. Participant characteristics
Baseline characteristics n = 25 (%)




Eastern European 1 (4)
European/African (parental heritage) 1 (4)
Smoking 5 (20)
Oral contraceptive usage 15 (60)
Length of menstrual cycle, days, median [IQR] 28 [28-28]
Protection during menses
Tampons 18 (72)
Sanitary pads 2 (8)
Tampons & sanitary pads 4 (16)
Menstrual cup 1 (4)
Has ever been pregnant 1 (4)
Parity > 0 0 (0)
*IQR = interquartile range
Microbiota composition and immunoglobulins over time
We investigated changes in vaginal microbiota, immunoglobulins bound to bacteria and 
unbound immunoglobulins over time. For most women, microbiota composition was 
stable during the study period (figure S1). In thirteen (52%) women the same bacterium 
was dominant during all three time points. L. crispatus was dominant in eight (32%) and L. 
iners in five (20%) of these women. In six of the twelve women with changing microbiota 
profiles, the dominant bacterium switched between different Lactobacillus species. Of the 
remaining six women, one had a diverse profile at all time points and the others switched 
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between either a Lactobacillus dominated profile and a profile dominated by Gardnerella 
vaginalis, Megasphaera or Bacterial Vaginosis Associated Bacterium 1 (BVAB1).
Bacteria bound IgA and IgG were highest during menses. Bound IgA was significantly 
increased during menses (T=1) compared to the second time point (T=2) (p=0.044, figure 
1A), while bound IgG was significantly increased at T=1 compared to both T=2 and the third 
time point (T=3) (p=0.006 and 0.042 respectively, figure 1B). Correlation analysis revealed 
a statistically significant positive correlation between IgA and IgG at all time points (T=1: 
spearman’s rho=0.74, p<0.0001. T=2: spearman’s rho=0.42, p=0.038, T=3: spearman’s 
rho=0.65, p=0.0004, figure S2).
Figure 1. Immunoglobulins bound to bacteria and unbound immunoglobulins over time. 
Immunoglobulin bound to bacteria and unbound immunoglobulins were measured during menstrual 
bleeding (T=1), time point 2 (T=2) and time point 3 (T=3). The level of (A) IgA and (B) IgG bound to 
bacteria and unbound (C) IgA and (D) IgG over time. Red line represents the mean. *p < 0.05, **p < 
0.01, ***p < 0.001, ****p < 0.0001
In vaginal fluid, unbound total IgA and IgG increased significantly during T=1 compared to 
T=2 and T=3 (p=0.0003 and p<0.001 respectively for IgA, p<0.0001 in both comparisons 
for IgG, figure 1C and 1D). IgA1 and IgA2 levels differed in contrasting patterns. IgA1 levels 
increased during T=1 compared to T=3 (p=0.019, figure S3A), while IgA2 levels decreased 
during T=1 compared to T=3 (p=0.002, figure S3B). SIgA levels showed a positive trend over 
time, but the differences between the time points were not statistically significant (figure 
S3C). Hormonal contraceptive usage did not have a statistically significant effect on bacteria 
bound or unbound immunoglobulin levels.
Immunoglobulin coating of clustered microbiota
Complete linkage hierarchical clustering was performed using median relative abundance 
of available samples, shown as a heat map with dendrogram in figure 2. According to the 
hierarchical clustering participants were divided in two groups, i.e., a L. crispatus dominant 
and a non-L. crispatus dominant group. Twelve women with a L. crispatus dominated vaginal 
microbiota composition clustered together. Women with other Lactobacillus spp. as dominant 
species (mainly L. iners) or with a diverse profile also clustered together, thirteen in total. The 
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microbiota of nine women in the latter group was dominated by either L. iners or L. jensenii 
and in four cases the vaginal microbiota was diversified with low levels of Lactobacillus spp.
Figure 2. Vaginal microbiota composition. Heat map and clustering analysis. Heat map depicts the 
top 20 most abundant vaginal species in the 25 study participants. Colors reflect the median relative 
abundance of all available microbiota measurements during the menstrual cycle.
We compared immunoglobulins that were bound to bacteria of women with L. crispatus 
dominant microbiota to women with non-L. crispatus dominant microbiota (figure 3A and 
3B). Using a linear mixed effect model for repeated measurements, the overall effect of 
microbiota composition on bacteria bound IgA and IgG for all time points was estimated. 
Women with L. crispatus dominant vaginal microbiota had on average higher bound IgA 
compared to non-L. crispatus dominant vaginal microbiota, with a mean difference 0.33 
10log coating index (95% confidence interval 0.11 - 0.55, p=0.005, figure 3C). There was no 
statistically significant effect of microbiota composition on IgG 10log coating index using linear 
mixed model analysis (figure 3D). Including hormonal contraceptive usage in the models 
did not influence the effect of microbiota composition on IgA and IgG coating index (data 
not shown). No significant differences were found for any of the unbound immunoglobulins 
over time when comparing women with a L. crispatus dominant microbiota versus a non-L. 
crispatus dominant microbiota (Figure S4). Including hormonal contraceptive usage in the 
models for made no difference for the unbound immunoglobulins (data not shown).
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Figure 3. Bacteria-bound immunoglobulins on L. crispatus dominant and non-L. crispatus dominant 
microbiota over time. Bacteria-bound (A) IgA and (B) IgG in women with L. crispatus dominant vaginal 
microbiota compared to women having non-L. crispatus dominant vaginal microbiota over time. 
Red line represents the mean. The linear mixed effect models for bacteria bound (C) IgA and (D) 
IgG. The filled lines represent the predicted values by the models, the dotted lines represent the 
95% confidence intervals of the predicted values. All data visualized as 10log coating index (coating 
index = percentage of immunoglobulin bound bacteria * median fluorescence intensity).
Bacterial bound IgA and IgG clustering
Bacterial immunoglobulin coating analysis based on contour plotting revealed distinct 
IgA- and IgG-coated bacterial populations (figure 4A). Per participant, a maximum of three 
different populations were present: no bound IgA and IgG (double negative population), 
bound IgA and IgG (double positive population) and an IgA dominant population with a 
higher IgA/IgG ratio compared to the double positive population (IgA dominant population). 
The percentages of bacteria per population per time point for each participant are shown in 
a heat map (figure 4B). All included samples from the first time point contained a population 
with bacteria that were coated by both IgA and IgG (double positive; DP) while only thirteen 
samples contained a populations of bacteria not coated by IgA and IgG (double negative; 
DN). An IgA dominant bacterial population appeared in eight participants at the second or 
third time point, which was strongly associated with L. crispatus dominant microbiota (seven 
out of eight participants had L. crispatus dominant microbiota, p=0.007). One participant in 
the non-L. crispatus dominant group defined by hierarchical clustering, had an IgA dominant 
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population at the second time point. Interestingly, at the second time point the dominant 
species was L. crispatus (VH25, figure S1).
Subsequently, we investigated the effect of the individual taxa on the appearance of an IgA 
dominant population by performing LEfse. L. crispatus, as individual taxon, was strongly 
associated with the presence of an IgA dominant population (figure 4C). Dialister spp, 
commonly found in women with a diverse microbial profile, was strongly associated with 
the absence of an IgA dominant population.
Figure 4. Bacterial clustering based on bacteria bound IgA and IgG. (A) Examples of contour plots 
of IgA- and IgG-coated bacterial populations. In red the manual gates are shown. Contour plots of 
a participant with L. crispatus dominant vaginal microbiota (VH16) and a participant with non-L. 
crispatus dominant vaginal microbiota (VH23). (B) Heat map depicting the percentage of bacterial 
cells per population (DN = double negative, DP = double positive and IgA dominant population). (C) 
The linear discriminant analysis (LDA) effect size analysis for the appearance of an IgA dominant 
population with an alpha-value set to 0.01. The Linear Discrimimant Analysis (LDA) score for the taxon 
more prevalent in women with a IgA dominant population at T=2 and/or T=3 is shown in green, the LDA 




In this explorative study we describe the association between microbiota and immunoglobulins 
in the vagina. We combined flow cytometry and microbiota analyses to investigate host-
microbe interactions in this mucosal niche. To our knowledge this is the first report describing 
immunoglobulin coating of the vaginal microbiota. We demonstrated that women with L. 
crispatus dominant vaginal microbiota have increased IgA coating of vaginal bacteria compared 
to women with other microbiota compositions. IgG levels (unbound and bound to bacteria) 
were not influenced by microbiota composition. Multiple sampling moments allowed us to 
investigate the influence of menstrual bleeding on immunoglobulins (unbound and bound 
to bacteria). We showed that coating of the vaginal microbiota with IgA and IgG was highest 
during menstrual bleeding compared to the other time points.
The role of IgA in regulating the vaginal microbiota composition is currently unknown. 
In the intestinal tract of healthy individuals the majority of gut bacteria are coated with 
IgA [23], implying a steady-state IgA response to commensal microbes. It is thought that 
IgA promotes the colonization of beneficial bacterial strains in the intestinal tract thereby 
maintaining a healthy and diversified intestinal microbiota [16]. Anti-inflammatory and 
regulatory properties of mucosal dendritic cells in Peyer’s patches are enhanced by 
IgA-coated L. rhamnosis compared to uncoated L. rhamnosis, thereby contributing to a 
tolerogenic profile [24]. We hypothesize that IgA in the female genital tract, similar as in the 
intestinal tract, enhances a beneficial microbiota composition dominated by L. crispatus.
A possible mechanism for decreased levels of IgA in dysbiotic vaginal microbiota is enhanced 
degradation of IgA by bacterial vaginosis-related bacteria [25]. While IgA is important for 
enhancing colonization of favorable commensals during health [26], it also has a role in 
first line of defense against pathogens through immune exclusion [27]. The degradation of 
IgA in diverse vaginal microbiota is a possible explanation for the increased susceptibility 
for HIV and other sexually transmitted infections among women with a diversified vaginal 
microbiome. Increased diversity of the vaginal microbiota is associated with increased 
proteolytic activity [2]. It was shown that SIgA is a substrate for bacterial vaginosis-associated 
degrading enzymes, suggesting increased hydrolysis and depletion of SIgA in women with 
bacterial vaginosis [28]. In this study we found lower levels of IgA bound to bacteria in 
non-L. crispatus dominant microbiota. Levels of unbound IgA did not differ between women 
with non-L. crispatus versus L. crispatus dominant microbiota. The non-L. crispatus group 
however mainly consisted of women with L. iners dominated vaginal microbiota, only four 
women had dysbiotic vaginal microbiota. Our study may thus have been underpowered to 
detect an effect of bacterial proteolytic activity in the non-L crispatus group.
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Preservation of stable L. crispatus dominated vaginal microbiota is beneficial for the 
host’ health. Women with L. crispatus dominant microbiota are less likely to shift to a 
diverse microbiota composition and are less vulnerable to infections [8]. In this study most 
women had stable vaginal microbiota composition over time. This is in line with previous 
studies where the majority of healthy natural cycling women had stable vaginal microbiota 
compositions during their menstrual cycle, with only modest fluctuations in species richness 
[29, 30]. However, it was also shown that vaginal diversity can reversibly change during 
menstrual bleeding with a 100-fold decrease in L. crispatus and an increase in bacterial 
vaginosis-associated species including L. iners, Gardnerella vaginalis, Prevotella bivia and 
Atopobium vaginae [9, 31, 32]. Discrepancies found between studies investigating the vaginal 
microbiota composition might be explained by the amount and duration of blood loss during 
menses, sexual activity and change of sexual partner, ethnicity and many other factors. 
Most women return to a favorable Lactobacillus dominated microbiota after menstrual 
bleeding which strengthens the view that presence of blood affects the vaginal microbiota 
composition temporarily. The fact that the bacterial vaginosis-related bacterium Gardnerella 
vaginalis can use hemoglobin as growth factor supports this hypothesis [31]. It remains 
unclear what causes the difference between a bacterial vaginosis-associated microbiota 
composition during menstrual bleeding and the clinical condition bacterial vaginosis.
Unlike in the intestinal tract, IgG dominates over IgA in the vagina and levels vary over 
the reproductive cycle [20]. Variations in immunoglobulin levels can be explained by 
several factors including the production rate of immunoglobulins, transport capacity of 
immunoglobulins and the origin of immunoglobulins at certain points during the cycle [33]. 
Previous studies showed fluctuations in unbound IgA and IgG levels in naturally cycling 
women, while oral contraceptive users contained more stable unbound IgA and IgG levels 
[20, 34, 35]. We found that vaginal IgG and IgA levels were highest during menstrual 
bleeding, which is consistent with existing literature [20, 36]. The increased total IgA and 
IgG levels during menstrual bleeding most likely derive from menstrual blood, as serum 
contains high levels of IgG (8-14 mg/ml) and IgA (2-3 mg/ml)[37]. Our findings are consistent 
with the concept that the presence of menstrual blood in the vagina plays an important 
role in modulation of local immunoglobulin concentrations.
Conclusion
In conclusion, L. crispatus dominant microbiota is associated with enhanced bacterial IgA 
coating. We propose that IgA can regulate the maintenance of stable vaginal microbiota in 




BCA = Bicinchoninic acid assay
BVAB = Bacterial Vaginosis Associated Bacterium
ELISA = Enzyme-linked immunosorbent assay
HIV = Human Immunodeficiency Virus
HRP = Horseradish peroxidase
IgA = Immunoglobulin A
IgG = Immunoglobulin B
IQR = Interquartile range
LEfse = Linear discriminant analysis effect size
MFI = Median Fluorescence Intensity
PBS = Phosphate Buffered Saline
SIgA = Secretory IgA
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Figure S1. Microbiota composition over time. Heat map depicting the top 20 most abundant species 
among the 25 study participants during menstrual bleeding (1), time point 2 (2) and time point 3 (3). 
Colors reflect the relative abundance.
Figure S2. Correlation between bacteria bound IgA and IgG. Correlation between bacteria bound 
IgA and IgG for all time points. Data visualized as 10log coating index (CI, coating index = percentage 
of immunoglobulin bound bacteria * median fluorescence intensity).
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Figure S3. Immunoglobulin levels in vaginal fluid over time. Unbound immunoglobulins were 
measured during menstrual bleeding (T=1), time point 2 (T=2) and time point 3 (T=3). The level of (A) 
unbound IgA1, (B) unbound IgA2 and (C) unbound SIgA over time. All data visualized as 10log of the 
unbound immunoglobulin concentration corrected for total protein. Red line represents the mean. 
* p < 0.05 ** p < 0.01.
Figure S4. Immunoglobulin levels in vaginal fluid over time. Unbound IgA, IgG, IgA1, IgA2 and SIgA 
in women with L. crispatus dominant vaginal microbiota compared to women having non-L. crispatus 
dominant vaginal microbiota over time. Data visualized as 10log of the unbound immunoglobulin 
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Preterm birth (PTB) is a major driver of perinatal morbidity and mortality, yet its etiology 
is poorly understood. Several risk factors for PTB have been identified, including ethnic 
background. Additionally, immunological factors have been hypothesized to play a role in 
the etiology of preterm birth, but have to date not been well explored. In this study we 
characterize local immune aspects in the vaginal mucosa in early pregnancy and investigate 
their association with spontaneous PTB (sPTB).
We performed a cohort study including 294 nulliparous pregnant women deemed at low 
risk of PTB to assess bacteria bound vaginal immunoglobulin levels with flow cytometry. 
In a nested case-control study we analyzed unbound vaginal immunoglobulins with ELISA 
and a broad variety of inflammatory mediators with a multiplex assay in 19 women with 
spontaneous preterm birth (cases, sPTB, <37 weeks) and 19 women with term birth (controls, 
TB, >37 weeks). We also investigated immunoglobulins that had bound to bacteria, unbound 
immunoglobulins and inflammatory mediators in women of different ethnic backgrounds.
We found no differences in bacteria bound immunoglobulins in women with TB compared 
to sPTB. White European women had increased levels of bacteria bound IgA and a higher 
prevalence of bacterial populations coated with predominantly IgA, while bacterial 
populations coated with predominantly IgG were more prevalent in non-White European 
women. Neither differences in unbound vaginal immunoglobulins nor the majority of 
inflammatory mediators were found when comparing women with TB to sPTB. Only the 
inflammatory antimicrobial peptide S100A8/A9 was significantly decreased in women with 
sPTB. Unbound IgA2 levels were significantly higher in White European women compared to 
non-White European women. Women with TB had a negative association between unbound 
IgA and S100A8/A9, which was not observed in women with sPTB. Ethnic background 
influenced S100A8/A9, IL-1β and IL-6 levels in women with sPTB and TB.
To conclude, neither vaginal unbound nor bacteria bound immunoglobulin levels differed 
in women with sPTB or TB. White European women had increased bacteria bound IgA and 
unbound IgA2 levels unrelated to preterm birth. However, loss of a negative association 
between unbound IgA and S100A8/A9 levels in women with sPTB suggests that immune 
regulation by IgA might be dysregulated, potentially resulting in inflammation and onset 
of preterm labor.
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Introduction
An estimated 15 million babies are born preterm each year [1]. Preterm birth (PTB) is defined 
as any birth before 37 completed weeks of gestation and is a major risk factor for neonatal 
morbidity and mortality [2]. Fortunately significant progress in caregiving to premature infants 
has been made in the last years, however PTB prevalence seem to have risen over the past 
20 years [3]. Currently the prevalence ranges from 5-18% across 184 countries. Sub-Saharan 
Africa and Asia have the highest rates accounting over 60% of the world’s preterm deliveries 
and over 80% of the world’s neonatal deaths related to preterm birth complications [4].
PTB can occur either spontaneously or can be the result of medical intervention because of 
maternal or fetal indication. Conditions like pre-eclampsia or intrauterine growth restriction 
can be a reason for indicated preterm birth (iPTB) [5]. In contrast, spontaneous PTB (sPTB) 
is caused by spontaneous onset of labor or by spontaneous preterm rupture of membranes 
without medical interference. Multiple risk factors, including a short mid-trimester cervical 
length, a low body mass index or abnormal vaginal microbiota can identify women at high risk of 
sPTB [6-8]. Nevertheless, the etiology of sPTB is multifactorial and remains poorly understood.
Vaginal microbiota have a particularly important role during pregnancy as imbalances 
in its composition are associated with complications including PTB [9-11]. In a healthy 
vaginal ecosystem optimal interaction between the host’s immune system and the vaginal 
microbiota is essential. Maintenance of this ecosystem is important for women’s health and 
successful reproduction. Vaginal microbiota is either of low diversity, mainly dominated 
by a single Lactobacillus species, or consists of a diverse range of (facultative) anaerobic 
bacteria [12]. Ethnicity significantly affects the vaginal microbiota composition, being more 
diversified in women with a sub-Saharan African descent and generally Lactobacillus spp. 
dominant in White European women [13]. A higher diversity of the vaginal microbiota is 
related to an increased susceptibly to invading pathogens and subsequent infections [14]. 
Infection and accompanying inflammatory responses are important factors for inducing 
labor in both term and preterm birth [15, 16]. About 40% of preterm births are associated 
with infection [17].
During pregnancy, a special balance between protection against infections and tolerance 
towards the allogenic fetus is required. Immunoglobulins in the mucosal tissue of the 
female genital tract are key mediators of mucosal immunology and are important in the 
fight against infections in the reproductive tract [18]. Immunological factors have been 
hypothesized to play a role in the etiology of preterm birth, but have to date not been well 
explored. Fluctuations in unbound vaginal immunoglobulin levels have been reported along 
the menstrual cycle [19, 20].
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Immunoglobulin (Ig)A is the most predominant antibody produced in the intestinal tract 
and the second most prevalent in the blood. IgA can be either IgA1 or IgA2. IgA1 dominates 
in the circulation, whereas IgA2, due to its proteolytic resistance, is primarily found in the 
colon where a high microbial density is present. [21, 22]. When IgA is transported through 
the epithelial layer towards the mucosal lumen a secretory component (SC) is attached to 
the IgA resulting in the formation of secretory IgA (SIgA). IgA is well known for its beneficial 
and protective functions in the intestinal tract [23]. The role of IgA in maintaining healthy 
intestinal microbiota composition gained more attention over the past years [24]. Deviations 
in immunoglobulin coating of intestinal bacteria have been associated with inflammatory 
bowel diseases [25, 26]. In the female genital tract approximately equal amounts of IgA1 
and IgA2 positive cells are present [27]. Furthermore, in contrast to other mucosal surfaces, 
vaginal IgG levels dominate over IgA [28]. Knowledge regarding immunoglobulins and 
coating of the vaginal microbiota with immunoglobulins, especially during pregnancy, is 
currently lacking.
In this study we investigated whether immunoglobulin levels in vaginal fluid and bound 
on bacteria are diverged in women with spontaneous preterm birth. Furthermore, we 
measured a broad set of inflammatory cytokines and chemokines in vaginal fluid. We aimed 
to get more insight in the vaginal level of inflammatory mediators and immunoglobulins 
in early stage pregnancy (8-12 weeks of gestation) and their association with sPTB within 
different ethnic groups.
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Material and methods
Study design and participants
For this study we used data and vaginal swab material from women included in the 
PROPELLOR cohort. The study protocol and methods are extensively described by Schuster 
et al (submitted). In short, nulliparous women ≥18 years who received antenatal care at 
participating midwifery practices before 24 weeks of gestation, and had a low risk singleton 
pregnancy at their first visit were eligible for inclusion. For this study, all participants of 
whom a vaginal swab and pregnancy outcome was available (no loss to follow-up) were 
included. Nulliparity was defined as never having had a pregnancy progress beyond 16 
weeks of gestation [29]. At the first prenatal visit, usually between 8-12 weeks pregnancy, 
women were approached about study participation by their midwife. Participants collected 
a self-administered vaginal swab (eSwab, Copan Diagnostics Inc., Murietta, CA) at inclusion. 
Swabs were stored at -20⁰C until transfer to the central storage facility at -80°C. Written 
informed consent was obtained from each participant. The study received ethical clearance 
through the local institutional review board (registration number NL43414.018.13).
Definitions
Spontaneous preterm birth (sPTB) was defined as birth following spontaneous onset of labor 
or spontaneous preterm rupture of membranes between 16 and 37 weeks of gestation. 
Medically indicated preterm birth (iPTB) was defined as birth between 16 and 37 weeks 
of gestation after induction of labor or caesarean section for fetal or maternal indications. 
Ethnicity was based on participant self-identification.
Cohort and nested case-control
Profiling of immunoglobulins bound to bacteria was performed for all participants included 
in the cohort study. The other analyses, which included measurements of unbound 
immunoglobulins, human beta defensin-2 level, cytokine and chemokine levels and total 
protein concentration, were performed for the participants included in the nested case-
control study. For the nested case-control study, 19 women with sPTB were matched based 
on their ethnicity and midwifery practice with 19 women with TB. If there was not an 
appropriate control available within the same midwifery practice, a control was chosen 
from a midwifery practice from a similar socio-economic region. Women with unknown 
ethnicities were excluded from analysis when distinctions based on ethnicity were made.
Profiling of immunoglobulins bound to vaginal bacteria
Vaginal swabs were vortexed for 10 seconds to extract bacteria from the swabs. Swab 
material was transferred to a 96-well v-bottom plate, centrifuged for 5 min (4000 rpm, 4°C), 
and blocked with 5% endotoxin free bovine serum albumin (BSA) (Akron Biotech, Boca Raton, 
FL) for 20 min on ice. Bacteria were stained with F(ab’)2 anti-human IgA-AF647 (1:100) and 
F(ab’)2 anti-human IgG-AF488 (1:100) (both Jackson ImmunoResearch, West Grove, PA) for 
30 min on ice. Samples were washed in PBS before flow cytometric analysis (LSRFortessa™ 
52
Chapter 3
X-20, BD Biosciences). For each sample approximately 30.000 events were recorded. 
Flowcytometric data was visualized and analyzed with FlowJo (version 10.6.2). Coating index 
was calculated by multiplying the percentage of bacteria with bound immunoglobulin with 
the median fluorescence intensity (MFI). In order to distinguish multiple IgA/IgG coated 
populations per sample automated contour plotting was performed by FlowJo. We defined 
the bacterial populations within a sample as no coat, coated with predominantly IgA, coated 
with predominantly IgG or non IgA/IgG dominant. The no coat population (bacteria without 
immunoglobulin coating) was defined as having a MFI for IgA and IgG below 100. An IgA/
IgG index was calculated by dividing the IgA MFI with the IgG MFI. An IgA/IgG index <1 was 
considered coated with predominantly IgG, an index between 1-2 was considered non IgA/
IgG dominant and an index >2 was considered coated with predominantly IgA.
Quantification of unbound immunoglobulins in vaginal fluid
Total IgA, IgA1, IgA2, secretory IgA (SIgA) and IgG levels in vaginal swabs were determined by 
enzyme-linked immunosorbent assay (ELISA). In brief, 96-well plates (Maxisorb Nalge Nunc 
International, Rochester, NY) were coated with 50 μL of the capture antibodies goat anti-
human serum IgA (2 μg/ml, Jackson ImmunoResearch, West Grove, PA), mouse anti-human 
Secretory Component (1:10.000, Sigma-Aldrich Corporation, St. Louis, MO) or goat anti-
human IgG (2 μg/ml, Invitrogen, Waltham, MA) in sodium carbonate buffer (15 mM NaCO3, 
pH 9,6) and incubated overnight at 4°C. Nonspecific-binding free sites were blocked with 200 
μl of blocking buffer (0.5% BSA in PBS containing 0.05% Tween20) for 60 min at 37°C. Vaginal 
swabs were thawed and spun (10.000 rpm, 7 min at 4°C) after which the supernatant was 
100-5000 times diluted in blocking buffer and 50 μl was incubated in duplicate for 60 min 
at 37°C. Wells were incubated with 50 μl of detecting antibodies F(ab’)2 goat anti-human 
IgA-HRP (1:2000, Invitrogen, Waltham, MA), mouse anti-human IgA1-biotin (1:1000, Abcam, 
Cambridge, United Kingdom), mouse anti-human IgA2-biotin (1:1000, Abcam, Cambridge, 
United Kingdom) or F(ab’)2 goat anti-human IgG-HRP (1:2000, Invitrogen, Waltham, MA) and 
incubated for 60 min at 37°C. For IgA1 and IgA2 detection, 50 μl of streptavidin poly-HRP 
(100 ng/ml, Sanquin, Amsterdam, The Netherlands) was added for 30 min at 37°C. Presence 
of immunoglobulins was detected with 50 μl/well of 12 ml of 0,1M sodium acetate (NaAc pH 
4) with 3 μl of 30% hydrogen peroxide and 200 μl of 6 mg/ml 3,3’,5,5’-Tetramethylbenzidine 
(TMB). The reaction was stopped with 50 μl of sulfuric acid (10% H2SO4) and absorbance 
was measured with a microplate reader (Bio-Rad, Berkeley, CA) at 450 nm.
Human beta defensin-2 levels in vaginal fluid
Human beta defensin-2 (HBD-2) levels in vaginal fluid were measured using the HBD-2 
ELISA development kit (cat# LS-F31336, LifeSpan BioSciences, Seattle, WA) following the 
manufacturer’s instruction with minor adaptations. In brief, 96-well plates (Maxisorb 
Nalge Nunc) were coated with 50 μL of capture antibody and incubated overnight at room 
temperature after which the wells were blocked with 150 μL of blocking buffer (0.5% BSA in 
PBS containing 0.05% Tween20) for 60 min at room temperature. Vaginal swabs were thawed 
and spun (10.000 rpm, 7 min at 4°C) after which the supernatant was diluted 10 times in 
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blocking buffer and 50 μl was incubated in duplicate for 120 min at room temperature. Wells 
were incubated with 50 μl detection antibody for 60 min at room temperature after which 
50 μl of Avidin-HRP conjugate was added for 30 min. Presence of HBD-2 was detected with 
50 μl/well of 12 ml of 0,1M sodium acetate (NaAc pH 4) with 3 μl of 30% hydrogen peroxide 
and 200 μl of 6 mg/ml 3,3’,5,5’-Tetramethylbenzidine (TMB). The reaction was stopped with 
50 μl of sulfuric acid (10% H2SO4) and absorbance was measured with a microplate reader 
(Bio-Rad) at 450 nm.
Cytokines and chemokines in vaginal fluid
Cytokine and chemokine levels in vaginal fluid were measured with a Human Custom 
ProcartaPlex Multiplex 11-plex assay (PPX-11-MXZTEX4, Thermo Fisher Scientific) using 
a Bio-Plex 200 (Bio-Rad, Hercules, California, USA) according to the manufacturer’s 
instructions. The following mediators were determined in vaginal fluid: Eotaxin (CCL11), 
interleukin 1 alpha (IL-1α), IL-1β, IL-2, IL-6, IL-8 (CXCL8), IL-10, IL-13, macrophage inflammatory 
protein 1β (MIP-1β), regulated on activation, normal T cell expressed and secreted (RANTES) 
and S100A8/A9. Values that were out of range were assigned the upper or lower limit of 
detection for the specific cytokine. Out of range levels of IL-8 and IL-1β were re-evaluated 
using their corresponding Ready-SET-Go! ELISA Kit (Sigma Aldrich) according to the 
manufacturer’s instructions.
Total protein concentration vaginal fluid
Total protein concentration of every vaginal swab sample was determined using PierceTM BCA 
Protein Assay Kits (ThermoFisher, Waltham, MA), according to manufacturer’s protocol. In 
brief, 10 μL of vaginal fluid (7 times diluted in PBS) was added to a 96-well flat bottom plate, 
mixed with 200 μL of BCA working reagent and incubated for 30 min at 37°C. Absorbance 
was measured with a microplate reader (Bio-Rad) at 562 nm when the plate was cooled to 
room temperature.
To correct for inter participant variation, unbound immunoglobulin and cytokine/chemokine 
levels (defined with ELISA and Luminex) were corrected for total protein content by dividing 
the measured mediators by total protein level.
Statistical analysis
Data were log-transformed. Nonetheless, this did not resulted in normally distributed data 
for all numerical variables. Therefore, non-parametric statistical tests were used for all 
analyses. The Mann-Whitney U test was used for comparing coating index between two 
groups and the Kruskall Wallis test for comparisons between more groups. The Chi-square 
test was used for categorical variables. Analysis of the samples was performed based on 
delivery (term birth >37 weeks of gestation (TB), medically indicated preterm birth <37 
weeks of gestation (iPTB) and spontaneous preterm birth <37 weeks of gestation (sPTB)) 
or ethnicity (White European and non-White European). If ethnicity was unknown, we 
disregarded these samples from analyses in which ethnicity was the primary determinant. 
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The samples were included in all other analyses. Nested case-control comparisons were 
analyzed using the Wilcoxon matched-pairs signed rank test. Linear regression was applied 
to investigate the association between unbound immunoglobulins (independent variable) 
and cytokines/chemokines (dependent variable). Correlations were analyzed using the 
Spearman’s rank correlation test. Statistical analyses were performed using IBM SPSS 
statistics (version 26). Data were visualized using GraphPad Prism (version 8.2.1.). A p value 
of ≤ 0.05 was considered statistically significant.
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For this study, 294 women were included. The mean age of the women included in this 
study was 28.6 years. The majority of the participants included were women with a White 
European descent (64.3%). Other ethnicities (African, Indian, Turkish, Middle Eastern, Asian, 
Mixed and other non-Western) were also represented (Table 1). Sixty-five percent of the 
women had a normal body mass index (BMI) between 18.5 and 25 and less than 4% of 
the women smoked during pregnancy. Almost 90% of the women gave birth >37 weeks of 
gestation (TB), 23 women (7.8%) had sPTB, 8 women (2.7%) had iPTB (including 1 stillbirth 
and 1 pregnancy termination due to congenital abnormalities) and 1 woman suffered a 
miscarriage. Among women of White European ethnicity 4% had sPTB, while 16% of the 
non-White European women had sPTB (figure S1).
Bacteria bound immunoglobulins
We compared bacteria bound immunoglobulin levels displayed as coating index of IgA and 
IgG on vaginal microbiota of women with TB (n=262) and women with iPTB (n=8) or sPTB 
(n=23) (figure 1A and B). Median bacteria bound IgA and IgG levels did not differ between 
the groups. The level of bacteria bound immunoglobulins showed large variation within the 
groups. Bacteria bound levels of IgA significantly positively correlated with bacteria bound 
IgG levels (p<0.001, figure 1C).
Figure 1. Immunoglobulins bound to vaginal bacteria (A) Bacteria bound IgA and (B) IgG in women 




Table 1. Participant characteristics
Participant characteristics, total = 294 n (%) missing
Maternal age in years at inclusion, mean (SD) 28.6 (4.1) 0
<25 44 (15.0)
25 - 29 122 (41.5)
30 - 34 108 (36.7)
>35 20 (6.8)






Middle Eastern 2 (0.7)
Asian 4 (1.4)
Mixed 15 (5.1)
Other non-Western 10 (3.4)
BMI (kg/m2), mean (SD) 2 (0.7)
Underweight (<18.5) 16 (5.4)
Normal (18.5 - 25) 191 (65.0)




Quit preconception 10 (3.4)
Quit during pregnancy 48 (16.3)





Miscarriage <16 weeks 1 (0.3)
Spontaneous preterm delivery (16 - 37 weeks) 23 (7.8)
Indicated preterm delivery (16 - 37 weeks) 8 (2.7)
Term delivery 262 (89.1)
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Women of White European descent had significantly increased levels of bacteria bound IgA 
compared to women with a non-White European origin (figure 2A). No differences in bacteria 
bound IgG levels were present between White European and non-White European women (figure 
2B). Analysis of immunoglobulin coated vaginal bacterial populations revealed that bacterial 
populations coated with predominantly IgA were more prevalent in White European women 
compared to non-White European women (25% and 12% respectively, p=0.027). In contrast, non-
White European women had higher prevalence of bacterial populations coated with predominantly 
IgG compared to White European women (51% and 31% respectively, p=0.004) (figure 2C).
We further investigated bacteria bound immunoglobulin levels of White European and non-
White European women and found no differences in bacteria bound IgA between women 
with TB, iPTB or sPTB (figure 2D). No differences in bacteria bound IgG were found within 
White European or non-White European women with TB, iPTB or sPTB (figure 2E).
Figure 2. Increased bacteria bound IgA levels in White European women. (A) Bacteria bound 
IgA and (B) IgG in White European and non-White European women. (C) Abundancy of different 
immunoglobulin bound bacterial populations in (left) White European and (right) non-White European 
women depicted as percentages. (D) Bacteria bound IgA and (E) IgG in White European and non-White 
European women divided in TB, iPTB or sPTB. All data visualized as 10log of the coating index. Black 




Next, the vaginal fluid of women with sPTB was compared to TB using a nested-case control 
study in which 19 women with sPTB were matched based on ethnicity and midwifery 
practice with 19 women with TB. Each group was composed of 8 White European women, 
8 African women, 1 Indian women, 1 woman with another non-western background and 1 
woman with an unknown ethnicity. Levels of IgA, IgA1, IgA2, SIgA and IgG in vaginal fluid did 
not differ between women with sPTB compared to those with TB. Levels of SIgA tended to 
be higher in women with sPTB, but this difference was not statistically significant (p=0.072, 
figure 3A). The level of IgA2 was significant lower in non-White European women compared 
to White European women (p=0.033). Similar trends, although not significant, were seen 
for IgA, IgA1 and SIgA (figure 3B).
Decreased levels of S100A8/A9 in vaginal fluid of women with sPTB
We explored levels of inflammatory mediators in vaginal fluid of women with sPTB and their 
matched counterparts with TB. Levels of inflammatory protein S100A8/A9 were significantly 
lower in vaginal fluid of women with sPTB (p=0.022, figure 4A). No differences in vaginal 
fluid levels of eotaxin, human beta defensin-2, interleukin (IL)-1α, IL-1β, IL-2, IL-6, IL-8, IL-10, 
IL-13, macrophage inflammatory protein (Mip)-1β and RANTES were found between women 
with TB or sPTB (figure S2). Furthermore, no differences were detected when comparing 
White European women to non-White European women (figure S3).
Positive associations between unbound IgA and IgG levels with IL-1β, IL-6, IL-8, Mip-1β 
and RANTES were found using linear regression (figure S4). Only S100A8/A9 levels were 
negatively associated with unbound IgA and IgG levels (figure 4B). The remaining mediators 
did not have an association with unbound IgA and IgG levels (data not shown). The negative 
association between S100A8/A9 and unbound IgG levels was statistically significant 
(p=0.034) (figure 4B, right). Furthermore, a significant negative association between 
unbound IgA and S100A8/A9 was present in women with TB (p=0.018), but not in women 
with sPTB (p=0.677) (figure 4C). Although not statistically significant, a similar negative 
association was found between bacteria bound IgA levels and S100A8/A9 in women with 
TB, but not in women with sPTB (figure S5). In contrast to IgA, a statistically significant 
negative association (p=0.007) between unbound IgG with S100A8/A9 levels was found in 
women with sPTB and not in women with TB (figure 4D).
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Figure 3. Unbound immunoglobulin levels. Level of unbound IgA, IgA1, IgA2, SIgA and IgG in vaginal 
fluid of (A) women with TB or sPTB or (B) White European or non-White European women in the 
nested case control study. All data visualized as 10log of the unbound immunoglobulin concentration 
corrected for total protein. Black line represents the median. *p<0.05.
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Figure 4. Decreased levels of S100A8/A9 in vaginal fluid of sPTB women. (A) Level of S100A8/A9 in 
vaginal fluid of women with TB and sPTB. (B) Linear regression of S100A8/A9 and (left) unbound IgA 
or (right) unbound IgG in TB and sPTB. (C) Linear regression of unbound IgA and S100A8/A9 levels 
in (left) TB women or (right) sPTB women. (D) Linear regression of unbound IgG and S100A8/A9 
levels in (left) TB women or (right) sPTB women. All data of the nested case control study. *p<0.05.
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Inflammatory mediators in vaginal fluid differ between White European 
and non-White European women with TB and sPTB
We further investigated levels of inflammatory mediators present in the vaginal fluid 
in relation to ethnicity and pregnancy outcome. S100A8/A9 was significantly lower in 
non-White European women with sPTB compared to TB (p=0.007, figure 5A). IL-1β was 
significantly higher in non-White European women with sPTB compared to TB (p=0.047, 
figure 5B). A similar trend was observed for IL-6, although this was not significant (figure 5C). 
In White European women, IL-6 levels were significantly lower in those with sPTB compared 
to TB (p=0.012). When comparing non-White European women to White European with 
sPTB, IL-6 levels were higher in non-White European compared to White European (p=0.041). 
IL-6 levels were significantly decreased in non-White European compared to White European 
women with TB (p=0.041).
Figure 5. (A) S100A8/A9, (B) IL-1β and (C) IL-6 levels in White and non-White European women divided 




In this study we investigated vaginal immune mediators, including the level of local 
immunoglobulins, in women who suffer spontaneous preterm birth among different ethnic 
groups. Our results demonstrate that local unbound and bacteria bound immunoglobulin 
levels are not associated with sPTB. We discovered that IgA2 and bacteria bound IgA levels 
are affected by ethnicity. Furthermore, in women with TB a significant negative association 
between unbound IgA and S100A8/A9 was present, which was lacking in women with sPTB.
Immunoglobulins have important roles in protecting the host against infections and 
maintaining homeostatic conditions [30]. It was demonstrated that the level of cervical 
IgA did not differ between women with threatened preterm birth, compared to healthy 
pregnant women [31]. In line with these results we found no differences between unbound 
levels of immunoglobulins between women with TB or sPTB. Interestingly, cervical IgA 
levels were lower in women with pathological vaginal bacteria and subsequent PTB [31]. 
When ethnic distinction was made we found significantly lower IgA2 and vaginal bacteria 
bound IgA levels in non-White European women. Furthermore, we observed that White 
European women tend to have increased proportions of bacterial populations coated with 
predominantly IgA while non-White European women have an increased prevalence of 
bacterial populations coated with predominantly IgG. These results imply that ethnicity is 
associated with immunoglobulin levels and binding of immunoglobulins to bacteria in the 
vaginal mucosa. In serum, differential immunoglobulin levels between ethnicity have been 
identified in studies performed several decades ago. Increased levels of IgG and IgA have 
been found in Black compared to White populations [32-34]. The underlying mechanisms 
in different immunoglobulin levels between ethnicity has been understudied and remains 
open for further investigation both in the circulation and at mucosal surfaces. It furthermore 
remains to be elucidated how unbound immunoglobulin levels relate to bacteria bound 
immunoglobulins, whether they affect each other and what their potential role is in PTB.
In the intestinal tract it has been demonstrated that the intestinal microbiota can shape IgA 
levels and vice versa IgA can modulate the maintenance of a healthy microbiota composition 
[23]. We hypothesize that a similar regulation can take place in the vaginal mucosa. The 
diverging vaginal immunoglobulin levels between White European women and non-White 
European women can potentially be regulated by the vaginal microbiota composition. A 
diversified vaginal microbiota composition, generally low in Lactobacillus spp., is more 
prevalent among healthy Black women, while healthy White European women tend to have 
increased proportions of Lactobacillus spp. [13, 35]. Black women are furthermore more 
often affected by sexual transmitted infections compared to White women and a decrease in 
Lactobacilli (rather than an increase in other bacterial species) is associated with an elevated 
risk of preterm birth [36, 37]. We found an increased PTB rate among non-White European 
women compared to White European women which is in line with previous studies [38-41].
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Furthermore, we demonstrated recently that bacteria bound IgA levels were increased in 
women with L. crispatus dominant vaginal microbiota composition compared to women 
with non-L. crispatus dominant vaginal microbiota [20]. L. crispatus dominant vaginal 
microbiota composition is found in 90% of White women, while this is less prevalent in other 
ethnic groups like Asian, Hispanic or Black women [14]. Although the vaginal microbiota 
composition was not investigated in this study, we anticipate that differences observed in 
unbound and bacteria bound IgA levels between ethnicities can be attributed to differential 
vaginal microbiota composition in White European and non-White European women. A 
potential lower abundancy of Lactobacillus spp. along with decreased unbound IgA2 and 
bacteria bound IgA levels in non-White European women could therefore account for the 
elevated prevalence of preterm birth.
We investigated several inflammatory mediators, including anti-microbial peptide S100A8/
A9, which stimulates leukocyte recruitment and induces cytokine release [42]. Increased 
levels of S100A8/A9 in serum during early pregnancy were associated with loss of pregnancy 
[43]. In cervicovaginal fluid S100A8 was found to be at least two times increased in women 
with sPTB compared to women with TB [44]. In contrast we found lower levels of S100A8/A9 
in vaginal fluid of women with sPTB compared to women with TB in this study. Interestingly, 
vaginal S100A8/A9 negatively correlated with unbound IgA in women with TB, but not 
in women with sPTB. As IgA is known to be a regulator of mucosal immunity, one can 
hypothesize that mucosal IgA regulates S100A8/A9 levels in order to maintain homeostatic 
conditions as observed in women with TB. Loss of this regulation might be harmful and 
a potential trigger for sPTB as immune balance is lost. This hypothesis is supported by 
previous findings which demonstrate that SIgA exerts a powerful anti-inflammatory effect 
by binding to specific receptors present on dendritic cells thereby promoting the release 
of the anti-inflammatory cytokine IL-10 and inhibiting pro-inflammatory cytokine release 
[45]. Similar, when SIgA was bound to Shigella flexneri IL-10 levels were maintained while 
pro-inflammatory TNF-α, IL-1β and IFN-γ levels were downregulated in intestinal tissue [46].
Recent studies showed increased levels of pro-inflammatory mediators including IL-1β, 
IL-6, eotaxin, Mip-1β and RANTES in vaginal fluid of women with sPTB compared to women 
with TB [11, 47, 48]. Conflicting, decreased levels of IL-8 and IL-1β have been found in 
cervicovaginal fluid (collected between 22-24 weeks of gestation) of high PTB risk women 
with PTB compared to high risk PTB women with TB [49]. We found no differences in these 
inflammatory mediators in women with sPTB compared to TB. One possible explanation for 
the discrepancies between studies might be the collection time point of the (cervico)vaginal 
fluid. In this study material was collected early in pregnancy (8-12 weeks), while other studies 
collected samples later in pregnancy (>22 weeks). It might be that inflammatory markers are 
increasing just before delivery and clear deviations are not found yet early in pregnancy. 
It was shown that IL-1β levels in cervicovaginal fluid of women with sPTB increased during 
pregnancy, while this was not the case for women with TB [48]. Another explanation for 
the observed discrepancies might be that cytokine levels are either corrected for the total 
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protein content of the sample or not. In this study we standardized cytokine and chemokine 
levels by correcting for total protein content. A recent study demonstrated increased levels 
of proteins (mainly involved in the regulation of cell membrane physiology) in cervicovaginal 
fluid of women with sPTB using shotgun proteomics [44]. Similar we found significantly 
higher total protein content in the vaginal swabs of women with sPTB compared to women 
with TB (data not shown). Furthermore, women included in this study did not have an 
increased risk of PTB, which could also account for different outcomes between studies.
The association between inflammatory mediators and PTB seems to be influenced by 
ethnicity as well. In amniotic fluid of Black American women with PTB, IL-1β levels were 
increased compared to them with TB [50]. Levels of IL-6, IL-8 and TNF-α were increased in 
amniotic fluid of White women with PTB compared to TB [50, 51]. It was demonstrated that 
bacteria isolated from amniotic fluid of women with PTB are pathogenic species found in 
the lower genital tract. Presence of a greater spectrum of bacteria in the amniotic fluid was 
associated with sPTB [52]. When we subdivided our study participants based on ethnicity, 
we found that non-White European women with sPTB had increased vaginal levels of 
IL-1β and IL-6, and decreased S100A8/A9 levels compared to them with TB. However, the 
increased levels of IL-1β present in vaginal fluid of non-White European women with sPTB 
reached similar absolute levels as found in vaginal fluid of White European women with 
either TB or sPTB. Surprisingly, in White European women IL-6 levels were significantly 
increased in TB. Vaginal cytokine levels in White and Black women have been reported 
to differ and to be influenced by vaginal microbiota composition [11, 53]. Pregnant White 
women with a healthy vaginal microbiota composition have increased levels of IL-1α, IL-6 
and IL-10 compared to pregnant Black women with a healthy vaginal microbiota composition 
[54]. Furthermore the level of IL-1α was increased in pregnant Black women with bacterial 
vaginosis compared to pregnant Black women with a healthy vaginal microbiota composition 
[54]. The concentration of IL-1β, IL-6 and IL-8 found in the vaginal fluid of women with a 
healthy vaginal microbiota composition enhanced the colonization of Lactobacillus spp. and 
inhibited growth of opportunistic E. coli and S. aureus. While women with bacterial vaginosis 
had increased vaginal levels of IL-1β, IL-6 and IL-8 which led to inhibition of Lactobacilli growth 
[55]. These results underline the importance of the regulation and interaction between 
the vaginal microbiota and the host’s immune system, which is influenced by ethnicity.
We hypothesize that non-White European women have a lower abundancy of vaginal 
Lactobacilli species. L. crispatus dominant vaginal microbiota are highly coated with IgA and 
are suggested to maintain vaginal (immune) homeostasis [20]. A decrease of bacterial IgA 
coating in diversified vaginal microbiota in non-White European women could be indicative 
for loss of immune homeostasis potentially resulting in PTB. A major drawback of this study 
is that the microbiota composition of the vaginal samples is currently unknown. Therefore, 
we cannot draw any conclusions regarding microbiota composition and its relation to 
unbound and bacteria bound immunoglobulin levels to date. Our aim is to define the 
vaginal microbiota composition in the near future to investigate the effect of host-microbe 
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interactions more specifically and to confirm assumptions in this discussion. Future studies 
conducted in the field should consider the source of samples, timing of sample collection 




Figure S1. Percentages of TB, PTB and sPTB in White European and non-White European women.
Figure S2. Normalized cytokine and chemokine levels in vaginal fluid of women who had TB or sPTB.
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Figure S3. Normalized cytokine and chemokine levels in vaginal fluid of White European (WE) or 
non-White European (non-WE) women.
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Figure S4. Positive correlations between the level of IgA (left column) and IgG (right column) with the 
levels of IL-1β, IL-6, IL-8, Mip-1β and RANTES in vaginal fluid of TB and sPTB women.
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Figure S5. Linear regression of S100A8/A9 and bacteria bound IgA in TB and sPTB women (left), TB 
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Effector T cell development is directly driven by antigen presenting cells (APCs), in 
particular by antigen-primed dendritic cells (DCs). Depending on the pathogenic stimulus 
and the microenvironment, DCs induce proliferation and polarization of naive CD4+ T 
cells into different effector subsets, such as Th1, Th2, Th17, or regulatory T cells. During 
inflammation, DCs are found in close proximity to other innate immune cells including all 
granulocyte subtypes, which potentially influence the immunomodulatory capacities of 
DCs. Neutrophils are rapidly recruited into infected tissues where their main function is to 
eliminate invading pathogens. Although neutrophils have always been considered essential 
in innate immunity, their ability to influence the development of adaptive immunity has 
long been overlooked. This view is now changing as multiple studies showed significant 
modulating effects of neutrophils on key players of adaptive immunity, including DCs 
and lymphocytes. Neutrophils regulate recruitment and activation of DCs through the 
release of mediators or via direct cell-cell contact, thereby influencing antigen-specific T 
cell responses. In this review, we will summarize the current knowledge on the impact of 
neutrophils on DC functioning and the subsequent putative consequences of this cross-talk 
on T cell proliferation and polarization. Together, this overview underscores the importance 
of neutrophil-DC communication to establish optimal immune responses.
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Introduction
Dendritic cells (DCs) are specialized antigen presenting cells (APCs) that play a key role in 
the initiation of antigen-specific immune responses, thereby forming an important link 
between innate and adaptive immunity [1, 2]. Multiple DC subsets have been described in 
both men and mice. In humans, plasmacytoid DCs (pDCs; CD11c-CD123+) and distinct subsets 
of conventional DCs (cDCs; CD11c+CD123-) are identified, like CD1c+, cross-presenting CD141+, 
CD1c-CD141-, and recently described siglec6+ DCs [3, 4]. In addition, specific DC subsets are 
present in various tissues, such as Langerhans cells (LCs) in the epidermis, CD16+LacNAc+ 
(slan) DCs in the dermis and blood, and CD103+ DCs at mucosal areas [5]. At inflammatory 
sites, monocyte-derived DCs (moDCs) may be present [6-8]. Although similar subsets exist in 
mice, discriminatory markers used to define human DC subsets are not found on murine DC 
subsets and vice versa, complicating extrapolation of data obtained in murine (DC) models 
to humans. Subset similarities have been described however, e.g. human CD1c+ cDCs are 
equivalent to murine CD11b cDCs, and human CD141+ cDCs are identified in mice as CD8+/
CD103+ cDC [9, 10]. The distinct DC populations differ in their ontogeny, localization, and 
function, but are not further outlined in detail here (extensively reviewed in [3, 9, 11, 12]).
In immature state, DCs serve as sentinels for invading pathogens [1]. After recognition 
and uptake of pathogens, DCs migrate to draining lymph nodes, where pathogenic 
antigens are processed and DCs will mature (characterized by the upregulation of major 
histocompatibility complex (MHC) molecules and costimulatory molecules (e.g. CD80 and 
CD86)). Mature DCs have the ultimate capacity to activate antigen-specific naïve T cells 
in the draining lymph nodes in order to initiate adequate adaptive immune responses [1]. 
Importantly, the type of DC-activating stimulus is decisive for the polarization of naïve CD4+ 
helper T (Th) cells into a final effector phenotype. Different Th cell subsets are involved in 
the clearance of selective sets of pathogenic microorganisms (or are associated with distinct 
chronic inflammatory disorders). For example, Th1 cells develop in response to intracellular 
pathogens (like viruses and mycobacteria), whereas extracellular pathogens mostly initiate 
DC-driven Th2 (e.g. parasites) or Th17 cell development (e.g. bacteria and fungi) [13]. In 
contrast, regulatory T cells (Tregs) suppress unnecessary persistent immune activation or 
pathogen-specific immune responses once the pathogen is cleared [14].
Interestingly, in recent years it is increasingly recognized that the presence of accessory 
cells facilitates DC-driven induction of early and appropriate adaptive immune responses. 
Neutrophils are important examples of such accessory cells that can significantly influence 
DC function. Generally, neutrophils have long been exclusively considered important 
players during innate immune responses, but recently their potential role in contributing 
to adaptive immune responses has been acknowledged [15, 16]. Neutrophils are the most 
abundant circulating granulocytes and have a relatively short life-span of up to several 
days. However, prolonged life-span is observed when they are rapidly recruited to sites of 
infection [17]. They have been shown to migrate to peripheral and lymphoid tissues during 
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inflammation [18, 19]. This tissue distribution enables neutrophils to encounter, interact, 
and communicate with DCs, and in such way act as important initiators as well as regulators 
of innate and adaptive immune responses [17, 20]. Here we will review how neutrophils 
contribute to the recruitment, maturation, and/or the modulation of DCs, and subsequent 
induction of adaptive immune responses.
Neutrophils
Neutrophils are the most abundant type of leukocytes, comprising 50-70% of the total 
circulating human white blood cell count [21, 22]. They are continuously generated in the 
bone marrow, achieving a production of 1 to 2 x 1011 cells per day in an adult human [23]. 
Mature neutrophils, characterized by a segmented nucleus and a cytoplasm enriched with 
secretory granules and vesicles, are released from the bone marrow into the blood where 
they are readily available for rapid recruitment into peripheral and lymphoid tissues in case 
of infection [19, 24, 25]. Traditionally, neutrophils have been considered as short-lived cells 
with a life-span of 8 hours in the human circulation. This dogma was challenged a few years 
ago [26], as labeling of human neutrophils with deuterium-oxide in vivo supported that 
neutrophils may have a half-life about 5 days [17, 21, 26]. Additionally, a longer life-span 
was observed at sites of inflammation where neutrophils get activated by cytokines and 
bacterial components, which delays apoptosis [27]. This ensures the prolonged presence 
of activated neutrophils at inflammatory sites in order to perform complex activities to 
eliminate pathogens and to contribute to resolution of infection [21].
Neutrophils can phagocytose and kill intracellular pathogens, mediated through granular 
antimicrobial proteins like myeloperoxidase (MPO), neutrophil elastase (NE), cathepsin-G 
and lactoferrin, and oxidative stress [21, 28]. Moreover, degranulation of neutrophils 
facilitates extracellular killing of nearby pathogens, through the release of granular 
antimicrobial proteins into the environment [21, 22]. A more recently discovered mechanism 
to trap and kill pathogens is the formation of neutrophil extracellular traps (NETs), which 
exist of DNA to which histones and granular proteins are attached [29]. Unfortunately, 
NETs can also cause major tissue damage [21], and they have been associated with the 
pathogenesis of a wide range of non-infectious pathophysiological conditions, like 
autoimmune diseases (rheumatoid arthritis, systemic lupus erythematosus, diabetes), 
vascular diseases (atherosclerosis, vasculitis), cancer, and acute injuries [30-34].
Migration of DCs
In addition to this first line of innate immune defense, activated neutrophils have been 
shown to release chemotactic factors which aid in the migration of both innate and adaptive 
immune cells, including DCs, to sites of infection and nearby lymph nodes (figure 1) [35-38]. 
Neutrophil-derived CCL3, CCL4, CCL5 and CCL20 induced the migration of murine bone 
marrow-derived DCs (BMDCs) in vitro [36, 37]. Correspondingly, infection with Leishmania 
major (L. major) led to a neutrophil-derived CCL3-dependent recruitment of moDCs, 
dermal DCs, and LC to the dermis of Ccl3-/- mice [36]. Other murine in vivo studies further 
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implicated a role for neutrophils in DC migration upon infection with pathogens [35, 38, 
39]. Both M. tuberculosis and A. fumigatus enhanced migration of CD11b+CD11c+ DCs from 
lungs to mediastinal lymph nodes in wild type (WT) mice as compared to mice that had 
been treated with neutrophil-depleting antibodies anti-Gr-1 or anti-Ly6G [35, 38], while 
Escherichia coli (E. coli)-infected neutrophils induced migration of dermal DCs containing 
neutrophil-derived material from the footpad to the draining lymph nodes [39]. Additionally, 
in a contact hypersensitivity model, CD11c+ DC migration from the skin to draining lymph 
nodes was enhanced in WT mice as compared to neutrophil-deficient (Mcl-1ΔMyelo) mice 
during the initiation of inflammation [37]. Surprisingly, infection with Leishmania Mexicana 
in the dermis of WT mice impaired the recruitment of CD45+CD11c+Ly6C+CD11b+ DC to 
the site of infection and subsequent draining lymph node, while DC recruitment was not 
abrogated in neutrophil-depleted mice (treated with anti-Ly6G antibodies) [40], indicating 
that in case of Leishmania Mexicana infection neutrophils hamper DC migration. Lactoferrin 
may be one of the mediators responsible for this inhibitory effect, since both murine and 
human studies demonstrated inhibited migration to, and reduced accumulation of DCs in 
the draining lymph nodes after injection of lactoferrin in the skin [41-43]. Additionally, MPO 
was shown to inhibit CCR7 expression on DCs [44].
DC modulation and T cell polarization
Neutrophils may not only affect the recruitment and migration of DCs but also their 
capacity to activate and polarize T cells. Both in vitro and in vivo studies have implicated 
that neutrophils and DCs cluster together, which depend on various molecules, 
including the C-type lectin DC-SIGN (CD209) and ICAM-1 on DCs, and neutrophil-specific 
glycosylated Mac-1 (CD11b/CD18), and CEACAM1 on neutrophils [25, 45-49]. Resting and 
Lipopolysaccharide (LPS)-, tumor necrosis factor (TNF)-α-, or N-Formylmethionyl-leucyl-
phenylalanine (fMLP)-activated human neutrophils interacted and clustered with moDCs 
either in a DC-SIGN-dependent [46] or -independent manner [50]. Moreover, neutrophils 
enhanced maturation of moDCs and slanDCs which was partially dependent on CD18, as 
well was survival and interleukin (IL)-12 production by slanDCs [45, 48, 49]. DC-SIGN was 
essential for A. fumigatus-induced maturation of lung CD11b+ DCs (upregulation of CD86, 
CD40 and MHC-II). Maturation was reduced when neutrophils had been depleted using 
anti-Gr-1 antibodies [35]. Moreover, in vivo ovalbumin (OVA)/LPS administration in the skin 
induced neutrophil infiltration of skin draining lymph nodes in C57BL/6 mice resulting in 
close interactions with CD11c+ DCs [44].
Human moDCs and murine BMDCs that had been co-cultured with LPS-, E. coli- Toxoplasma 
gondii-, M. tuberculosis-, or Bacillus Calmette-Guérin (BCG) vaccine-stimulated neutrophils 
showed an upregulated expression of CD80, CD83, CD86 and HLA-DR, reduced IL-10 release, 
and increased IL-12 production. Moreover, enhanced capacity to induce DC dependent 
CD8+ T cell proliferation and concomitant T cell-derived interferon (IFN)-γ production was 
promoted by BCG-, Candida albicans-, LPS-, E. coli-, Toxoplasma gondii- or M. tuberculosis-
activated neutrophils [39, 45, 50-53]. It was shown that the presence of neutrophil-derived 
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TNF-α was an essential driver for upregulation of MHC-II and costimulatory molecules on 
murine DCs [50, 51], but direct cell-cell contact was crucial for Th1 polarization [38, 53].
It has been demonstrated that both human and murine DCs have the capacity to internalize 
neutrophils. In vitro, internalization of human neutrophils by moDCs depended partially on 
CD18 [39] and in vivo studies demonstrated that injection of OVA-activated neutrophils into 
the footpad of C57BL/6 mice resulted in OT-I T cell proliferation in the skin draining lymph 
node, [39] suggesting uptake of neutrophil-derived antigens into DCs. Similarly, L. major-
infected neutrophils that had been injected in ears of WT C57BL/6 mice were internalized 
by DCs. In contrast however, this resulted in an unexpected decrease of CD40, CD86 and 
MHC-II on DCs, and reduced T cell proliferation and Th1 polarization [54], suggesting that 
L. major, when internalized in neutrophils, induced immune suppression.
Effect of NETs and soluble mediators on DC modulation and T cell polarization
Activated neutrophils can release multiple antimicrobial mediators from their granules that 
have been shown to modulate DC activation, like MPO, cathepsin-G, neutrophil elastase (NE), 
LL-37, and lactoferrin (figure 1) [55-58]. These antimicrobial peptides can either be released 
as soluble molecules via degranulation or bound to neutrophil extracellular traps (NETs). 
The exact role of NETs in modulating DCs is still unclear, and conflicting results have been 
reported. Short term (30 min) exposure to NETs decreased the expression of HLA-DR, CD40, 
CD80 and CD86 on, and the LPS-induced production of TNF-α, IL-6, IL-8, IL-10, IL-12, and IL-23 
by human moDC in one study [59]. In contrast, NETs induced CD80 and CD86 expression on 
human moDCs in another study [60]. Although unclear, this discrepancy may be explained 
by the differences in NETs introduced by variations in the methods used for their release 
and isolation. Furthermore, CD4+ T cell proliferation and IFN-γ, IL-17 and IL-10 production by 
T cells was partially inhibited by NET-stimulated moDCs. However, IL-5 and IL-13 production 
increased, suggesting that NETs block the onset of Th1/Th17 responses (as established by 
LPS), and favor Th2 induction instead [59]. Neutrophil DNA mixed with secretory leukocyte 
protease inhibitor and NE [61], LL-37 [57] or cathepsin-G [58] (all resembling NET-like 
structures) induced type 1 interferon release by human pDCs via Toll-like receptor (TLR)-
9 activation [57]. Additionally, neutrophils from systemic lupus erythematosus patients 
containing high levels of LL-37 released more NETs after activation, resulting in a higher 
potential to trigger pDC activation (CD80, CD83 and CD86) and release of IFN-α, TNF-α, and 
IL-6 by pDCs [57, 62, 63]. Likewise, results regarding the modulatory effect of lactoferrin on 
DCs are contradicting as well. Maturation of human moDCs and CD1c+ DCs (upregulation 
of CD80, CD83, CD86 and HLA-DR) [55, 64], release of IL-6, TNF-α, IL-1β and IL-12(p70), and 
proliferation of T cells as well as Th1 induction by DCs was induced by lactoferrin [55, 65]. 
However, unstimulated and BCG vaccine-stimulated murine BMDCs released IL-6 and IL-
12(p40), which was reduced when lactoferrin was present [65], suggesting that lactoferrin 
has the capacity to suppress the primary induced Th1 polarization. LL-37 changed the in 
vitro morphology of immature human moDCs (bigger, adherent, and more dendrites), 
enhanced their endocytic capacity, induced expression of CD86, CD11c, CD11b and CD18, 
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but decreased the expression of DC-SIGN, CD16 and CD32, and thereby abrogating receptor-
mediated phagocytic capacity Furthermore, LL-37-stimulated mature moDCs produced high 
levels of IL-12 and IL-6, and induced IFN-γ production by T cells [56]. In contrast, neutrophil-
derived MPO interacted with CD11c+ DCs in draining inguinal lymph nodes resulting in 
reduced CD4+ T cells activity and response to antigens. Additionally, enzymatically active 
MPO decreased maturation of murine BMDCs and human moDCs (downregulated CD86 
and HLA-DR expression), and reduced IL-12 production by both DC subsets in vitro [44]. 
However, in the presence of an anti-Mac-1 antibody, IL-12 production increased, indicating 
an modulatory role of MPO on DCs via Mac-1 [44]. Human moDCs treated with NE produced 
high levels of transforming growth factor (TGF)-β, and favored the generation of CD4+FoxP3+ 
T cells [66, 67].
DC modulation by neutrophil extracellular vesicles
Next to soluble mediators and NETs, neutrophils also rapidly release membrane vesicles 
after activation, also referred to as ectosomes, or extracellular vesicles (EVs) [68]. EVs are 
submicron vesicles that are composed of a selective set of lipids, proteins, and nucleic 
acids, and play a role in intercellular communication [69]. Neutrophil-derived EVs were 
shown to contain a repertoire of different (phospo)lipids and proteins, including the ‘eat me’ 
signal phosphatidylserine, MPO, lactoferrin and NE [70, 71]. EVs released by fMLP-activated 
neutrophils modulated morphology and endocytic capacity of human moDCs [72]. Like EVs, 
apoptotic and necrotic neutrophils expose phosphatidylserine on the outer membranes [45, 
53], and thereby partially suppressed human moDC and pDC maturation (downregulated 
CD40, CD80, CD83, CD86 and HLA-DR) [62, 72, 73]. In the presence of annexin V (competitive 
binding for phosphatidylserine), moDC maturation was enhanced, supporting that 
phosphatidylserine was essential for decreased maturation of moDCs [72]. Production 
of IL-10, IL-12, TNF-α, IL-8 and IFN-γ by moDCs was significantly reduced in the presence 
of fMLP-activated neutrophil-derived EVs, apoptotic or necrotic neutrophils, while TGF-β 
release was induced by fMLP-activated neutrophil-derived EVs [72, 73]. In either condition, 
subsequent DC-induced lymphocyte proliferation was significantly diminished [72, 73].
Figure 1. Schematic representation of neutrophils, their major pre-formed mediators, cellular markers, 
and putative influence on DCs. Adhesion molecules and mediators involved in the communication 
with DCs, and modulation of DC migration, maturation, and cytokine/chemokine release are indicated. 
Depending on the mode of activation neutrophils can influence DC-driven development of Th1, Th2, 




To summarize, neutrophils have multiple immunomodulatory effects on DC function that 
may be mediated via cell-cell contact, or the release of soluble factors, NETs, and EVs 
(figure 1). Depending on the activation trigger, neutrophils can either induce or inhibit DC 
maturation and activation, and modulate their specific T cell polarizing capacity. Research 
performed over the last decades emphasizes the important and complex role of neutrophils 
in the onset and efficient regulation of adaptive immunity.
It should be noted that most of the described data were obtained using in vitro or mouse 
model systems. Confirmation in human (model) systems is required, because of known 
differences in DC subsets and neutrophils between mice and men. For example, some 
murine DC subsets are thought to be orthologous with human DCs, while other subsets 
are considered phenotypically and functionally distinct. Moreover, neutrophil numbers and 
tissue distribution can significantly differ, and mouse and human neutrophils can respond 
differently to certain stimuli by releasing distinct protein patterns upon activation.
Nevertheless, taken these considerations into account, the data reviewed here clearly 
implicate an important task for granulocytes in modulating DC functions and shaping DC-
mediated adaptive immune responses.
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CHAPTER 5
Immunoglobulin A-activated neutrophils recruit 





Maintaining a delicate equilibrium between tolerating harmless particles and initiating 
effective immune responses against pathogens is essential at mucosal sites. Tolerogenic 
dendritic cells (DCs) are abundantly present in the intestinal mucosa to aid in preserving 
homeostatic conditions. When pathogens breach the intestinal barrier, neutrophils are 
rapidly recruited to the infected tissue to eliminate infiltrated pathogens. Furthermore, 
infiltrating monocytes can differentiate into monocyte-derived dendritic cells (moDCs) 
thereby contributing to the inflammatory environment and its resolution. In the intestinal 
mucosa immunoglobulin A (IgA) is the most abundant antibody present.
Here we show that IgA-activated neutrophils secreted chemotactic mediators for neutrophils 
and enhanced migration of monocytes. Neutrophils migrated to lower concentrations of 
leukotriene B4 (LTB4) compared to monocytes. Secretion of the chemokines CCL2, CCL3 and 
CCL4 was observed eight hours after Fc alpha receptor I (FcαRI) crosslinking on neutrophils. 
Activation of neutrophils with IgA promoted maturation (as indicated by CD86 expression) 
and pro-inflammatory cytokine production (IL-6 and IL-12p40) by moDCs. Close interactions 
of DCs and neutrophils were observed in intestinal tissue sections of inflammatory bowel 
disease patients.
FcαRI triggering on neutrophils ensures both efficient neutrophil and monocyte recruitment 
and activation of moDCs which are balanced processes to maintain mucosal homeostasis. 
Aberrant FcαRI-IgA triggered cell activation and cellular interactions in presence of IgA 
however, might result in tissue damage and pathology as observed in inflammatory 
autoimmune conditions like ulcerative colitis or Crohn’s disease.
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Introduction
Mucosal surfaces (e.g. gastrointestinal, respiratory and genitourinary tracts) cover an 
area of over 300m2 in the adult human body [1]. They are continuously exposed to food 
or inhaled antigens and commensal bacteria. It is essential to keep a tight balance by 
tolerating harmless substances versus providing protection against harmful pathogens. The 
epithelial layer of mucosal surfaces is covered with a thick layer of mucus in which beneficial 
commensal bacteria colonize and antimicrobial peptides are present which protect the host 
against infiltrating pathogens [2]. IgA is the most abundant antibody produced in mucosal 
areas and is secreted into the lumen where it resides in, and on top of, the mucus layer. This 
secretory IgA (SIgA) aids in protecting the host by neutralizing pathogens and preventing 
them from entering the epithelial layers after which they can be eliminated via bodily fluids 
like feces or sputum [3].
In homeostatic conditions tissue resident tolerogenic DCs are essential in maintaining central 
and peripheral tolerance [4, 5]. Intestinal CD103+ DCs are described to enhance tolerance 
towards non-harmful particles by migrating from the lamina propria to the mesenteric lymph 
nodes where they induce gut-homing regulatory T cells [6-8]. Furthermore, homeostatic 
conditions are maintained by CD103+ DCs by activating T helper cells and innate lymphoid 
cells [9]. CX3CR1 expressing dendritic cells can sample luminal antigens by extending their 
dendrites between epithelial cells. They can present processed antigens to T cells thereby 
inducing regulatory T cells to maintain immune homeostasis at steady state [10]. Although 
continuous surveillance by antigen sampling dendritic cells in the lamina propria mainly 
induces tolerance, sampling of foreign particles induces an effective immune response [11].
When pathogens breach the protective intestinal barrier and infiltrate the underlying 
tissues, a rapid influx of neutrophils is induced by chemoattractants that are released by 
tissue resident macrophages [12, 13]. Neutrophils are the most abundant type of leukocytes 
and have for many years been considered as simple defenders with restricted functions 
in innate immunity. However, research conducted over the past decade revealed that 
neutrophils can in fact act as sentinel cells by communicating with DCs and have complex 
functions in regulating immune responses. Close interaction between neutrophils and DCs 
has been described in several studies [14-19]. Neutrophils are able to influence the activation 
of DCs, depending on neutrophil activation status, the type of neutrophil cell death 
(apoptosis, necrosis, NETosis, pyroptosis), and the microenvironment in which neutrophil-DC 
interactions take place [20]. Furthermore, activated neutrophils have a prolonged lifespan, 
which can be enhanced by inflammatory factors released by DCs as well [21].
92
Chapter 5
In the lamina propria of the intestinal mucosa dimeric IgA (dIgA) is abundantly present. 
Tolerogenic CD103+ and CX3CR1+ DCs produce B cell activating factors like BAFF, APRIL and 
TGF-β, which enhance IgA production [10, 22]. Unlike the SIgA present in the lumen, dIgA 
complexes can be phagocytosed by neutrophils [23, 24]. Furthermore, neutrophils activated 
through IgA by crosslinking its Fc receptor for IgA (FcαRI, CD89) enhance the recruitment 
of more neutrophils to the affected site by producing a potent lipid chemotactic mediator 
leukotriene B4 (LTB4) [23, 25]. Influx of circulating neutrophils into infected tissues occurs 
within minutes to hours after infection. Monocytes shortly follow after the neutrophil influx 
[16]. Release of various chemokines by neutrophils ensures recruitment of more neutrophils 
and monocytes [26-32]. Moreover, exposure of granule proteins including neutrophil-
derived cathepsin G and LL-37 attracts monocytes [33, 34]. Infiltrated neutrophils efficiently 
phagocytose pathogens thereby contributing to resolution of inflammation. Monocytes can 
convert into tissue residing DCs which have an important role in antimicrobial defense [35]. 
Apoptotic neutrophils are ingested by tissue resident macrophages and dendritic cells to 
restore homeostatic conditions and to prevent tissue necrosis and pathology [20, 36, 37].
Continuous presence of activated neutrophils can contribute to tissue damage as observed 
in patients suffering from inflammatory bowel disease, including ulcerative colitis and 
Crohn’s disease [23, 38-40]. In the mucosa of ulcerative colitis patients neutrophils that had 
taken up IgA were observed [23]. Moreover, inflammatory stimuli influence the expression 
of a large number of surface proteins present on DCs which can affect cellular functionality 
as well [41]. In mice, tolerogenic DCs from the intestinal tract lose their CD103 surface 
expression during colitis [42]. Furthermore, the expression of a DC-specific ICAM-3 grabbing 
non-integrin (DC-SIGN) on DCs increased in Crohn’s disease patients and these cells were 
described to have close interactions with infiltrated neutrophils in intestinal tissue sections 
of these patients [4, 15, 43]. Here we investigate the effect of IgA-activated neutrophils 
on monocytes and dendritic cells (DCs) to gain more insight in the role of IgA in cell-cell 
communication in inflammatory conditions.
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Polymorphonuclear leukocytes (PMN) were isolated from peripheral blood obtained 
from healthy donors using Lymphoprep (Axis-Shield, Oslo, Norway) density gradient 
centrifugation, after which erythrocytes were lysed in ammonium chloride buffer (155mM 
NH4Cl, 10mM KHCO3 and 0.11mM EDTA, 10min, RT). After lysis, PMN were washed in 
phosphate buffered saline (PBS; B.Braun, Melsungen, Germany) and, if indicated, purified 
using the EasySep™ Human Neutrophil Isolation Kit (StemCell Technologies, Grenoble, 
France) following the manufacturer’s instructions. PMN and ultrapure neutrophils (purity 
>99.5%) were resuspended in RPMI 1640 (Gibco BRL, Paisley, UK) supplemented with 10% 
heat-inactivated fetal calf serum, glutamine and antibiotics (complete RPMI). Cells were 
incubated for 30 min (37°C, 5% CO2) prior to use. The interphase layer containing peripheral 
blood mononuclear cells was collected after density gradient centrifugation and washed 
in PBS. Monocytes were isolated using MACS CD14 MicroBeads human (Miltenyi Biotec, 
Bergisch Gladbach, Germany) according to the manufacturer’s protocol. Blood samples were 
collected according to the guidelines of the Medical Ethical Committee of the Amsterdam 
University Medical Center (The Netherlands), in accordance with the Declaration of Helsinki. 
All donors gave written informed consent.
In vitro generation of monocyte derived- and retinoic acid dendritic cells
Monocytes were cultured in complete RPMI supplemented with 20ng/ml IL-4 and 20ng/
ml GM-CSF (ImmunoTools, Friesoythe, Germany) for 6-7 days to obtain immature moDCs. 
Retinoic acid DCs were obtained by adding 1μM retinoic acid (Sigma Aldrich) to the 
supplemented complete RPMI.
ALDEFLUOR assay
Aldehyde dehydrogenase (ALDH) expression in DCs was measured using the ALDEFLUOR assay 
kit (StemCell Technologies, Grenoble, France) following the manufacturer’s instructions. In 
brief, BODIPY-aminoacetaldehyde (BAAA), a fluorescent substrate for ALDH was added to the 
cells for 40 min at 37°C. BAAA is converted into BODIPY-amino acetate (BAA) in the presence 
of ALDH and is retained in the cell. Diethylaminobenzaldehyde (DEAB), a specific inhibitor of 
ALDH, served as control for background fluorescence. Fluorescence intensity is proportional 
to the amount of ALDH activity in the cells and was analyzed using flow cytometry.
Coating of beads with BSA, IgA or IgG
Latex non-fluorescent (0.9μm) or green fluorescent (1.0μm) beads (carboxylate-modified 
polystyrene, Sigma Aldrich) were washed with sterile 2-(N-morpholino) ethanesulfonic 
(MES) buffer (30mM, pH 6.1) and resuspended in MES buffer with 2mg/ml endotoxin free 
bovine serum albumin (BSA) (Akron Biotech, Boca Raton, FL), human serum IgA (Cappel, MP 
Biomedicals, Santa Ana, CA) or human serum IgG (Sigma Aldrich) in the presence of N-(3-
Dimethylaminopropyl)-N’-acid ethylcarbodimide hydrochlorid (Sigma Aldrich) and incubated 
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O/N at RT (overhead shaker). Beads were washed, resuspended in sterile PBS containing 
0.5% BSA and used in a sterile environment. Alternatively, 30 mg/ml BSA, IgA or IgG was 
coupled to cyanogen bromide-activated Sepharose beads according to the manufacturer’s 
instructions (GE Healthcare Bio-Sciences, Uppsala, Sweden).
Bacteria culture and coating
Escherichia coli (E.coli, ATCC 25922) bacteria were cultured in Lysogeny broth (LB) medium 
without antibiotics (O/N, 37°C). Bacteria were heat-treated for 60 min in a 70°C water bath 
and coated with BSA or human serum IgA (1mg/ml) for 30 min at 37°C.
Supernatant for cytokine production
Neutrophils (1 x 106/ml) were stimulated with 100mg/ml BSA-, IgA- or IgG-coated Sepharose 
bead suspension embedded in a collagen gel (to prevent chemokine breakdown by 
neutrophil proteases). Supernatants were collected after 0, 4, 8, 24 and 48h to measure 
cytokine production using standard ELISA.
Chemotaxis assay
Blind well chambers were filled with supernatant of migration experiments. LTB4 (Sigma) 
or n-formyl-Methionyl-Leucyl-Phenylalanine (fMLP, 1 x 10-8M, Sigma) were used as positive 
controls. Migration towards complete RPMI served as background. Polyvinylpyrrolidone 
(PVP)-free polycarbonate filters (pore size 5μm) were used. In top wells, 50μl of monocyte 
suspension (4 x 105 cells/ml) was added. After incubation (37°C, 5% CO2) for several time 
periods, migrated cells were quantified. The upper side of the filters were cleared of cells 
after which the filter was stained using Coomassie Brilliant Blue solution. Ten high power 
fields were counted per well using light microscopy to determine the percentage of cells 
that migrated to the lower chamber (on lower side filters). Chemotaxis assays were also 
performed in the presence of 100mg/ml anti-BLT1 mAb (BD Biosciences, Franklin Lakes, 
NJ) or 10mM BLT1 antagonist U-75302 (Sigma). Neutrophil migration was performed using 
PVP containing polycarbonate filters. Calcein AM-labelled neutrophils (1 x 106 /ml) were 
added to top wells. The lower wells contained LTB4 in different concentrations. Migrated 
cells were quantified using a fluorimeter (485 excitation/520 emission filters).
Neutrophil-DC co-culture
When indicated, ultrapure neutrophils and moDCs were labeled with Cell Proliferation 
Dye eFluor™ 670 or Cell Proliferation Dye eFluor™ 450 (ThermoFisher, Waltham, MA), 
respectively, according to the manufacturer’s protocol. Neutrophils were activated with 
green fluorescent BSA-, serum IgA-, or serum IgG-coated latex beads (E:T ratio 1:100) for 30 
min at 37°C, 5% CO2. After phagocytosis, cells were carefully washed with complete RPMI to 
eliminate non-phagocytosed beads. Neutrophils and moDCs were plated in a 96-well round 
bottom plate, each at concentration 2 x 106/ml in an end volume of 200μl complete RPMI. 
The co-culture was incubated for 4 or 24h at 37°C, 5% CO2 after which supernatant and 
cells were collected. Supernatants were analyzed for cytokine production using standard 
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ELISA. Cells were analyzed directly using imaging flow cytometry (Amnis® ImageStream®X) 
to analyze cell-cell interactions or conventional flow cytometry (LSRFortessa™ X-20, BD 
Biosciences) to investigate maturation of moDCs using the following antibodies; anti-human 
CD80-APC (2D10), anti-human CD86-PE/Dazzle 594 (IT2.2) and anti-human HLA-DR-PerCP/
Cy5.5 (L243) (all BioLegend, San Diego, CA). Alternatively, neutrophils and moDCs were 
plated in an µ-Slide 8 Well Chamber Slide (Ibidi, Gräfelfing, Germany) each at concentration 
1 x 106/ml in an end volume of 300μl complete RPMI. The co-culture was incubated at 37°C, 




Maintenance of tolerogenic DC properties in presence of IgA-activated 
neutrophils
To investigate the effect of IgA-activated neutrophils during infection on residing tolerogenic 
DCs, we generated tolerogenic DCs in vitro. Retinoic acid is described to drive in vitro 
differentiation of monocytes toward tolerogenic CD103+ DCs [44] and as such we used 
similar conditions to obtain tolerogenic DCs - hereafter referred to as RADCs -. RADCs 
had increased intracellular expression of aldefluor (resembling ALDH activity) and surface 
expression of CD103 compared to monocyte-derived DCs (moDCs) (Figure 1A). Morphologic 
characterization showed that in vitro generated RADCs had longer dendrites and were 
more adherent compared to moDCs (Figure 1B), suggesting a mature phenotype. After 
intestinal infections, neutrophils are the first cells to infiltrate the tissue to defend the 
host against pathogens. We therefore questioned how IgA-activated neutrophils affected 
RADCs. In mucosal areas IgA is produced as a dimeric molecule. However, as dimeric IgA is 
produced in the lamina propria it is difficult to obtain. Furthermore, isolated dimeric IgA may 
contain bacterial products. Since previous studies showed equal activation of neutrophils by 
serum IgA and dimeric IgA [23, 24], serum IgA was used in these experiments to avoid any 
influence of contaminating bacterial components present in dimeric IgA. As IgG can bind 
to multiple Fc gamma receptors on neutrophils, and it is present in lower concentrations 
at most mucosal surfaces IgG-activated neutrophils were included as well for comparison. 
Co-culture of RADCs with IgA-activated neutrophils did not enhance IL-6 release (Figure 
1C). Presence of IgA-activated or IgG-activated neutrophils reduced release of IL-12p40 
by RADCs compared to presence of BSA-activated neutrophils (Figure 1D). These results 
demonstrate that tolerogenic DCs are not driven to release pro-inflammatory cytokines 
in presence of IgA- or IgG-activated neutrophils, suggesting that RADC maintain their 
tolerogenic properties in inflammatory conditions.
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Figure 1. CD103+ DCs do not produce pro-inflammatory cytokines after co-culture with IgA-activated 
neutrophils. (A) Left panel: ALDH activity, measured by Aldefluor positivity, of RADCs and moDCs. 
Right panel: CD103 expression of RADC and moDCs. (B) Morphology of moDCs and RADCs after 6 days 
of culture. (C) IL-6 production by 6-day old RADCs after 24h co-culture with BSA- or IgA-activated 
neutrophils. (D) IL-12p40 production by 6-day old RADCs after 24h co-culture with BSA-, IgA- or IgG-
activated neutrophils. [Statistics: Bar represent mean ± SD. Ordinary one way ANOVA with Bonferroni 
Post-Hoc; *p<0.05]
IgA-activated neutrophils attract monocytes through LTB4
To further investigate whether other cell types involved in intestinal inflammation could 
be influenced by IgA-activated neutrophils, we checked which cells are recruited by IgA-
activated neutrophils. Previously, our group showed that chemotactic stimuli produced by 
IgA-activated neutrophils enhanced recruitment of neutrophils [23]. Now we investigated 
whether monocytes migrated towards supernatant of IgA-activated neutrophils as 
well. Migratory capacity of monocytes towards supernatant of neutrophils which had 
phagocytosed E.coli bacteria was investigated. E.coli are among the most common species 
in the intestinal tract [45]. Supernatants of neutrophils activated with IgA-opsonized E.coli 
enhanced the migratory response of monocytes significantly compared to supernatants of 
neutrophils activated with BSA-opsonized E.coli (Figure 2A). Similar monocyte migration 
was observed towards the bacterial product formyl-methyl-leucine-phenylalanine (fMLP). 
As bacterial products are potent activators of neutrophils and monocytes, IgA-coated 
beads were used to further investigate the effect of IgA, in order to exclude interference 
of bacterial components. Supernatants of IgA-activated neutrophils, harvested after 30 
or 60 minutes stimulation, induced monocyte migration compared to supernatants of 
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BSA- or IgG-activated neutrophils (Figure 2B). Stimulation of neutrophils with IgA in the 
presence of MIP8a, a monoclonal blocking antibody for the Fc receptor of IgA (FcαRI, 
CD89), decreased monocyte migration capacity towards the supernatant (Figure 2C). As 
stimulation of neutrophils for 30 minutes was sufficient to release monocyte chemotactic 
factors in the supernatant, either release of chemokines from granules or rapid synthesis 
of lipid mediators is supported. To distinguish between chemokines and lipid mediators, 
supernatants of IgA-activated neutrophils were heated to denature proteins prior to 
use in migration assays. Heating of supernatants did not influence monocyte migration , 
supporting that lipid mediators were the key chemotactic stimuli for monocytes released 
by IgA-activated neutrophils after 30 to 60 minutes stimulation (Figure 2D). Nonetheless, 
neutrophils also produced the chemokines CCL2, CCL3, CCL4 and IL-8 after stimulation with 
IgA-coated beads for 8, 24 or 48 hours, which was not observed with BSA- and IgG-activated 
neutrophils (Figure 2E).
We previously demonstrated that the lipid mediator leukotriene B4 (LTB4) is released 
by neutrophils after FcαRI crosslinking by IgA and induced neutrophil migration [23]. To 
investigate whether LTB4 could play a role in monocyte migration as well, we showed that 
BLT1, the high affinity receptor for LTB4 was expressed by monocytes (Figure 3A). Monocytes 
migrated towards LTB4 similar as towards the bacterial product fMLP, a known potent 
chemoattractant for monocytes, as well as to supernatants of IgA-activated neutrophils 
(Figure 3B). Migration towards supernatants of IgA-activated neutrophils was decreased up 
to fifty percent in presence of either a blocking anti-BLT1 monoclonal antibody (left panel) 
or a BLT1 antagonist (U75302) (right panel) (Figure 3B), supporting that presence of LTB4 
in supernatants of IgA-activated neutrophils is partly accountable for monocyte migration.
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Figure 2. Monocytes migrate towards supernatant of IgA-activated neutrophils. (A) Migration 
of monocytes towards supernatant derived from neutrophils that phagocytosed BSA- (white) or 
IgA- (grey) opsonized E.coli. Migration towards fMLP and medium served as positive and negative 
control respectively. (B) Migration of monocytes towards supernatant neutrophils that had been 
stimulated with BSA- (white), IgA- (grey), or IgG- (black) coated sepharose beads for 30 or 60 minutes. 
(C) Migration of monocytes towards supernatants of neutrophils stimulated with BSA- (white) or IgA- 
(grey) coated sepharose beads in the absence (-) or presence (+) of anti-FcαRI mAb MIP8a. Migration 
to medium served as negative control. (D) Migration of monocytes towards unheated (-) or heated 
(+, 70°C, 15min) supernatants of neutrophils activated with BSA- (white), IgA- (grey) or IgG- (black) 
coated sepharose beads for 30 or 60 minutes. (E) Release of CCL2, CCL3, CCL4 and IL-8 by neutrophils 
after stimulation with BSA- (white), IgA- (grey) or IgG- (black) coated sepharose beads for different 
time periods. [Statistics: Bar represent mean ± SD. Ordinary one way ANOVA (2A) or two way ANOVA 
(2B-2E) with Bonferroni Post-Hoc; *p<0.05, **p<0.005, ***p<0.0005, ****p<0.0001]
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Figure 3. Monocytes migrate towards LTB4. (A) Expression of the LTB4 receptor BLT1 on 
neutrophils (light grey) and monocytes (dark grey). [Control; secondary antibody only; dotted line] 
(B) Migration of monocytes towards LTB4 (dark grey) and supernatants of neutrophils stimulated 
with IgA-coated sepharose beads for 30 or 60 minutes (grey) in the absence (-) or presence (+) 
of anti-BLT1 mAb (left) or BLT1 antagonist U75302 (right). Migration towards fMLP (striped) and 
medium (white) served as positive and negative controls respectively. [Statistics: Bar represent 
mean ± SD. Two way ANOVA (3B) with Bonferroni Post-Hoc; *p<0.05, **p<0.005, ****p<0.0001]
Since both neutrophils and monocytes migrated towards LTB4 present in supernatants 
of IgA-activated neutrophils, we next investigated whether kinetics of migration was 
similar, by studying migration capacity towards different concentrations of LTB4 or in time. 
Neutrophil migration towards LTB4 peaked at a concentration of 10-8M, while the optimal 
LTB4 concentration for monocyte recruitment was tenfold higher (10-7M) (Figure 4A). 
Furthermore, migration of neutrophils towards the optimal LTB4 concentration (10-8M), 
was observed after 20 minutes while monocyte migration towards LTB4 (10-7m) started 
after 40 minutes (Figure 4B).
101
IgA-activated neutrophils recruit monocytes and induce moDC activation
5
Figure 4. Kinetics of neutrophil and monocyte migration towards LTB4. (A) Neutrophil and 
monocyte migration towards different concentrations of LTB4 (range 10-10 M to 10-6 M). (B) Migration 
of neutrophils and monocytes towards their respective optimum concentration LTB4 (10-8 M for 
neutrophils, 10-7 M for monocytes) at different time points in minutes. Results representative of four 
independent experiments.
Neutrophils interact with moDCs independent of their activation stimulus
Next we assessed whether IgA had an effect on cellular interactions between neutrophils 
and moDCs. Activated neutrophils interacted with monocyte-derived dendritic cells 
(moDCs) (Figure 5A). No difference was observed between activation via BSA-, IgA- or IgG-
coated beads (Figure 5B). To further visualize the interaction between neutrophils and 
moDCs, live cell imaging was performed. IgA-activated neutrophils attached to moDCs and 
transferred green-fluorescent IgA-coated beads to moDCs (Figure 5C). After bead transfer 
neutrophils and moDCs detached. With imaging flow cytometry cells were closely localized 
or firmly attached. Additionally, the percentage of moDCs that had taken up neutrophils 
was determined (Figure 5D). Although a higher percentage of IgG-activated neutrophils 
was internalized by moDCs compared to BSA- and IgA-activated neutrophils (Figure 5E), no 
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statistical significant difference between BSA-, IgA- or IgG-activated neutrophils and their 
interaction with moDCs were confirmed.
During homeostatic conditions neutrophils are absent in the intestinal lamina propria (data 
not shown). However, during inflammation in the intestinal tract high influx of neutrophils 
is observed [46-48] (and Amelie Bos, personal communication). To investigate whether 
neutrophils can also interact with DCs in tissue, intestinal tissue sections of patients with 
inflammatory bowel disease were stained. Neutrophils (green) were closely localized to 
DC-SIGN+ DCs (red) in inflamed tissue sections of patients with Crohn’s disease (Figure 5F). 
These data suggest that infiltrated neutrophils can interact with inflammatory DC-SIGN+ 
DCs and potentially modulate their maturation and effector functions in vivo as well.
IgA-activated neutrophils enhance activation of moDCs
Recruitment of monocytes into inflamed tissue is essential for host defense. During 
inflammation extravasated blood monocytes contribute to the tissue DC and macrophage 
pool [35]. Monocyte-derived DCs (moDCs) serve as an in vitro model to mimic inflammatory 
DCs [49, 50]. Therefore we investigated moDCs activation after co-culture with IgA-activated 
neutrophils. Presence of IgA-activated neutrophils in the development of monocytes 
towards moDCs led to significantly increased levels of the maturation marker CD86 (Figure 
6A, middle panel). No upregulation of CD80 and HLA-DR on moDCs was induced by IgA-
activated neutrophils. Furthermore, moDCs produced significantly increased levels of IL-6 
and IL-12p40 after co-culture with IgA-activated neutrophils (Figure 6B).
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Figure 5. Neutrophils interact with moDCs independent of their stimulus. (A) Neutrophils activated 
with green fluorescent BSA- (left), IgA- (middle) and IgG- (left) coated latex beads interact with moDCs 
after 4h co-culture. Neutrophils and moDCs were stained with eFluor670 or eFluor450 cell proliferation 
dye, respectively. Interacting cells are double positive for both dyes. Representative figure of n=12. 
(B) Quantification of double positive events (neutrophil-moDC interaction). (C) Live cell imaging of an 
IgA-activated neutrophil interacting with a moDC. First image after 45min co-culture. Pictures made 
with a 5min time-interval. Neutrophils were stained with eFluor670 (red fluorescence) and activated 
with green fluorescent IgA-coated latex beads. MoDCs were unstained. (D) Imaging flow cytometric 
visualization of neutrophils activated with green fluorescent IgA-coated beads with moDC after 4h co-
culture. Cells are in close localization of each other (upper panel), firmly attached to each other (middle 
panel) or neutrophils have been taken up by moDCs (lower panel). (E) Quantification of imaging 
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flow cytometry of neutrophils stimulated with BSA-, IgA- or IgG-coated latex beads interacting with 
moDCs after 4h co-culture. (F) Neutrophils (CD66b, green), DCs (DC-SIGN, red) and nuclei (DAPI, blue) 
stained in colonic tissue of a Crohn’s disease patient. [Statistics: Bar represent mean ± SD. Ordinary 
one way ANOVA (5B) or two way ANOVA (5E) with Bonferroni Post-Hoc; no significant differences]
Figure 6. Increased maturation and production of pro-inflammatory by moDCs after co-culture with 
IgA-activated neutrophils. (A) moDC expression of maturation markers CD80 (left), CD86 (middle) 
and HLA-DR (right) after 24h stimulation with supernatants of neutrophils activated with BSA- (white), 
IgA- (grey) or IgG- (black) coated latex beads. (B) Neutrophils activated with BSA- (white), IgA- (grey), 
or IgG- (black) coated beads were co-cultured with 6 day-old moDCs for 24h, after which supernatant 
was collected and IL-6 and IL-12p40 levels were evaluated with ELISA. [Statistics: Bar represent mean 
± SD. Ordinary one way ANOVA with Bonferroni Post-Hoc; *p<0.05, ****p<0.0001]
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Discussion
During homeostatic conditions neutrophils are absent from intestinal tissue. However, 
inflamed intestinal tissue of Crohn’s disease and ulcerative colitis patients is amongst 
others characterized by damage of the epithelial lining and infiltration of neutrophils 
[47, 48] (and Amelie Bos, personal communication). We investigated whether activated 
neutrophils, which are numerously present during intestinal inflammation, affected residing 
tolerogenic DCs. In vivo it was shown that during colitis murine intestinal DCs lose their 
CD103 expression [42], implying that environmental factors can affect the phenotype of 
residing DCs. We found that neutrophils activated with IgA did not induce IL-6 and IL-12p40 
release by CD103+ RADCs, which suggests that residing CD103+ DCs retain their tolerogenic 
profile during neutrophil infiltration. We then explored whether IgA-activated neutrophils 
can affect infiltrating cells during infection and found that supernatant of IgA-activated 
neutrophils enhanced monocyte migration.
Recruitment of neutrophils and monocytes after infection occurs in two waves. Neutrophils 
are the first cells to arrive and produce chemotactic factors only hours after infection 
after which an influx of monocytes follows [13, 32, 51]. We previously showed that IgA-
mediated cross-linking of FcαRI on neutrophils resulted in the release of LTB4, which 
enhanced neutrophil recruitment [23]. We now demonstrated that IgA-induced LTB4 
produced by neutrophils is important for monocyte recruitment as well. It has been 
described that monocytes express the LTB4 receptors BLT1 and BLT2 [52]. Blocking the 
high affinity receptor for LTB4, BLT1, reduced monocyte migration towards supernatant of 
IgA-activated neutrophils with approximately 50%. As anti-BLT1 antibodies and antagonist 
U75302 specifically inhibit BLT1, the remaining migratory effect may have been due to the 
expression of the low affinity BLT2 receptor on monocytes. Release of LTB4 by neutrophils 
depended on IgA-mediated FcαRI crosslinking, as blocking FcαRI with MIP8a resulted in 
reduced migration of monocytes towards this supernatant. Furthermore, IgA-activated 
neutrophils secreted other chemokines including CCL2, CCL3 and CCL4 which may contribute 
to monocyte recruitment in a later stage. Although the amount of chemokines secreted per 
neutrophil is low, the abundant presence of neutrophils in infected tissue ensures significant 
contribution to the total chemokine concentration [53].
Monocytes contribute to the pool of tissue resident cells, including macrophages and DCs 
in inflamed tissue [36]. In inflammatory conditions monocytes are thought to be the source 
of inflammatory DCs. It was demonstrated that moDCs express BLT2 and migrated towards 
LTB4 [54]. We found intermediate BLT1 expression on moDCs (data not shown), which 
supports the hypothesis that when monocytes differentiate into moDCs they retain their 
capacity to migrate to infected sites where IgA-activated neutrophils secrete LTB4.
Multiple studies showed that neutrophils can influence DC activation [16, 18, 29, 55-58]. 
These effects can be dependent on cell-cell contact, but factors secreted by neutrophils, 
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including soluble factors, neutrophil extracellular traps and vesicles, might also influence 
the DC activation state [21]. Previous studies reported that neutrophil granule proteins 
including neutrophil elastase, LL-37 and cathepsin-G triggered TLR-9 activation resulting in 
type 1 interferon release by DCs [59-61]. LL-37 enhanced DC IL-12 and IL-6 production [62], 
while myeloperoxidase inhibited DC maturation and IL-12 release [28]. Results regarding 
the effect of lactoferrin (neutrophil granule protein) on DC activation are contradictory as 
either enhanced or inhibited IL-6 release by DCs was measured after lactoferrin stimulation 
[63, 64]. In addition, we found that IgA-activated neutrophils enhanced IL-6 and IL-12p40 
release by moDCs, but not RADCs. IL-12p40 is the β-subunit of both IL-12 (IL-12p35/IL-12p40) 
and IL-23 (IL-23p19/IL-12p40) and is required for secretion of these bioactive cytokines 
which promote (chronic) inflammation [65]. IL-6 has a pathological effect in autoimmune 
diseases and during chronic inflammation. Several animal models demonstrated preventive 
or therapeutic potential of anti-IL-6 or anti-IL-6 receptor antibodies in rheumatoid arthritis, 
systemic lupus erythematosus and many other disease models [66]. Moreover, clinical trials 
in Crohn’s disease patients using anti-IL-6 receptor resulted in remission along with reduced 
inflammatory markers in serum [67]. Anti-IL-6 antibodies similarly induced remission, however 
adverse effects including gastrointestinal perforations and abscesses were found [68].
Close interactions between neutrophils and DC-SIGN+ DCs were found in tissue of Crohn’s 
disease patients. Previous work demonstrated that cellular interactions might be regulated 
by several molecules, including DC-SIGN, ICAM-1, CD11b/CD18 and CEACAM1, as well as 
cell-specific glycosylation [14-19]. DC-SIGN+ DCs were demonstrated to be important in the 
pathogenesis of Crohn’s disease, as they secrete IL-12 and IL-18, which induce generation 
of Th1 cells. Presence and activation of Th1 cells is a main cause of pathology in Crohn’s 
disease [43]. Furthermore, IgA autoantibodies are elevated in serum of inflammatory bowel 
disease patients [69], which suggests that they can be involved in the pathogenesis of 
inflammatory bowel disease.
Neutrophil activation through IgA differs from activation trough IgG in multiple ways. IgA 
stimulation enhanced cytokine release by neutrophils compared to stimulation with IgG (see 
chapter 6). This observation might explain why IgA-activated neutrophils specifically affect 
moDC activation while this is not the case for IgG-activated neutrophils. Cross-linking of 
the FcαRI and FcγRs triggers a signaling cascade resulting in downstream effector functions 
including phagocytosis, cytokine release and antibody dependent cellular cytotoxicity. 
Signaling via these Fc receptors depends on immunoreceptor tyrosine-based activation 
motifs (ITAM) and recruitment of Src and Syk tyrosine kinases [70]. Human neutrophils 
express the transmembrane receptor FcγRIIa, carrying an ITAM in its cytoplasmic 
tail, and the extracellular FcγRIIIb which is anchored to the plasma membrane with a 
glycosylphosphatidylinositol (GPI)-linked molecule. In order to execute optimal effector 
functions, the FcαRI requires association with the common FcR γ-chain, which contains two 
ITAM motifs, while the FcγRIIa only has one cytoplasmic domain ITAM [71]. Functionality 
may be affected by differences in ITAM, as FcαRI transfectants containing FcR γ-chain ITAM 
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(2 motifs) released cytokines and presented antigens, in contrast to FcαRI transfectants 
containing the FcγRIIa γ-chain in which only one ITAM motif is present [72]. As such it is 
likely that neutrophils release more monocyte chemotactic factors and potentially moDC 
modulating cytokines via FcαRI targeting compared to FcγRIIa cross-linking.
Figure 7. Model of cell recruitment after IgA induced neutrophil activation. Tolerogenic DCs reside in 
the lamina propria where they contribute in maintaining immune tolerance and homeostasis. When 
homeostatic conditions are disturbed and pathogens are able to breach the intestinal barrier (time 
0h), invading pathogens can be opsonized with dimeric IgA. Neutrophils express the Fc receptor for 
IgA (FcαRI, CD89), which will be cross-linked upon recognition of IgA immune complexes resulting 
in the production of LTB4. This leads to recruitment of more neutrophils which will be activated by 
IgA immune complexes resulting in higher concentrations of LTB4. Eventually LTB4 levels will attract 
monocytes to the site of infection. A few hours after infection, neutrophils will release CCL2, CCL3 and 
CCL4, hereby further contributing to monocyte recruitment. In tissue, monocytes will differentiate into 
monocyte derived dendritic cells (moDCs) under inflammatory conditions. IgA-activated neutrophils 
can interact with moDCs, modulate their maturation and induce cytokine release (IL-6 & IL-12).
Homeostatic conditions in the intestine are characterized by an environment in which 
surveillance of immune cells induces tolerance and neutrophils are absent. Pathogen 
infiltration will lead to rapid recruitment of neutrophils. We have shown before that IgA 
activation of neutrophils results in the release of LTB4. Low concentrations of LTB4 recruits 
more neutrophils to the affected tissue and when LTB4 levels build up monocytes will influx 
as well. In a later stage neutrophils furthermore secreted chemotactic factors including 
CCL2, CCL3 and CCL4 which can attract monocytes. Tissue infiltrated monocytes can 
differentiate into moDCs which contribute to the inflammatory response by interacting with 
IgA-activated neutrophils (Figure 7). Ultimately neutrophils are responsible for clearing the 
infection resulting in subsequent restoration of immune homeostasis. However, continuous 
activation of immune cells can result in pathology as observed in inflammatory bowel 
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disease patients. The observed co-localization of neutrophils with DC-SIGN+ DCs supports 
the hypothesis that activated neutrophils can modulate DC functioning and transfer antigens 
to DCs to initiate T cell activation responsible for pathology.
IgA serves a dual role as it is essential in efficient pathogen elimination after infection, 
but prolonged activation of the FcαRI on neutrophils can cause significant tissue damage. 
Therefore, targeting aberrant FcαRI-IgA mediated neutrophil activation by using specific 
FcαRI-blocking antibodies might be a therapeutic strategy for patients suffering from 
inflammatory bowel disease. By inhibiting exaggerated FcαRI-IgA mediated neutrophil 
activation, downstream effects of neutrophils on other immune cells including DCs can 
also be affected in a positive way by breaching the pro-inflammatory feedback loop.
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Serum IgA has a potent pro-inflammatory 




Immunoglobulin A (IgA) is the second most abundant antibody in the circulation after IgG. 
Nonetheless, its role in host-pathogen defense is poorly understood. Here we show that 
individuals vaccinated against typhoid fever and patients with Lyme borreliosis develop 
antigen-specific serum IgA and IgG titers up till at least twelve weeks after vaccination 
or confirmed disease. Whole transcriptome and gene set enrichment analysis of human 
CD14+ monocytes after stimulation with IgA-complexes resulted in significantly upregulated 
molecular pathways of the immune system, which were not observed after stimulation with 
IgG. Similarly, stimulation of human peripheral neutrophils and monocytes with serum IgA-
complexes or IgA-opsonized bacteria led to enhanced release of inflammatory cytokines, 
chemokines, and lipids. Thus, serum IgA-complexes induced more potent inflammatory 
immune responses by both neutrophils and monocytes, compared to serum IgG-complexes. 
These findings support an important, but previously overlooked, role for serum IgA in 
systemic immunity.
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Introduction
Immunoglobulins are a hallmark of humoral immunity. By neutralizing pathogens, activating 
complement and inducing immune cell effector functions, immunoglobulins contribute to 
homeostasis and immune defense [1]. The antigen binding affinity is determined by the 
immunoglobulin variable antigen-binding fragment (Fab), whereas the constant fragment 
crystallizable (Fc) domain initiates complement and immune cell activation. Based on the 
Fc domain, five isotypes (IgM, IgD, IgG, IgA, and IgE) have been classified, each with distinct 
immune effector functions [2, 3].
IgG is the most abundant immunoglobulin in the circulation (6.0-16.0 g/L) providing systemic 
immunity. Innate immune cells can express activating and inhibitory IgG Fc receptors 
(FcγRIa/b, FcγRIIa/b/c, FcγRIIIa/b) initiating well established effective immune responses [4]. 
Single nucleotide polymorphisms (SNPs) in IgG Fc receptors can influence these responses 
by affecting the binding affinity to their cognate ligand [5]. At mucosal sites IgA is the 
predominant immunoglobulin isotype and is considered to play a more passive role in 
immunity [6]. It is secreted into the lumen as secretory IgA (SIgA), which mainly functions 
as a neutralizing antibody. Additionally, mucosal IgA plays an essential role in diversifying 
the microbiome and promoting host-microbiota symbiosis [7-9]. SIgA is however a poor 
opsonin, as binding to the IgA Fc receptor (FcαRI, CD89) is partly hampered by the secretory 
component that is an integral part of SIgA [10].
IgA is also the second most abundant immunoglobulin in the circulation (0.8-3.0 g/L) [11]. 
The role of serum IgA is however poorly understood. Monomeric serum IgA binds with 
moderate affinity (Ka = 10
6 M−1) to FcαRI, resulting in inhibitory (i.e. ITAMi) signaling [12]. 
As such, serum IgA can inhibit IgG- and IgE-mediated effector functions and was suggested 
to play an immunomodulatory role in maintaining homeostasis [13, 14]. By contrast, serum 
IgA immune complexes (e.g. serum IgA-opsonized bacteria) bind with higher avidity and 
induce cross-linking of FcαRI, leading to pro-inflammatory effects [11, 15]. Here we report 
the presence of pathogen-specific IgA titers against Salmonella typhi (S. typhi) or Borrelia 
burgdorferi (B. burgdorferi) in sera of individuals vaccinated against typhoid fever or in 
patients with Lyme borreliosis respectively. Serum IgA-complexes and IgA-opsonized 
bacteria induced more potent immune responses in human peripheral neutrophils and 
monocytes compared to IgG, demonstrating a potent immune activating role for serum 




Bacterial strains and culture
Escherichia coli (E. coli, ATCC 25922TM), Staphylococcus aureus (S. aureus, ATCC 29213TM), 
Staphylococcus epidermidis (S. epidermidis, ATCC 12228TM), Streptococcus pneumonia (S. 
pneumonia, ATCC 49619TM), Salmonella typhi (S. typhi, ATCC 19430TM) and Salmonella 
typhimurium (S. typhimurium, ATCC 14028TM) were cultured overnight in standard Lysogeny 
Broth (LB) medium at 37 °C, shaking 280 rpm. Bifidobacterium longum (B. longum) and breve 
(B. breve) were cultured in MRS broth (Sigma-Aldrich, St louis, MO) supplemented with 
0.5 g/l cysteine in anaerobic conditions at 37 °C for 24-72 hours. Lactobacillus crispatus (L. 
crispatus), iners (L. iners), casei (L. casei), gasseri (L. gasseri), rhamnosus (L. rhamnosus) and 
plantarum (L. plantarum) were cultured in MRS broth in anaerobic conditions at 37 °C for 
24-72 hours. B. burgdorferi sensu stricto, B. afzelii and B. garinii were cultured as previously 
described [16]. Bifidobacterium and Lactobacillus strains were kindly provided by dr. Dries 
Budding (Amsterdam UMC, location VUmc, Amsterdam, the Netherlands). Colony forming 
units were determined (# colonies/ml = # colonies x dilution / volume of dilution on plate) 
and standardized aliquots were stored in 40% glycerol at -80 °C.
Cohorts
Sera of individuals who received the non-live parenteral Vi capsular polysaccharide vaccine 
(typhoid fever vaccine, TFV) from an explorative, single-center, randomized, non-controlled 
open trial (n=29) were used. Characteristics of the study population and study design were 
described previously [17]. In short, this cohort includes adult volunteers with no history 
of prior TFV vaccination and no known pathology at the time of inclusion. All participants 
were vaccinated with Typhim Vi (Sanofi Pasteur, SA) using a standard dose of 0.5 ml 
intramuscularly containing 0.05 mg/ml purified Vi capsular polysaccharide of S.typhi Ty2 
strain. Blood was drawn prior to vaccination (T0) and subsequently two (T2) and twelve 
weeks (T12) after vaccination. Additionally, sera from a cohort patients diagnosed with Lyme 
borreliosis (n=50, LymeProspect NTR4998) were used. In short, this cohort includes patients 
with confirmed early Lyme borreliosis displaying erythema migrans. Inclusion criteria were 
described previously [18]. Sera samples at presentation (T1), six (T6) and twelve weeks 
(T12) after physician-confirmed Lyme borreliosis were included. Both studies have been 
approved by the medical ethics committee (METC) Noord-Holland (NL50227.094.14) and 
CMO Arnhem-Nijmegen (2012/089), and were conducted according to the principles of the 
Declaration of Helsinki.
Vi- and C6-specific ELISAs
96-wells Nunc MaxiSorp™ flat-bottom plates (Thermo Fisher Scientific, Vienna, Austria) were 
coated with 25 μg/ml Typhim Vi vaccine (Sanofi Pasteur Europe, Lyon, France, RVG 17568 
U.R., P1E433V) overnight at 4°C. Nonspecific binding sites were blocked by incubation with 
phosphate-buffered saline (PBS, B. Braun, Melsungen, Germany) containing 0.05% Tween-
20 (PBS-T, Sigma-Aldrich) and 0.5% bovine serum albumin (BSA, Roche Diagnostics, Basel, 
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Switzerland) for 1 hour at room temperature (RT). After washing with PBS-T, plates were 
incubated with TFV sera samples (1:100 in PBS-T) for 1 hour at 37°C. Plates were washed and 
incubated with HRP-conjugated F(ab’)2 fragments of goat anti-human IgM (1:2000, Thermo 
Fisher Scientific), F(ab’)2 fragments of goat anti-human IgG (1:2000, Thermo Fisher Scientific), 
and F(ab’)2 fragments of goat anti-human IgA (1:4000, Thermo Fisher Scientific) for 1 hour 
at 37°C. After washing with PBS-T, coloring substrate (3,3’, 5,5’-tetramethylbenzidine) was 
added and the reaction was stopped with 10% sulfuric acid (H2SO4).
The FDA approved C6 Lyme ELISA kit (Immunetics, Boston, MA) was used according to the 
manufacturer’s instructions to determine IgM/IgG antibodies against C6 peptide in sera 
of Lyme patients. To determine IgA antibodies against C6 peptide, the detection antibody 
enzyme conjugate was replaced by F(ab’)2 goat anti-human IgA secondary antibody HRP 
(1:4000, Thermo Fisher Scientific). Plates were read with a microplate reader (Bio-Rad, 
Berkeley, CA, USA) at 450 nm. The results of the individual test samples were read and 
expressed as optical density (OD). OD450 ≥ 0.5 were considered positive.
Isolation of human neutrophils and monocytes
Peripheral blood mononuclear cells (PBMCs) and polymorphonuclear cells (PMNs) were 
isolated from peripheral blood of healthy donors and buffy coats (Sanquin blood bank, 
Amsterdam, the Netherlands) using Lymphoprep (Axis-Shielt, Oslo, Norway) density gradient 
centrifugation. To isolate PMNs, erythrocytes were lysed in ammonium chloride buffer 
(155 mM NH4Cl, 10 mM KHCO3 and 0.11 mM EDTA) for 10 minutes at room temperature. 
Highly purified neutrophils were enriched from PMNs using EasySep Neutrophil Isolation 
kit (StemCell Technologies, Köln, Germany) according to the manufacturer’s protocol. Purity 
was >99,5% as assessed by Diff-Quick staining of cytospins according to the manufacturer’s 
guidelines (Medion Diagnostics, Düdingen, Switzerland). In total 1000 cells were counted 
per cytsopin and purity was determined based on morphology. Monocytes were isolated 
from PBMCs using CD14 MicroBeads (Miltenyi Biotec, Paris, France) according to the 
manufacturer’s protocol.
Immunoglobulin coating of latex beads
Carboxylate-modified polystyrene latex beads (non-fluorescent (0.9 μm) or green fluorescent 
(1.0 μm), Sigma-Aldrich) were washed twice with 2-(N-morpholino) ethanesulfonic (MES) 
buffer (30 mM, pH 6.1) and resuspended in MES buffer with 2 mg/ml endotoxin free BSA 
(Akron Biotech, Boca Raton, FL), human serum IgA (Cappel, MP Biomedicals, Santa Ana, CA) 
or human serum IgG (Cappel). Latex beads were incubated overnight (overhead shaker) at 
room temperature in the presence of N-(3-Dimethylaminopropyl)-N’-acid ethylcarbodimide 
hydrochlorid (EDAC, Sigma-Aldrich). After incubation, latex beads were washed and 
resuspended in PBS containing 0.1% BSA. Cyanogen bromide-activated sepharose beads 
(6.7 mg/ml, GE Healthcare Bio-Sciences, Uppsala, Sweden) were coated with 300 μg of BSA, 
serum IgA (Cappel), or serum IgG (Cappel) according to the manufacturer’s instructions.
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Opsonization and flow cytometric analysis of bacteria
Bacteria (2 x 107 colony forming units, CFU) were incubated with 1.5 mg/ml BSA (Roche 
Diagnostics), serum IgA (Cappel), serum IgG (Cappel), or sera from cohorts (diluted 1:10) for 
30 minutes at 37°C. Bacteria were washed with PBS and stained with F(ab’)2 goat anti-human 
IgA Alexa Fluor 647 (1:200, Jackson ImmunoResearch Laboratories, St. Thomas Place, MN), 
F(ab’)2 rabbit anti-human IgG Alexa Fluor 488 (1:100, Jackson ImmunoResearch Laboratories) 
and F(ab’)2 goat anti-human IgM Alexa Fluor 594 (1:200, Jackson ImmunoResearch 
Laboratories) in PBS for 30 min on ice. Opsonization was measured with flow cytometry 
(LSRFortessa, BD Biosciences, Franklin Lakes, NJ,) and analysed using FlowJo software 
(version X 10.0.7, Tree Star, Inc., Ashland, OR).
Phagocytosis assay
Human peripheral CD14+ monocytes and neutrophils were stimulated with BSA-, IgA,- or IgG 
coated fluorescent latex beads (Sigma-Aldrich) in an effector target (ET) ratio 1:100 for 30 
min at 37°C. Phagocytosis was measured with flow cytometry (LSRFortessa, BD Biosciences) 
and the phagocytic index (% green fluorescent positive cells x median fluorescence) was 
calculated using FlowJo software (version X 10.0.7, Tree Star).
Cytokine and chemokine release
Cytokine and chemokine release of human peripheral CD14+ monocytes and highly purified 
neutrophils was determined after 24 hours of stimulation with BSA-, IgA-, or IgG coated 
latex beads (ET ratio 1:100 and 1:60) using a Human Custom ProcartaPlex Multiplex 14-
plex assay (PPX-14-MX322WA, Thermo Fisher Scientific) measured by Bio-Plex 200 (Bio-
Rad, Hercules, CA) according to manufacturer’s instructions. The following factors were 
determined in supernatants of stimulated human peripheral CD14+ monocytes: granulocyte-
colony stimulating factor (G-CSF), gro-alpha, interleukin 1 alpha (IL-1α), IL-1β, IL-6, IL-7, IL-8, 
IL-10, IL-27, macrophage inflammatory protein 1α (MIP-1α), MIP-1β, MIP-3α, chemokine 
(C-C motif) ligand 5 (CCL5), and tumor necrosis factor alpha (TNF-α). The following factors 
were determined in supernatants of stimulated highly purified human neutrophils: IL-8, 
TNF-α, monocyte chemoattractant protein-1 (MCP-1), MIP-1α, and MIP-1β. IL-6 and IL-1β 
release by human peripheral CD14+ monocytes after 24 hours of stimulation with opsonized 
bacteria was measured with the Ready-SET-Go! ELISA Kit (Sigma Aldrich) according to the 
manufacturer’s instructions.
Quantitative analysis of ROS production and NET release
To measure the induction of ROS, neutrophils were loaded for 20 min at 37°C with the 
cell permeable fluorescent probe 5-(and-6)-chloromethyl-2’7’-dichlorodihydrofluorescein 
diacetate (Invitrogen Life Technologies; 10 μM), according to the manufacturer’s 
instructions. After washing, cells were resuspended in medium and allowed to settle for 30 
min at 37ºC. Neutrophils were stimulated with non-fluorescent latex beads coated with BSA, 
IgA or IgG (ET 1:150) in black 96-well plates (FLUOTRAC 200; Greiner Bio-One). Fluorescence 
was measured every 5 minutes for 3 hours in a preheated fluorimeter at 37°C at 480 nm 
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excitation, 520 nm emission (FLUOstar/POLARstar; BMG Labtech, Offenburg, Germany). 
NET release was determined by measuring extracellular DNA after uptake of coated beads 
by neutrophils, as described previously [19].
2D migration assay
PMNs were fluorescently labeled for 30 min at 37°C with the fluorescent probe calcein-AM 
(1 μM; Molecular Probes, Eugene, OR). After incubation, PMNs were washed twice and 
carefully resuspended in RPMI supplemented with 1% BSA. PMNs (2.5 x 105/well) were 
seeded and rested in 96-well flat bottom plates (Greiner Bio-One). Immunoglobulin-coated 
sepharose beads (10 μl/well) were added to the PMNs and incubated for 40 min at 37°C. 
After incubation, beads were washed to remove unbound PMNs. Beads were incubated 
with a buffer containing 2.0 g/l hexadecyltrimethyl ammonium bromide, 1.0 g/l Tween 
20, 2.0 g/l BSA, and 7.44 g/l ethylenediaminetetraacetic acid in PBS to lyse bound PMNs. 
Fluorescence was measured using 485 excitation and 520 emission filters (Fluostar Galaxy, 
BMG Labtechnologies, Offenburg, Germany).
Sample preparation for oxylipid analysis
Purified neutrophils and human peripheral CD14+ monocytes (106 cells in 250 µl) were 
stimulated with BSA-, IgA- or IgG coated latex beads (ET 1:150). After 1 or 4 hours stimulation, 
supernatant was collected and stored at -80°C. To 200 µl supernatant 4 µl internal standards 
solution (final concentration: 1 ng/ml PGE2-d4, LTB4-d4 and 15-HETE-d8 and 10 ng/ml 
DHA-d5; all from Cayman Chemicals, Ann Arbor, MI) and 1 ml 0.1 M sodium acetate pH 3.5 
solution were added. The samples were mixed and loaded on Waters Sep-Pak C18 cartridges 
200 mg, 3 ml (Waters, Milford, MA). Conditioning was done sequentially with 3 ml MeOH 
(LC-MS grade, Merck) and 3 ml water (LC-MS grade, VWR Chemicals), after samples had 
been loaded, cartridges were washed with 3 ml water and 3 ml n-hexane (Sigma-Aldrich) 
and eluted using 3 ml methyl formate (spectrophotometric grade, Sigma-Aldrich). Eluates 
were dried at 40˚C under a gentle stream of nitrogen and reconstituted in 200 µl 40% MeOH, 
after a final centrifugation step (16100 ×g, 4 °C, 5 min.) samples were transferred to micro 
vial inserts and stored at -80°C until analysis.
LC-MS analysis of oxylipids
Oxylipids were measured using a targeted RPLC-MS/MS method as previously described, 
with minor modifications [20]. Separation was accomplished on a Shimadzu LC-system, 
consisting of two LC-30AD pumps, a SIL-30AC autosampler held at 6°C and a CTO-20AC 
column oven held at 50°C (Shimadzu, ‘s-Hertogenbosch, The Netherlands). 40 µl of sample 
was injected. Compounds were separated on a Kinetex C18 50 × 2.1 mm, 1.7 µm column, 
protected with a C8 precolumn (Phenomenex, Utrecht, The Netherlands) and were eluted 
using a gradient of water with 0.01% acetic acid (eluent A) and MeOH with 0.01% acetic acid 
(eluent B) at a constant flowrate of 400 µl/min. The gradient started at 30% B for 1 min., 
was then ramped to 45% at 1.1 min., to 53.5% at 2 min., to 55.5% at 4 min., to 90% at 7 min. 
and to 100% B at 7.1 min., at which it was held until 9 min. MS analysis was done on a QTrap 
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6500 (Sciex, Nieuwerkerk a/d IJssel, The Netherlands) in negative electrospray ionization 
mode. The needle voltage was set at -4500 V, the drying temperature at 450 °C, ion source 
gas 1 and ion source gas 2 (both air) were set at respectively 40 and 30 psi and nebulizer 
gas (nitrogen) was set at 30 psi. The entrance potential was set at -10 V and the collision 
gas flow at medium. The instrument was used in scheduled MRM mode. The transitions 
and other individually optimized parameters for the compounds measured are shown in 
Supplementary Table 2. Substances were identified based on relative retention times in 
combination with characteristic mass transitions compared to authentic standard material.
RNA isolation
Total RNA from human peripheral CD14+ monocytes (2 x 106) and highly purified neutrophils 
(107) was isolated using TRIzol Reagent (Invitrogen) following the manufacturer’s protocol. 
RNA quality and yield was analyzed with the Agilent RNA 6000 Nano Kit (Agilent Technologies, 
Foster City, CA) according to the manufacturer’s protocol using capillary electrophoreses 
(Agilent 2100 Bioanalyzer, Agilent Technologies). RNA samples with a RNA Integrity Number 
(RIN) below 7.5 were excluded.
Real-Time PCR
Reverse transcription of RNA was performed using the Promega A3500 kit according to 
the manufacturer’s instructions (Promega, Fitchburg, WI,). Melt curves were recorded and 
analyzed using a StepOne Real Time PCR System (ThermoFisher Scientific). Genes of interest 
(Supplementary Table 1) were normalized against the reference gene elongation factor 
1a (EF1a). The final value of relative quantification was described as fold change of gene 
expression in the test sample compared to BSA-stimulated cells using –ΔΔCt analysis.
RNA sequencing
cDNA sequencing libraries were prepared with 1 μg RNA input of human peripheral CD14+ 
monocytes according to Illumina TruSeq Stranded mRNA Sample Preparation Guide (Illumina 
Inc., San Diego, CA). In brief, total RNA was treated with DNase I and poly-T oligo attached 
magnetic beads to elute poly-(A+) mRNA. To synthesize the first-strand cDNA, purified mRNA 
was fragmented and primed using random-hexamer primers and reverse transcriptase. 
Second strand cDNA was synthesized by incorporating dUTPs using DNA polymerase I. 
Subsequently, the 3’ends of double-stranded cDNA were adenylated and unique barcoding 
adapters were ligated to the ends. Barcode-ligated cDNA fragments were selectively 
enriched using PCR to create cDNA libraries for sequencing. Eighteen unique barcode 
sequences were applied for simultaneous analysis of multiple samples. The quality and 
yield of the resulting libraries were assessed using the Agilent D5000 ScreenTape (Agilent 
Technologies) before sequencing. Libraries were loaded onto an Illumina cluster station 
(Illumina Inc.) and sequenced using Illumina HiSeq 4000 (Illumina Inc.). The optimal read 
depth to analyze the mRNA transcriptome of primary human monocytes was determined 
at 10 million reads per sample using single reads with 50 cycles per read.
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RNA sequencing data analysis
Data was analyzed with the R-package ShrinkBayes [21, 22]. For two-group comparisons the 
effect sizes were modeled by a spike-and-slab mixture with a spike on zero to capture the 
non-differential genes, and two Gaussian slabs to capture positive and negative differential 
effects. ShrinkBayes then computes the (posterior) probability that a gene is differentially 
expressed to provide a local false discovery rate (lfdr) estimate for each gene. For multi-
group comparisons, a mixture of a spike on zero (no difference between groups) and non-
informative Gaussian slabs was used to model the group-specific effect sizes. The Bayes 
factor, quantifying the relative likelihood of the absence of any group effect versus the 
presence of it, weighted by the prior odds of being non-differentially expressed renders 
the lfdr [23]. These odds were estimated from the data using empirical Bayes [22]. Genes 
with lfdr ≤ 0.05 were considered significant.
Pathway enrichment and cluster analysis
Genes were ranked by −log10 lfdr value multiplied by the sign of log-transformed fold 
change. Gene set enrichment analysis (GSEA) was performed using the GSEA Desktop 
Application (v.3.0) [24] and Reactome database [25] from MsigDB (v.6.2) [26] gene 
signatures. GSEA has been performed with the default parameters with a number of 
permutations fixed at n = 1000, the number of max genes at n = 2000, and the number 
of min genes at n = 15. GSEA analysis results are visualized and interpreted in Cytoscape 
(v.3.7.1) [27] using its EnrichmentMap (v.3.2.0) [28] application. Pathways with a Q value ≤ 
0.01 were considered significantly enriched. Clustering analysis was performed using the 
Singular Value Decomposition (SVD) with imputation algorithm in ClustVis, a web-based 
multivariate data analysis tool [29]. Log-transformed significant regulated genes (lfdr ≤ 
0.05) were subjected to unsupervised hierarchical clustering (Euclidian distance measure 
and the Ward’s linkage method).
Statistical analysis
Statistical analysis was performed with GraphPad Prism version 8.2.1 (GraphPad, San 
Diego, CA). Statistical differences were determined using unpaired Student two-tailed t 
tests (two groups), one-way ANOVA (more than two groups) for normally distributed data, 
and Mann-Whitney U tests (two groups) or Kruskall-Wallis tests (more than two groups) 
for not normally distributed data. Results were considered statistically significant when 




Antigen-specific IgM, IgG and IgA antibody titers after typhoid fever vac-
cination and during Lyme borreliosis
The presence of antigen-specific antibodies was investigated in sera of healthy individuals 
who received a single dose typhoid fever vaccination (TFV) containing Vi capsular 
polysaccharide (Vi) of S.typhi Ty2 strain [17]. Sera were obtained at three time points, i.e. 
at baseline (T0), and two (T2) and twelve weeks (T12) after vaccination. Vi-specific IgM, IgG 
and IgA titers were significantly increased at T2 compared to T0. Vi-specific IgG and IgA 
were still detectable at T12, although significantly decreased compared to T2 (Figure 1A, and 
Supplementary Figure 1A). The capacity of Vi-specific antibodies to opsonize S. typhi was 
next assessed, with T0 sera considered as baseline situation. Increased binding of IgM and 
IgA to S. typhi was detected at T2 compared to T0. Binding of IgM and IgA to S. typhi at T12 
was significantly decreased, which was in line with reduced Vi-specific antibody levels over 
time as measured by ELISA. No significantly increased opsonization of S. typhi with IgG was 
observed at T2 and T12 compared to T0 (Figure 1B), in spite of detection of Vi-specific IgG 
antibody titers (Figure 1A). Additionally, antigen-specific antibodies against B. burgdorferi 
were investigated in sera of Lyme borreliosis patients (LymeProspect cohort) [18]. Serum 
samples at presentation (T1), as well as six (T6) and twelve weeks (T12) after physician-
confirmed Lyme borreliosis were measured. Of note, control serum before infection was 
not available. Borrelia-specific C6 peptide IgM/IgG and IgA antibodies (OD450 ≥ 0.5) were 
present at T1 in approximately 32% and 24% of the patients, respectively with no significant 
changes at T6 or T12 (Figure 2A, and Supplementary Figure 1B). Although binding of IgM, 
IgG and IgA to Borrelia strains varied between Lyme borreliosis patients, opsonization was 
detected at all three time points (T1, T6 and T12, Figure 2B). Thus, after vaccination with TFV 
as well as during Lyme borreliosis, antigen-specific IgM, IgG and IgA antibodies were present.
Human peripheral monocytes upregulate inflammatory pathways after 
IgA stimulation
To compare the immune activating properties of serum IgG- and IgA-complexes, cross-
linking of Fcγ receptors or FcαRI was induced by stimulation of human peripheral CD14+ 
monocytes with serum IgG- or IgA-opsonized beads. BSA-opsonized beads served as a 
negative control. Of note, to exclude the influence of pattern recognition receptors, beads 
were used instead of bacteria. Whole transcriptome and gene set enrichment analysis 
(GSEA) of stimulated monocytes resulted in the detection of 19,150 genes of which 322 
genes were significantly different expressed after stimulation with serum IgA- compared to 
IgG-complexes (Figure 3A & B). Principal component analysis (PCA) of log-transformed gene 
expression revealed three independent segregated clusters based on stimulation (Figure 
3C). Hierarchical clustering (Euclidian distance measure and the Ward’s linkage method) of 
significantly different regulated log-transformed genes (lfdr ≤ 0.05) resulted in separated 
clusters for serum IgA- and IgG-complex stimulation (Figure 3D).
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Figure 1. Antigen-specific antibodies after typhoid fever vaccination. (A) Specific IgM (first panel), 
IgG (second panel) and IgA (third panel) antibodies against Vi capsular polysaccharide (Vi) in sera of 
healthy individuals that received the non-live parenteral Vi capsular polysaccharide vaccine (TFV, 
n=29). Serum samples were taken at baseline (T0), 2 weeks (T2), and 12 weeks post-vaccination (T12). 
Antibody titers are expressed as optical density measured at 450 nm (OD450). (B) Median fluorescent 
intensity (MFI) of IgM (first panel), IgG (second panel), and IgA (third panel) binding to Salmonella 
typhi (S. typhi) opsonized with sera of TFV vaccinated individuals at baseline T0, T2, and T12. Data 
was analyzed using One-way ANOVA with post-hoc Tukey test; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; 
**** p ≤ 0.0001; ns, not significant.
126
Chapter 6
Figure 2. Antigen-specific antibodies during Lyme borreliosis. (A) Specific IgM/IgG (first panel) and 
IgA (second panel) against C6 peptide in sera of Lyme borreliosis patients (n=50) at presentation (T1), 
six weeks (T6), and twelve weeks (T12) after physician-confirmed Lyme borreliosis. Antibody titers are 
expressed as optical density measured at 450 nm (OD450) and represented with a negative control 
(NC, human source material containing no detectable antibodies to B. burgdorferi) for IgM/IgG and 
IgA and a positive control (PC, human source material containing high detectable antibodies to B. 
burgdorferi) for IgM/IgG. Each symbol represents one patient. (B) Median fluorescent intensity (MFI) 
of IgM (first panel), IgG (second panel), and IgA (third panel) binding to a mixture of Borrelia species 
garinii, afzelii, and sensu stricto (Borrelia) opsonized with sera of Lyme borreliosis patients at T1, T6, 
and T12. Each symbol represents one individual or patient. Data was analyzed using One-way ANOVA 
with post-hoc Tukey test; ns, not significant.
GSEA identified significantly upregulated molecular pathways regarding the immune system 
(FDR Q value ≤ 0.01), i.e. cytokine signaling, interferon signaling, and chemokine receptors 
bind chemokines, in monocytes after stimulation with serum IgA-complexes (Figure 3E). An 
overview of upregulated pathways after stimulation with serum IgA-complexes is listed in 
Supplementary Figure 2. Although 122 genes were significantly upregulated after stimulation 
with IgG-complexes, no upregulated molecular pathways were identified.
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Figure 3. Upregulation of inflammatory pathways in IgA-activated monocytes. (A) Volcano plot of all 
19,150 genes expressed by human peripheral CD14+ monocytes stimulated for 4 hours with IgG- and 
IgA-opsonized beads. X-axis represents log2 fold change of log-transformed RNA-seq counts, y-axis 
represents the local false discovery rate (lfdr). (B) Overview of 444 significantly different regulated 
genes (lfdr ≤ 0.05) of human peripheral CD14+ monocytes stimulated for 4 hours with IgG- (blue) or 
IgA- (red) opsonized beads. (C) Principal component analysis (PCA) of log-transformed RNA-seq counts 
of human peripheral CD14+ monocytes stimulated for 4 hours with BSA- (n=5, green), IgG- (n=8, blue), 
and IgA- (n=10, red) opsonized beads. Component % variance; PC1 = 73.1%, PC2 = 5.1%. Each symbol 
represents one donor. (D) Hierarchical clustering of log-transformed RNA-seq counts of significantly 
different regulated genes (lfdr ≤ 0.05) for all three stimuli (BSA; green, IgG; blue, IgA; red) using the 
Euclidian distance measure and the Ward’s linkage method. Gene expression is visualized in arbitrary 
units (AU). (E) Significant upregulated pathways in IgA cluster compared to IgG cluster (FDR Q value ≤ 
0.01) based on gene set enrichment analysis (GSEA) ranked by −log10 lfdr value multiplied by the sign 
of log-transformed fold change. Data was analyzed with the R-package ShrinkBayes.
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IgA stimulation of human peripheral monocytes and neutrophils induces 
inflammatory cytokine, chemokine and lipid release
To follow up on upregulated molecular pathways, cellular effector functions of human 
peripheral neutrophils and CD14+ monocytes were compared after stimulation with serum 
IgA- and IgG-complexes (Figure 4 and 5). The phagocytic index of both neutrophils and 
monocytes was significant increased after stimulation with serum IgG- and IgA-complexes 
compared to BSA-complexes. Large variation was observed between donors, but overall, 
no differences in phagocytosis of serum IgG- and IgA-complexes was observed (Figure 4A 
and Figure 5A). In monocytes, the expression of 82 genes of the immune system pathway 
were significantly increased after stimulation with serum IgA-complexes compared to 
IgG (Figure 4B), of which the secretion of 14 cytokines and chemokines was assessed on 
protein level (Figure 4C). Significantly increased release of IL-1α, IL-1β, IL-6, IL-7, IL-10, IL-27, 
granulocyte colony-stimulating factor (G-CSF), chemokine (C-X-C motif) ligand (CXCL) 1, 
chemokine (C-C motif) ligand (CCL) 3, CCL4, and CCL20 was detected after stimulation with 
serum IgA-complexes compared to IgG-complexes. No significant differences were detected 
for the release of IL-8, TNF-α, and CCL-5. To exclude the influence of SNPs in Fcγ receptors 
on monocyte activation by serum IgG-complexes, SNP genotyping of FcγRIIa (FCGR2A, 
rs1801274; 131H) and FcγRIIIa (FCGR3A, rs396991; 158V) was performed. Allele frequencies 
of 29.63% RR, 59.26% RH, and 11.11% HH were detected in FCGR2A, and 25.93% FF, 25.93% 
FV, and 44.44% VV in FCGR3A (Supplementary Figure 3). Different allele frequencies of 
FCGR2A and FCGR3A did not influence cytokine release by monocytes (Figure 4C).
During phagocytosis, neutrophils generate reactive oxygen species (ROS) to promote 
microbial killing and induce the formation of neutrophil extracellular traps (NETs) [30]. 
Low ROS production was observed in neutrophils stimulated with BSA-complexes. Uptake 
of either serum IgG- or IgA-complexes induced a similar increase in ROS production over 
time (Figure 5B), as well as NET release after 3 hours (Figure 5C). In contrast, migration 
of neutrophils towards large immunoglobulin-coated beads was only observed towards 
serum IgA-, but not IgG-opsonized beads. The presence of IgG on beads with different 
IgA:IgG ratios diminished migration presumably through lowering the IgA concentration 
(Figure 5D). Furthermore, significantly increased IL-8 and TNF-α were released by neutrophils 
after stimulation with serum IgA-complexes. A similar trend was detected for monocyte 
chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1α (Mip-1α), and 
Mip-1β (Figure 5E and Supplementary Figure 4).
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Figure 4. Cytokine and chemokine release by monocytes upon IgG and IgA immune complex 
stimulation. (A) Phagocytosis of BSA-, IgA-, or IgG-opsonized beads by human peripheral CD14+ 
monocytes. Phagocytic index was calculated as the percentage of cells that had taken up beads 
multiplied by the median fluorescence intensity of bead-positive cells. Each symbol represents the 
mean of one healthy donor measured in duplo. (B) Significant (lfdr ≤ 0.05) differential expressed genes 
in the immune system pathway by human peripheral CD14+ monocytes stimulated for 4 hours with 
IgG- (n=8), and IgA- (n=10) opsonized beads. Coloring represents log expression of the significant 
differential expressed genes. Protein expression of bold highlighted genes is determined using a 
multiplex Luminex assay. (C) Multiplex Luminex assay of unstimulated (n=4) human peripheral CD14+ 
monocytes or stimulated for 24 hours with BSA-(n=4), IgA- (n=10), or IgG- (n=9) opsonized beads. 
Each dot represents the mean of one donor in duplo. Data is presented as mean ± SD. Of note, values 
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above detection limit were excluded. Data was analyzed using One-way ANOVA with post-hoc Tukey 
test; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; ns not significant.
We previously showed that neutrophils release leukotriene B4 (LTB4), an important 
neutrophil chemoattractant, only after stimulation with serum IgA-, but not IgG-complexes 
[31]. To assess the release of inflammatory leukotrienes (LTs) and prostaglandins (PGs) of 
the arachidonic acid metabolism pathway in human peripheral neutrophils and CD14+ 
monocytes, lipid metabolite analyses were performed. Additionally, the expression of 
the enzymes cyclo-oxygenase 2 (COX-2) and 5-lipoxygenase (5-LOX), important for the 
conversion of arachidonic acid into LTs and PGs, were determined. COX-2 expression 
was significantly increased in monocytes after 4 hours of stimulation with serum IgA-
complexes compared to IgG-complexes (Figure 6A), but no difference was observed for 
5-LOX expression (Figure 6B). Furthermore, significantly enhanced release of prostaglandin 
E2 (PGE2, Figure 6C) as well as eicosanoids of the 5-LOX pathway were detected after both 1 
hour and 4 hours of serum IgA-complex stimulation, including upregulation of 5-HETE, LTB4, 
20-OH LTB4, 6-trans-LTB4, and 6t,12epi-LTB4 (Figure 6D-H). The release of inflammatory 
lipids by neutrophils after stimulation with serum IgA- and IgG-complexes resulted in 
similar patterns as depicted for monocytes, albeit less distinct (Supplementary Figure 5). 
Thus, stimulation of either human peripheral CD14+ monocytes or neutrophils with serum 
IgA-complexes resulted in more pronounced pro-inflammatory responses compared to 
stimulation with serum IgG-complexes.
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Figure 5. Cellular activation and cytokine release of neutrophils upon immune complex 
stimulation. (A) Phagocytosis of BSA-, IgA- or IgG-opsonized beads by human neutrophils. Phagocytic 
index was calculated as the percentage of cells that had taken up beads multiplied by the median 
fluorescence intensity of bead-positive cells. Each symbol represents the mean of one healthy donor 
measured in duplo. (B) Induction of reactive oxygen species (ROS) was measured by incubating human 
neutrophils with BSA-, IgA-, or IgG-opsonized beads for 3 hours. One experiment of a healthy donor is 
shown as mean ± SD, each point represents the mean of triplicates. Figure is representative for 4 different 
healthy donors, measured in 4 independent experiments. (C) Quantification of extracellular DNA 
(reflecting release of NETs) after stimulating human neutrophils with BSA-, IgA- or IgG-opsonized beads. 
Each symbol represents the mean of one healthy donor measured in triplo. (D) Migration of human 
neutrophils towards cyanogen bromide-activated sepharose beads opsonized with BSA or different 
ratios of IgA and IgG. One experiment of a healthy donor is shown as mean ± SD. Figure is representative 
for 3 different healthy donors, measured in 3 independent experiments. (E) Concentration of indicated 
cytokines and chemokines in supernatant after stimulating purified human neutrophils for 24 hours with 
BSA-, IgA- or IgG-opsonized beads. Each dot represents mean of one donor in duplo. Data was analyzed 
using One-way ANOVA with post-hoc Tukey test; * p ≤ 0.05; ** p ≤ 0.01; **** p ≤ 0.0001; ns not significant.
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Figure 6. Secretion of inflammatory lipids from arachidonic acid by monocytes. (A-B) COX-2 and 
5-LOX mRNA induction in human peripheral CD14+ monocytes stimulated for 4 hours with BSA- (n=3), 
IgA- (n=3), or IgG- (n=3) opsonized beads. The relative gene mRNA level was normalized to reference 
gene (GAPDH), and BSA stimulation was set as 1. Each dot represents one donor. (C-H) Lipid mediators 
in the supernatant of human peripheral CD14+ monocytes stimulated for 1 or 4 hours with BSA-, IgA-, 
or IgG-opsonized beads. Values are presented as area under the curve in ratio to internal standards. 
Mean ± SD of technical triplicates of one donor is depicted. Data is presented as mean ± SD. PGE2, 
prostaglandin E2; COX, cyclooxygenase; 5-LOX, 5 lipoxygenase, 5-HETE, 5-Hydroxyeicosatetraenoic 
acid; 5-HPETE, Arachidonic acid 5-hydroperoxide; LTA4, leukotriene A4; LTA4H, leukotriene A4 
hydroxylase; LTB4, leukotriene B4; 20-OH-LTB4, 20-hydroxy leukotriene B4; 6t,12epi-LTB4, 6-trans, 
12-epi leukotriene B4. Data was analyzed using One-way ANOVA with post-hoc Tukey test; * p ≤ 0.05; 
** p ≤ 0.01; *** p ≤ 0.001; **** p ≤ 0.0001; ns not significant
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IgA-opsonized bacteria induce the release of inflammatory cytokines 
IL-6 and IL-1β by human peripheral monocytes
To compare the inflammatory responses of serum IgA to serum IgG in a more physiological 
setting, human peripheral CD14+ monocytes were stimulated with different bacterial species 
(Supplementary Table 3) opsonized with either pooled human serum IgA or IgG. Immune 
activation was assessed by the secretion of the cytokines IL-6 and IL-1β after 24 hours of 
stimulation. Bifidobacterium, Escherichia, Lactobacillus, Staphylococcus, Streptococcus and 
Borrelia bacterial species that had been opsonized with serum IgA significantly enhanced 
the release of IL-6 by monocytes compared to uncoated or serum IgG-opsonized bacteria 
(Figure 7). Stimulation with serum IgA-opsonized S. typhimurium or S. typhi, did not result 
in significant enhanced release of IL-6. Similar results were detected for the release of 
IL-1β (Figure 8), although no significant differences in IL-1β release were detected after 
stimulation with E. coli, L. jensenii, S. aureus, and S.typhi opsonized with serum IgA or IgG. 
Overall, these findings demonstrate that opsonization of bacteria with serum IgA induces 
significant increased release of pro-inflammatory cytokines by human peripheral CD14+ 
monocytes compared to serum IgG opsonization, supporting an important role for serum 
IgA in combating bacterial infections.
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Figure 7. IgA-opsonized bacteria induce the release of IL-6 by monocytes. Concentration of IL-6 (pg/
ml) in supernatant after stimulating human peripheral CD14+ monocytes for 24 hours with uncoated 
and human pooled serum IgA- or IgG-opsonized bacterial species. Data is presented as mean ± SD. 
Data was analyzed using One-way ANOVA with post-hoc Tukey test; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 
0.001; **** p ≤ 0.0001; ns not significant.
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Figure 8. IgA-opsonized bacteria induce the release of IL-1β by monocytes. Concentration of IL-1β 
in supernatant after stimulating human CD14+ monocytes for 24 hours with uncoated and human 
pooled serum IgA-, or IgG-opsonized bacterial strains. Data is presented as mean ± SD. Data was 
analyzed using One-way ANOVA with post-hoc Tukey test; * p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; **** 




In this study, we showed the induction of antigen-specific serum IgA after vaccination with 
TFV and during Lyme borreliosis. In contrast to the current generally held notion that serum 
IgA plays a passive role in immunity, we demonstrated that serum IgA-complexes proved 
significantly more potent in inducing inflammatory responses by human peripheral CD14+ 
monocytes and neutrophils, compared to IgG-complexes. These findings support an important, 
but previous overlooked, role for serum IgA in protective systemic humoral immunity.
In serum, IgA is the second most abundant antibody after IgG. Nonetheless, the exact 
functions of serum IgA are relatively unexplored. An immune modulatory role for serum IgA 
was proposed because monovalent targeting of FcαRI resulted in the inhibition of oxidative 
burst activity, chemotaxis and IgG-mediated phagocytosis and cytokine production [14, 
32-34]. FcαRI associates with the FcR γ-chain subunit, which contains an immunoreceptor 
tyrosine-based activation motif (ITAM) [35]. Low-level engagement of FcαRI leads to partial 
phosphorylation of the FcR γ-chain resulting in inhibitory ITAM (ITAMi) signaling [13]. This 
phenomenon proved to be, however, not specific for FcαRI, as it was also demonstrated for 
FcγRIIa [36]. It is therefore suggested that low avidity ligand stimulation of ITAM-bearing Fc 
receptors in general may result in inhibitory signaling [37]. The current perception of IgA 
as a non-inflammatory antibody is furthermore supported by the fact that IgA is a poor 
activator of the classical complement pathway and has a shorter half-life (~5 days) than IgG 
(~21 days) [11]. Low serum concentration and a short half-life are also described for IgE, 
which is a potent key inflammatory immunoglobulin in allergic diseases [38]. We therefore 
propose that the shorter half-life of serum IgA and the lack of classical complement 
activation are in fact properties to prevent excessive immune cell activation through FcαRI 
similarly as for IgE and FcεRI [39]. Here we demonstrate that even though serum IgG- and 
IgA-complexes were equally phagocytosed by human peripheral neutrophils and CD14+ 
monocytes, molecular pathways regarding the immune system such as cytokine signaling 
and signaling by interleukins were only significantly upregulated after serum IgA-complex 
stimulation. Moreover, pro-inflammatory cytokines, chemokines, and lipid mediators were 
secreted in significantly higher concentrations after serum IgA- compared to serum IgG-
complex stimulation.
To induce cell signaling Fc receptors require ITAMs, either present in their cytoplasmic tail 
or via associated subunits (FcRγ or FcεRIβ chain). Signaling via the high affinity FcγRI and 
FcαRI signaling occurs via FcR γ-chain, which contains ITAMs, whereas FcγRIIa signals via 
its own intracellular ITAM motif. FcγRIIIb is a glycophosphatidylinositol-anchored protein in 
the membrane with no signaling capacity by itself [40, 41]. Resting neutrophils have limited 
to no FcγRI expression and are likely activated via constitutively expressed FcγRIIa, after 
binding of IgG complexes [42]. Dissimilarity in ITAM signaling between FcαRI and FcγRIIa 
may explain the differences in cytokine release in neutrophils. It has been suggested that 
FcγRIIa does not induce cytokine release, as FcγRIIA-ITAM expression in B-cell transfectants 
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was unable to induce IL-2 production, whereas IL-2 release was detected after swapping 
the FcγRIIa-ITAM with a FcR γ-chain-ITAM [43, 44]. Monocytes however were shown to 
secrete significant amounts of IL-8 after cross-linking of FcγRIIa [45]. In this study, IL-8 release 
was also detected by monocytes after stimulation with serum IgG-complexes. Moreover, 
monocytes express the high-affinity receptor FcγRI, which signals via the FcR γ-chain. 
Low cytokine release by monocytes after stimulation with serum IgG-complexes might be 
explained by the competition for FcR γ-chain between FcαRI and FcγRI as described for 
FcεRI and FcγRIII [46].
The general conception of systemic induction of IgG and local mucosal induction of IgA titers 
after pathogen encounter is likely oversimplified. Vi-specific IgM, IgG, as well as IgA titers 
were detected in sera of healthy individuals vaccinated with TFV until twelve weeks post-
vaccination. Subsequently, increased opsonization of S. typhi with serum IgA was observed 
two weeks post-vaccination. Since monocytes secreted high amounts of IL-6 and IL-1β after 
stimulation with uncoated S. typhi, the additive effect of serum IgA and IgG opsonization 
could not be determined. This might be explained by the fact that S. typhi is an intracellular 
pathogen able to infect monocytes and induce pro-inflammatory responses through 
pathogen recognition receptors [47]. A recent study showed that the quantity and avidity 
of Vi-specific serum IgA correlated with protection against S. typhi infection [48]. How 
these antibodies contribute to protective immunity remains elusive. High titers of antigen-
specific serum IgA have also been observed in human immunodeficiency virus 1 (HIV-1) elite 
responders, who spontaneously control HIV-1 viremia, and in individuals with Clostridium 
difficile infection [49, 50]. On average, antigen-specific serum IgA was also detected in 
patients with coronavirus disease 2019 (COVID-19) eight days after symptom onset, which 
contributed to the neutralization of severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) in vitro [51, 52]. We showed that monocytes significantly enhanced IL-1β and 
IL-6 production after stimulation with multiple bacterial species opsonized with serum IgA 
compared to IgG. Moreover, crosstalk between pathogen recognition receptors and FcαRI 
may result in enhanced cytokine release by monocytes [53]. As such, vaccine-elicited serum 
IgA may contribute to systemic protection against typhoid fever and other infections.
C6 peptide-specific IgM, IgG, and IgA titers against Borrelia species were measured in Lyme 
borreliosis patients and were still detectable at twelve weeks after confirmed disease. 
Stimulation of monocytes with serum IgA-opsonized Borrelia species resulted in the release 
of IL-6 and IL-1β, which was not detected for serum IgG-opsonized Borrelia. Antibodies 
against B. burgdorferi are described to ameliorate disease symptoms in experimental 
models, yet are not always capable of clearing the infection due to multiple immune evasion 
mechanisms of B. burgdorferi [54, 55]. During post-disease Lyme syndrome, antibody 
responses are suggested to play a detrimental role contributing to disease symptoms through 
immune cell activation and cytokine production [56]. Antigen-specific serum IgA during early 
Lyme borreliosis has been evaluated in one study in which C6-specific IgA correlated with 
disseminated infection and possibly neurologic manifestations or arthralgia. However, this 
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association was only seen in a small study population [57]. IgA (auto)antibodies have also 
been described to contribute to inflammation in diseases such as IgA nephropathy, linear IgA 
bullous disease and rheumatoid arthritis [58-60]. We put forward that excessive activation 
of immune cells by serum IgA-complexes via FcαRI cross-linking might contribute to tissue 
damage and disease pathology [61]. A better understanding of IgA-FcαRI interactions in 
these diseases may therefore provide novel therapeutic interventions.
In conclusion, the present study indicates that serum IgA plays an important role in initiating 
potent immune responses, which challenges the widely held notion of serum IgA being 
passively involved in immunity and inhibiting pro-inflammatory responses of other receptors 
through ITAMi signaling. We anticipate that serum IgA and FcαRI-mediated immune 
responses play an important role in infectious diseases, which supports novel vaccination 
strategies to boost the development of IgA responses.
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Supplementary Figures
Supplementary Figure 1. Overview of antigen-specific antibodies after TFV vaccination and during 
Lyme’s disease. (A) Specific IgM (first panel), IgG (second panel) and IgA (third panel antibodies 
against Vi capsular polysaccharide (Vi) in sera of each healthy individual (one individual per row) that 
received the non-live parenteral Vi capsular polysaccharide vaccine (TFV, n=29) pre-vaccination (T0), 
two weeks (T2), and twelve weeks (T12) post-vaccination. (B) Specific IgM/IgG (first panel) and IgA 
(second panel) against C6 peptide in sera for each Lyme borreliosis patient (one individual per row, 
n=50) at presentation (T1), six weeks (T6), and twelve weeks (T12) after physician-confirmed Lyme 
borreliosis. Antibody titers are depicted as a gradient from low (green) to high (red) based on optical 
density measured at 450 nm.
140
Chapter 6
Supplementary Figure 2. Overview of upregulated pathways in monocytes upon IgA stimulation. 
Significant upregulated pathways in human peripheral CD14+ monocytes stimulated with serum IgA-
complexes compared to IgG-complexes (FDR Q value ≤ 0.01) based on gene set enrichment analysis 
(GSEA) of genes ranked by −log10 lfdr value multiplied by the sign of log-transformed fold change. 
Data is depicted as negative log10 Q value.
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6Supplementary Figure 3. FcγR2A and FcγR3A SNPs in monocytes. Single nucleotide polymorphisms 
(SNPs) in FcγRIIa (FCGR2A, rs1801274; 131H) and FcγRIIIa (FCGR3A, rs396991; 158V) in human 
peripheral CD14+ monocyte donors used for RNA-sequencing (n=23). Percentages of homozygous 
and heterozygous for the different alleles are depicted in a pie chart. Discrimination between the 
different donors is visualized in a allelic discrimination plot.
Supplementary Figure 4. Neutrophil cytokine regulation upon immune complex stimulation. Fold 
change in mRNA level of cytokines and chemokines after stimulation of purified human neutrophils 
for 4 hours with BSA-, IgA- or IgG-opsonized beads. The relative gene mRNA level was normalized to 




Supplementary Figure 5. Neutrophil arachidonic acid lipid secretion upon immune complex 
stimulation. (A-B) COX-2 and 5-LOX mRNA induction in purified human neutrophils stimulated for 
4 hours with BSA- (n = 3), IgA- (n = 3), or IgG- (n = 3) opsonized beads. The relative gene mRNA level 
was normalized to reference gene (GAPDH), and BSA stimulation was set as 1. Each dot represents 
one donor. (C-H) Lipid mediators in the supernatant of purified human neutrophils stimulated for 1 
or 4 hours with BSA-, IgA-, or IgG-opsonized beads. Values are presented as area under the curve 
in ratio to internal standards. Mean ± SD of technical triplicates of one donor is depicted. Data is 
presented as mean ± SD. PGE2, prostaglandin E2; COX, cyclooxygenase; 5-LOX, 5 lipoxygenase, 5-HETE, 
5-Hydroxyeicosatetraenoic acid; 5-HPETE, Arachidonic acid 5-hydroperoxide; LTA4, leukotriene A4; 
LTA4H, leukotriene A4 hydroxylase; LTB4, leukotriene B4; 20-OH-LTB4, 20-hydroxy leukotriene B4; 
6t,12epi-LTB4, 6-trans, 12-epi leukotriene B4. Data was analyzes using One-way ANOVA with post-hoc 
Tukey test; * p ≤ 0.05; *** p ≤ 0.001; ns, not significant.
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Supplementary Tables
Supplementary Table 1. qPCR primers. FW, forward; RV, reverse




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Main organ of 
residence/infection Metabolism
Bifidobacterium adolescentis Gram positive Gastrointestinal tract Anearobic
Bifidobacterium breve Gram positive Gastrointestinal tract Aerobic
Bifidobacterium longum Gram positive Gastrointestinal tract Anearobic





Lactobacillus crispatus Gram positive Vagina
Facultative 
anaerobic










Lactobacillus iners Gram positive Vagina
Facultative 
anaerobic
Lactobacillus jensenii Gram positive Vagina
Facultative 
anaerobic
Lactobacillus rhamnosus Gram positive Vagina
Facultative 
anaerobic
Staphylococcus aureus Gram positive Skin
Facultative 
anaerobic
Staphylococcus epidermidis Gram positive Skin Anearobic
Streptococcus pneumoniae Gram positive Respiratory tract Anearobic
Salmonella typhimurium Gram negative Gastrointestinal tract
Facultative 
anaerobic
Salmonella typhi Gram negative Gastrointestinal tract
Facultative 
anaerobic
Borrelia garinii, afzelii, and 
sensu stricto (mix) Gram negative Skin Microaerobic
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Autoantibodies are detected in most patients with rheumatoid arthritis (RA) and can be 
of the IgM, IgG or IgA subclass. Correlations between IgA autoantibodies and more severe 
disease activity have been reported, but the functional role of IgA autoantibodies in the 
pathogenesis of RA is ill understood. We explored the effect of IgA immune complexes on 
osteoclast mediated bone resorption.
Autoantibody levels in synovial fluid of RA patients were measured with ELISA. Monocytes 
and neutrophils were stimulated with immune complexes isolated from synovial fluid 
of RA patients and IgA or IgG-coated beads after which supernatant was collected, and 
cytokine and neutrophil extracellular trap (NET) release were measured. Bone resorption 
by osteoclasts was quantified with microscopy.
Anti-citrullinated protein antibody (ACPA) IgA levels correlated with the release of IL-6 and 
IL-8 by monocytes after stimulation with synovial fluid immune complexes. Osteoclasts 
resorbed significantly more bone in presence of supernatant of IgA-activated monocytes 
compared to supernatant of IgG-activated monocytes (p=0.0233). NET formation was 
enhanced by synovial fluid immune complexes. Osteoclasts expressed the Fc receptor for 
IgA (FcαRI; CD89), but lacked Fc gamma receptors. IgA-activated osteoclasts produced 
significantly increased levels of IL-6 (p<0.0001) and IL-8 (p=0.0007) compared to IgG-
activated osteoclasts. Both IL-6 and IL-8 enhanced bone resorption.
IgA autoantibodies enhance bone resorption by osteoclasts directly, and indirectly via 
cytokines released by immune cells, which can result in more severe disease activity in 
RA patients. Targeting IgA-FcαRI interactions therefore represents a promising novel 
therapeutic strategy for RA patients with IgA autoantibodies.
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Introduction
Rheumatoid arthritis (RA) is a heterogeneous chronic inflammatory disease that is mainly 
characterized by swelling and pain in the joints. Approximately 0.5-1% of the population is 
affected and the incidence in women is higher compared to men. Distinct clinical phenotypes 
of RA can develop, which are thought to be a consequence of interactions between genetic 
and environmental factors [1]. Autoantibodies often appear long before any signs of joint 
inflammation emerge [2-5]. The majority of RA patients develop antibodies against the Fc 
region of IgG (rheumatoid factor; RF). However, IgG RF autoantibodies can also be found 
patients with other rheumatic diseases and in non-rheumatic patients. As such, IgG RF is not 
considered a suitable diagnostic marker. Antibodies against post-translationally modified 
proteins including anti-citrullinated protein antibodies (ACPAs) and anti-carbamylated 
protein (anti-CarP) antibodies are highly specific. ACPAs can be locally produced by plasma 
cells in joints of RA patients and are detected in sera of up to 70% of RA patients [6]. 
They recognize citrullinated proteins or peptides, which can be found throughout the body 
including cartilage and bone. Anti-CarP antibodies are detected in sera of 45% of RA patients 
and recognize carbamylated proteins [7].
Currently, presence of ACPA and RF in serum are the most commonly used diagnostic 
markers for RA. Tested antibodies are predominantly of the IgG and IgM isotype. RF, ACPA 
and anti-CarP antibodies have been associated with bone loss in patients with established 
RA, suggesting a pathogenic role [3, 7, 8]. Notably, bone loss has also been reported in 
ACPA-positive individuals who did not have joint inflammation, suggesting an adverse effect 
of ACPA on bone [9].
Bone remodeling is a process in which osteoblasts generate new bone and osteoclasts resorb 
bone to maintain bone homeostasis. This balance is lost in RA patients [10]. Osteoclasts 
are large multinucleated cells, which form by fusion of mononuclear progenitors from the 
CD14+ monocyte/macrophage lineage. Differentiation, survival and activity of osteoclasts 
depends on the presence of receptor activator of NF-κB ligand (RANK-L) and macrophage 
colony-stimulating factor (M-CSF) [11]. Osteoclasts and their precursors express RANK, 
which interacts with RANK-L. The formation of osteoclasts is enhanced in an inflammatory 
environment by several cytokines, including interleukin (IL)-1β, IL-6, IL-8 and, in low doses 
by transforming growth factor (TGF)-β, which triggers RANK expression on osteoclast 
precursors [12, 13]. Increased levels of these cytokines have been found in synovial fluid 
of RA patients and have been reported to contribute to RA disease activity [14]. These 
cytokines can be produced by inflammatory cells in the joint, such as monocytes and 
macrophages. Additionally, neutrophils are abundantly present and have been reported 
to express RANK-L. Their contribution in osteoclast activation is however debated [15, 16]. In 
the presence of autoantibodies neutrophils can form NETs and contribute to tissue damage 
by releasing their granule content [17].
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Interestingly, neutrophils are particularly potently activated by IgA antibodies [18]. Although 
they are not routinely tested in RA, more attention has been payed to IgA autoantibodies in 
RA in the last decade. A considerable proportion (~30%) of RA patients is negative for ACPA 
IgG and RF IgM [19]. About one third of ACPA IgG and/or RF IgM seronegative patients had 
IgA autoantibody levels in their sera (RF, ACPA or anti-CarP) [3, 7, 19, 20]. Several studies 
have reported a correlation between the amount of IgA and disease severity in RA patients 
[21]. Elevated levels of serum RF IgA were associated with extra-articular manifestations 
in RA patients and worse disease outcome [22, 23]. Moreover, patients having erosions 
in the bones of their hands had higher serum levels of RF IgA [24]. Similarly, presence of 
anti-CarP IgA was associated with more severe disease [7]. Nonetheless, the role of IgA 
autoantibodies on bone erosion is currently unknown. In this study we investigated the 
effect of IgA complexes and immune complexes isolated from synovial fluid of RA patients 
on bone resorption. We demonstrated that bone resorption was enhanced indirectly 
through activation of immune cells by IgA and directly by IgA-activated osteoclasts.
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Synovial fluid from the knee (n=26) and serum (n=20) of RA patients was anonymously 
collected during their visit to the rheumatology department at the Leiden University Medical 
Center or the Amsterdam University Medical Center. Patients gave their written informed 
consent in accordance with the guidelines of the Medial Ethical Committee of the Leiden 
University Medical Center (reference no. B15.003) or the Amsterdam University Medical 
Center (reference no. 2013.234).
Precipitation of immune complexes from synovial fluid and serum
Synovial fluids or sera were centrifuged at 3300xg for 5 minutes before use. Supernatants 
were mixed with an equal volume of 10% PEG6000 (Sigma Aldrich, St. Louis, MO) and 
incubated overnight at 4°C. Precipitates were collected after centrifugation for 10 minutes at 
9500xg and resuspended in phosphate buffered saline (PBS; B.Braun, Melsungen, Germany) 
to the original volume of the synovial fluid/serum.
Serum collection and isolation of human monocytes and PMN
Serum was collected from healthy donors. Monocytes and polymorphonuclear leukocytes 
(PMNs) were isolated from peripheral blood obtained from healthy donors or from buffy 
coats (Sanquin, Amsterdam, The Netherlands). Monocytes were isolated using MACS CD14 
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according the manufacturer’s 
protocol. In brief, peripheral blood mononuclear cells (PBMCs) and PMNs were collected 
after Lymphoprep (Axis-Shield, Oslo, Norway) density gradient centrifugation. PBMCs were 
washed in PBS and incubated with MACS CD14 MicroBeads after which CD14+ monocytes 
were isolated. Erythrocytes present in the PMN fraction were lysed with ammonium chloride 
buffer (155mM NH4Cl, 10mM KHCO3 and 0.11mM EDTA). Cells were resuspended in RPMI 
1640 (Gibco BRL, Paisley, UK) supplemented with 1% heat-inactivated fetal calf serum (FCS), 
glutamine and antibiotics. PMN were incubated for 30 minutes (37°C, 5% CO2) prior to use.
Coating of beads with BSA, IgA or IgG
Latex beads (carboxylate-modified polystyrene, green fluorescent (1.0 μm); Sigma Aldrich) 
were washed with sterile 2-(N-morpholino) ethanesulfonic (MES) buffer (30 mM, pH 6.1) 
and resuspended in MES buffer with 2 mg/ml endotoxin free bovine serum albumin (BSA) 
(Akron Biotech, Boca Raton, FL), human serum IgA (Cappel, MP Biomedicals, Santa Ana, 
CA) or human serum IgG (Sigma Aldrich) in the presence of N-(3-Dimethylaminopropyl)-
N’-acid ethylcarbodimide hydrochlorid (Sigma Aldrich) and incubated overnight at room 




Monocyte stimulation with immune complexes
CD14+ monocytes (2x106/ml) were stimulated for 24 hours with BSA-, IgA-, or IgG coated 
beads in an effector target (ET) ratio of 1:100. Alternatively, 1x105 monocytes were 
stimulated for 24 hours with 10, 20 or 40 μl of immune complexes isolated from synovial 
fluid of RA patients. Supernatants were harvested and stored at -20°C.
NETs release after stimulation with immune complexes
PMNs (1x105) were incubated in RPMI with 1% FCS in black 96 well plates (FLUORTRAC 
200, Greiner Bio-One) with 10 μl precipitated immune complexes from synovial fluid or 
serum from RA patients or healthy controls for 3 hours at 37°C. Release of extracellular 
DNA was detected by adding nucleic acid label SYTOX green (2,5 μg/ml; Invitrogen Life 
Technologies). Optical density was measured using a fluorimeter (FLUOstar/POLARstar BMG 
Labtech GmbH, Offenburg, Germany) at 480nm excitation and 520nm emission.
Osteoclast generation
Isolated CD14+ monocytes (2x106/ml) were resuspended in minimum essential medium, 
α modification (α-MEM) (Gibco BRL), supplemented with 10% FCS, 25 ng/ml M-CSF 
(ImmunoTools, Friesoythe, Germany), and 50 ng/ml RANKL (BioLegend, San Diego, CA). Cells 
were seeded in 3 well ibidi slides (removable chamber) (Ibidi, Gräfelfing, Germany) or 48 well 
plates and cultured for 7 days at 37°C, 5% CO2. Medium was changed twice weekly. Tartrate-
resistant acid phosphatase (TRAcP) activity in osteoclasts was measured with the leukocyte 
acid phosphatase kit 386A (Sigma Aldrich) according to the manufacturer’s instruction and 
as previously described [25] with slight modifications. Cells were washed with PBS, fixed 
using 1% paraformaldehyde (PFA) for 10 minutes, washed with MilliQ and incubated with 
1 mM tartrate solution for 60 minutes at 37°C. Nuclei and cell membranes were stained 
with 4’,6-diamidino-2-phenylindole (DAPI) and Wheat germ agglutinin (WGA)-AF488 (both 
ThermoFisher, Waltham, MA), respectively. Osteoclasts were visualized with microscopy 
(Leica DM6000, Leica, Wetzlar, Germany).
Detection of αVβ3 & Fc receptors on osteoclasts
Osteoclasts were detached by scraping after 7 day culture. Cells were washed in PBS and 
stained with fixable viability dye eFluor506 (ThermoFisher) for 20 minutes on ice after which 
cells were blocked in 5% PBSA for 30 minutes. Cells were stained with anti-human CD14-
AF488 (Clone HCD14, Biolegend) and anti-human CD51/CD61-APC (Clone 23C6, Miltenyi 
Biotec) for 30 minutes on ice. To investigate Fc receptor expression, cells were stained with 
anti-human CD14-AF488 combined with anti-human CD89-PE-Cy7 (Clone A59, Biolegend), 
anti-human CD16-APC-eFluor780 (Clone 3G8, ThermoFisher), anti-human CD32-PE-Cy7 
(Clone 6C4, ThermoFisher) or anti-human CD64-APC (Clone 10.1, ThermoFisher) for 30 
minutes on ice. Integrin and Fc receptor expression was analyzed with flow cytometry 
(LSRFortessa™ X-20, BD Biosciences). Data was processed in FlowJo version 10.6.2. (Tree 
Star, Inc., Ashland, OR).
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Bone resorption assay
Bovine cortical bone was cut in slices of 0.5 mm thick and cut to fit in 96 well plates. Bone 
slices were sonicated, washed with PBS and incubated in α-MEM (Gibco BRL) for 30 minutes 
at 37°C after which 0.5x106 CD14+ monocytes resuspended in α-MEM supplemented with 
10% FCS, 25 ng/ml M-CSF (ImmunoTools) and 50 ng/ml RANKL (BioLegend) were seeded in 
96 well plates for 21 days. Supernatant of unstimulated monocytes or monocytes that had 
been stimulated with BSA-, IgA-, or IgG-coated beads for 24 hours was added (1:1) when 
indicated. Supernatants and medium were replaced twice weekly and when indicated, 
medium was supplemented with 25 ng/ml IL-6 (ImmunoTools), 10 ng/ml IL-8 or 5 ng/ml 
TNF-α (both Peprotech, Rocky Hill, NJ). After 21 days bone slices were stored in water 
(4°C) and bone resorption was visualized as previously described [26]. In brief, bone slices 
were sonicated for 30 minutes in 10% NH4OH, washed in distilled water, shortly dried on 
filter paper and transferred to new wells containing water saturated aluminium potassium 
sulfate dodecahydrate (Merck Millipore, Burlington, MA) for 10 minutes. Bone slices were 
washed twice in distilled water, after which they were washed once under a strong current 
of distilled water and dried between filter paper. Bone slices were stained with Coomassie 
brilliant blue solution (PhastGel® blue R, PlusOne Coomassie tablets, Pharmacia, Uppsala 
Sweden) for 1 minute, and dried between filter paper. Bone resorption pits were visualized 
with an inverted microscope (Nikon TE-300, Nikon, Tokyo, Japan) and quantified with Image 
J version 1.49v.
Purification and stimulation of CD14 negative osteoclasts
Generated osteoclasts (7 day culture) were scraped from 48 well plates and incubated with 
MACS CD14 MicroBeads human (Miltenyi Biotec) according the manufacturer’s instruction. 
The flow through containing CD14 negative cells was collected. To confirm purity of CD14 
negative cells, cells were washed in 0.5% PBSA, blocked in 5% PBSA for 30 minutes on ice and 
stained with anti-human CD14-AF488 (Clone HCD14, Cat#325610, Biolegend) for 30 minutes 
on ice. Cells were measured with flow cytometry (LSRFortessa™ X-20, BD Biosciences) and 
data was analyzed with FlowJo version 10.6.2 (Tree Star, Inc.). CD14 negative cells were 
resuspended in α-MEM supplemented with 10% FCS, 25 ng/ml M-CSF (ImmunoTools) and 50 
ng/ml RANKL (BioLegend) and plated in 48 well plates for 24 hours. Medium was refreshed 
and cells were stimulated with 5 μl of BSA-, IgA-, or IgG-coated beads or 40 μl of immune 
complexes isolated from synovial fluid of RA patients for 24 hours, after which supernatants 





Levels of IL-6 and IL-8 were measured with enzyme-linked immunosorbent assay 
(ELISA) following the manufacturer’s protocol (Human uncoated ELISA kits, Invitrogen, 
ThermoFisher).
Anti-citrullinated protein antibody (ACPA), anti-carbamylated protein (anti-CarP) anti-
body and rheumatoid factor (RF) IgA and IgG
ACPA IgA and IgG levels were determined in synovial fluids of RA patients according to the 
protocol previously described [20] with minor adaptations. Microtitre ELISA plates (Nunc 
MaxiSorp™ flat-bottom plates; ThermoFisher) were coated with 50 μl of 1 μg/ml streptavidin 
(ThermoFisher) and incubated overnight at 4°C after which 50 μl of 1 μg/ml biotinylated 
CCP2-cittruline or CCP2-arginine (kindly provided by Dr. J.W. Drijfhout, Department of 
Immunohematology and Blood Transfusion (Leiden University Medical Center)) was added 
for 1 hour at RT.
Anti-Carp IgA and IgG were determined in synovial fluids of RA patients according to 
protocols previously described [7] with minor adaptations. Microtitre ELISA plates 
(ThermoFisher) were coated with 50 μl of 10 μg/ml carbamylated bovine serum albumin 
(Ca-BSA) or non-modified BSA and incubated overnight at 4°C after which wells were blocked 
with 1% PBSA for 6 hours at 4°C.
RF IgA levels were determined in synovial fluid of RA patients. Microtitre ELISA plates 
(ThermoFisher) were coated with 50 μl of 50 μg/ml human serum IgG (Sigma Aldrich) and 
incubated overnight at 4°C after which wells were blocked with 1% PBSA for 1h at 37°C.
Synovial fluid (1:10 diluted) was added for 1 hour at 37°C (ACPA and RF ELISA) or overnight 
at 4°C (anti-CarP ELISA). Wells were washed and incubated with F(ab’)2 goat anti-human 
IgA-HRP (1:4000, ThermoFisher) or F(ab’)2 goat anti-human IgG-HRP (1:4000, ThermoFisher) 
for 1 hour at 37°C. Fifty μl of 3,3’,5,5’-Tetramethylbenzidine (TMB) substrate was added after 
which the reaction was stopped with 50 μl of sulfuric acid (10% H2SO4). Absorbance was 
measured with a microplate reader (Bio-Rad, Berkeley, CA) at 450nm.
Statistical analysis
Statistical analysis were performed with GraphPad Prism version 8.2.1 (GraphPad, San Diego, 
CA). Statistical differences were determined with unpaired Student two-tailed t tests (two 
groups) or one-way ANOVA (more than two groups) for normally distributed data. Mann-
Whitney U tests (two groups) or Kruskall-Wallis tests (more than two groups) were applied to 
not normally distributed data. Correlations were determined with nonparametric Spearman 
correlation coefficients. P values <0.05 were considered statistically significant.
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Results
Autoantibodies in synovial fluid induce immune cell activation
To investigate whether local autoantibodies have a potential pathogenic role in RA, we 
first determined ACPA and anti-CarP IgA and IgG levels in synovial fluid of 26 RA patients 
(figure 1A). Because we previously demonstrated that in contrast to IgG RF, IgA RF were 
specifically present in RA patients [27], IgA RF was determined as well. Both IgA and IgG 
autoantibody levels showed great inter-patient variation. For every patient a profile of IgA 
and IgG autoantibodies present in their synovial fluid was created (figure 1B).
When neutrophils were stimulated with immune complexes isolated from synovial fluid of 
RA patients they formed NETs (figure 2A). The level of NET formation varied greatly between 
samples. Immune complexes isolated from serum of either healthy controls or RA patients 
did not induced NET release (figure 2A). NET release induced by SF immune complexes 
significantly positively correlated with ACPA IgA, ACPA IgG and anti-CarP IgG levels present 
in SF (supplementary figure 1A, 1B). Neither anti-CarP IgA nor RF IgA levels in SF correlated 
with NET release (supplementary figure 1B, 1C).
Next, monocytes were activated with immune complexes isolated from synovial fluid of 
RA patients and IL-6 production was determined (figure 2B). Of note, monocytes were not 
stimulated with immune complexes isolated from serum of RA patients as neutrophils were 
not activated by serum immune complexes. Addition of a higher volume of SF immune 
complexes to monocytes resulted in increased IL-6 release. Furthermore, monocyte IL-8 
production after stimulation with 40 μl of immune complexes was enhanced compared to 
unstimulated monocytes (figure 2C) and positively correlated with IL-6 release (p=0.0003) 
(supplementary figure 2A). Immune complexes are large aggregates of autoantibodies and 
contain multiple antibody isotypes. ACPA IgA levels significantly correlated (p=0.0197) 
with monocyte IL-6 release induced by these immune complexes (figure 2D). Anti-CarP 
IgA and RF IgA followed a similar trend, but did not significantly correlate with IL-6 release 
(supplementary figure 2B). Neither ACPA nor anti-CarP IgG autoantibodies correlated with 
IL-6 release (supplementary figure 2C). Significant positive correlations between ACPA IgA 
(p=0.0011), ACPA IgG (p=0.0397) and RF IgA (p=0.0015) with monocyte IL-8 release induced 
by synovial fluid immune complexes were found (figure 2E). While anti-CarP IgA and anti-
CarP IgG did not significantly correlate with monocyte IL-8 release (supplementary figure 2D).
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Figure 1. IgA and IgG autoantibody levels in synovial fluid of RA patients (A) left panel; ACPA, 
anti-CarP and RF IgA levels and right panel; ACPA and anti-CarP IgG levels in synovial fluid of RA 
patients (expressed as OD value). Dotted lines represent blanc OD values of each independent ELISA. 
(B) Synovial fluid profile of ACPA, anti-CarP and RF IgA and IgG levels of 26 RA patients [# IgG levels 
not determined]. AU= arbitrary units.
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Figure 2. Cytokine release after synovial fluid immune complex stimulation correlates with IgA 
autoantibody levels in synovial fluid. (A) NET release by neutrophils stimulated with immune 
complexes isolated from healthy control (HC) serum, rheumatoid arthritis (RA) serum or synovial 
fluid of RA patients (RA SF). Dotted line represents unstimulated neutrophils. (B, C) Monocyte (B) IL-6 
and (C) IL-8 release (pooled data from 2 independent experiments) after stimulation with immune 
complexes isolated from RA SF. Dotted lines represent unstimulated monocytes. (D) Correlation 
between immune complex-induced monocyte IL-6 release with ACPA IgA levels. (E) Correlations 
between monocyte IL-8 release induced by immune complexes isolated from RA SF with (left) ACPA 
IgA levels, (middle) ACPA IgG levels or (right) RF IgA levels Average cytokine release is displayed (n=2). 
Data was analyzed using two way ANOVA with Bonferroni post-hoc or using the Spearman correlation 
coefficient; *** p ≤ 0.001, **** p ≤ 0.0001.
Osteoclasts formation and activity
In vitro generated osteoclasts (OCs) are defined as large multinucleated cells, which express 
the enzyme tartrate-resistant acid phosphatase (TRAcP) and can resorb bone [28]. When 
osteoclasts mature, CD14 expression is lost and the expression of TRAcP increases [29, 
30]. We generated multinucleated cells by culturing CD14+ monocytes for 7 days in the 
presence of M-CSF and RANK-L which expressed TRAcP (figure 3A). We defined osteoclasts 
as multinucleated CD14 negative cells expressing high levels of TRAcP and αVβ3. The αVβ3 
integrin enables the osteoclast to connect to the bone matrix [31]. Not all multinucleated 
cells differentiated into osteoclasts as TRAcP and the αVβ3 integrin were absent. These cells 
are likely osteoclast precursors which did not achieve a mature state yet. Since TGF-β is 
an important modulator of osteoclasts, we analyzed whether TGF-β influenced osteoclast 
formation. Addition of TGF-β to the 7 day culture resulted in formation of larger OCs with 
increased TRAcP expression (figure 3A). Moreover, presence of TGF-β resulted in the 
formation of more OCs (~80%) compared to absence of TGF-β (~20%) (figure 3B). The formed 
OCs expressed high levels of the αVβ3 integrin independently of TGF-β presence (figure 3C).
OCs cultured on bone slices for 21 days in presence of M-CSF and RANK-L resorbed bone 
as visualized by formed bone resorption pits and tracks (figure 3D, left panel). Presence of 
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TGF-β significantly increased bone resorption by OCs (figure 3D, right panel). OCs in absence 
of TGF-β resorbed ~5000 μm2 bone, while OCs in presence of TGF-β resorbed significantly 
more bone (~15000 μm2) (p=0.0445) (figure 3E).
Figure 3. Enhanced osteoclast formation and activity in presence of TGF-β. (A) Osteoclast TRAcP 
expression (purple) in presence of M-CSF and RANK-L (upper left panel) and in presence of M-CSF, 
RANK-L and TGF-β (lower left panel) after 7 days culture. [Blue (DAPI) = nuclei, green (WGA) = cell 
membrane]. (B) CD14 expression on osteoclasts in absence (upper panel) or presence of TGF-β (lower 
panel) after 7 days culture. (C) Expression of αVβ3 on formed osteoclasts in absence (blue (top) 
histogram) or presence of TGF-β (red (second) histogram) after 7 days culture. Residing CD14+ cells 
(black histogram) and non-stained cells (dotted histogram) served as controls. (D) Bone resorption 
by human osteoclasts after 21 days in presence of M-CSF and RANK-L (left panel) or M-CSF, RANK-L 
and TGF-β (right panel) (representative of n=2 experiments). (E) Quantification of bone resorption by 
osteoclasts in absence of TGF-β (white bar) or presence of TGF-β (grey bar) presented as area in μm2 
bone resorption. Data was analyzed using unpaired student’s two-tailed T test; * p ≤ 0.05.
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IgA activated monocytes induce osteoclast-mediated bone resorption
Supernatant of (activated) monocytes was added to osteoclasts which were plated on bone 
slices to study its effect on bone resorption. Unstimulated and BSA-activated monocytes 
supernatant served as control conditions and only induced little bone resorption by 
osteoclasts (respectively ~3300 μm2 and ~7300 μm2) as visualized by dark bone resorption 
pits (figure 4A). Supernatant of monocytes that had been activated with IgA complexes 
enhanced osteoclast induced bone resorption compared to supernatant of IgG-activated 
monocytes (figure 4A). OCs in presence of supernatant of IgA-activated monocytes resorbed 
on average ~15000 μm2 of the bone slices, while supernatant of IgG-activated monocytes 
only induced resorption of ~2600 μm2 bone by OCs (p=0.0233) (figure 4B).
Figure 4. Significantly enhanced bone resorption in presence of supernatant of IgA-activated 
monocytes. (A) Bone resorption by osteoclasts in the presence of supernatant of unstimulated 
monocytes (upper left panel), BSA-stimulated monocytes (upper right panel), IgG-activated 
monocytes (lower left panel), or IgA-activated monocytes (lower right panel). (B) Quantification of 
bone resorption (area in um2) induced by osteoclasts in presence of supernatant of unstimulated 
monocytes (white bar), BSA-activated monocytes (light grey bar), IgA-activated monocytes (dark 
grey bar) or IgG-activated monocytes (black bar). Data was analyzed using one way ANOVA with 
Tukey post-hoc; * p ≤ 0.05.
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Osteoclasts express FcαRI and are activated by IgA
Next, we questioned whether presence of IgA autoantibodies also directly affects osteoclast 
activation. Human osteoclasts highly expressed FcαRI, but not the Fc receptors for IgG; 
CD16 (FcγRIII), CD32 (FcγRII) or CD64 (FcγRI) (figure 5A, upper panels). Remaining CD14+ 
cells expressed high levels of CD16, CD32 and CD89, and intermediate levels of CD64 (figure 
5A, lower panels).
To investigate the effect of IgA-FcαRI interactions on the bone resorptive capacity of 
osteoclasts, we separated CD14 negative osteoclasts from the remaining CD14 positive 
cells. Of the sorted osteoclasts >80% was alive and their purity was >95% (supplementary 
figure 3). OCs activated with immune complexes isolated from synovial fluid of RA patients 
produced IL-8 (figure 5B). However, similar levels of IL-8 were released by unstimulated 
osteoclasts. Production of IL-6 by osteoclasts after stimulation with SF immune complexes 
varied a lot between samples, but was not produced by unstimulated osteoclasts (figure 
5C). To investigate whether cytokine production was mediated by IgA or IgG, we stimulated 
OCs with IgA-, or IgG-coated beads. IgA-activated OCs produced significantly higher levels 
of IL-8 compared to unstimulated, BSA or IgG-activated OCs (figure 5D). IL-6 was only 
produced by OCs after IgA activation (figure 5E). Bone resorptive capacity of osteoclasts 
was significantly enhanced in the presence of IL-8 (p=0.0054) or IL-6 (p=0.03) (figure 5F). 
These results support previous findings that IgA autoantibody levels in RA patients correlate 
with increased bone resorption. We now show that this can be a direct consequence of IgA-
mediated activation of osteoclasts through the enhanced release of IL-8 and IL-6.
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Figure 5. Osteoclasts are activated by IgA immune complexes. (A) Expression of CD16, CD32, 
CD64 and CD89 on CD14 negative OCs (upper panels; dark grey histograms) and remaining CD14+ 
cells (lower panels; light grey histograms) (B+C) IL-8 (B) and IL-6 (C) release by OCs stimulated with 
immune complexes isolated from synovial fluid of RA patients. (D+E) IL-8 (D) and IL-6 (E) release by 
unstimulated OCs (white bar) and after stimulation with BSA- (light grey bar), IgA- (dark grey bar) or 
IgG- (black bar) coated beads. (F) Quantification of bone resorption by OCs in presence of M-CSF and 
RANK-L (unstim, white bar) and added cytokines IL-6 (25 ng/ml, light grey bar) or IL-8 (10 ng/ml, dark 
grey bar). Data was analyzed using one way ANOVA with Tukey post-hoc; * p ≤ 0.05; ** p ≤ 0.01; *** 




Bone remodeling in RA patients is disturbed, resulting in bone loss and eventually loss of 
function [10]. In this study we demonstrated that IgA enhanced bone resorption indirectly 
through cytokines released by immune cells, and directly by activating osteoclasts through 
FcαRI crosslinking. Our results show that IgA has a significant effect on bone resorption and 
in this way is likely responsible for worse pathology in RA patients.
The exact process of bone remodeling in RA patients is incompletely understood. It has been 
reported that multinucleated cells that express typical osteoclast lineage markers including 
TRAcP and cathepsin K are found at sites of bone erosion in RA patients [32]. Multiple in 
vivo studies with osteoclast deficient mice support the critical role of osteoclasts in bone 
loss [33, 34]. Bone loss in RA patients was strongly associated with presence of ACPA or 
anti-CarP antibodies [7, 35-37]. In contrast to our results, it was shown that bone resorption 
was enhanced by ACPA IgG containing immune complexes in vitro [38]. Increased numbers 
of bone resorbing cells were responsible for this enhanced bone resorption and was also 
observed in presence of non-ACPA IgG containing immune complexes [38]. Presence of 
ACPA IgA or IgG and anti-CarP antibodies in sera were predictive for the development of 
RA [3, 7, 39], whereas only ACPA-IgA levels were associated with more active disease [40].
Next to osteoclasts, inflammatory cells present in the joint can indirectly contribute to 
bone resorption. Neutrophils are the most abundant immune cells present in the inflamed 
joint and can get highly activated by IgA and IgG resulting in the formation of NETs [18, 
41]. NET release was induced by immune complexes isolated from synovial fluid of RA 
patients. Variations in the abundancy of NET formation is likely due to different levels of 
autoantibodies in SF, influencing the level of neutrophil activation. NET release was not 
induced by immune complexes derived from serum, which may be due to less presence of 
immune complexes compared to synovial fluid. NETs can contribute to the autoimmune 
profile of RA patients, as myeloperoxidase can convert thiocyanate into cyanate, which 
is essential for carbamylation [42]. Previously it was shown that NET formation was 
significantly increased in neutrophils stimulated with synovial fluid containing ACPAs 
compared to stimulation with ACPA-negative synovial fluids [43]. Similarly we reported 
positive correlations between NET release and ACPA IgA and IgG levels. NETs may further 
contribute to the pathogenesis of RA as source of citrullinated autoantigens. In complex with 
ACPAs they can enhance the production of pro-inflammatory cytokines IL-6 and IL-8 by local 
(immune) cells [41]. Recently a humanized anti-ACPA therapeutic antibody was described 
to inhibit NET formation by human neutrophils activated with SF of gout patients [44], 
supporting the importance of this autoantibody in the pathology of RA as well.
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We showed that incubation of monocytes and osteoclasts stimulated with SF immune 
complexes resulted in the production of IL-6 and IL-8, both by monocytes and osteoclasts. The 
variable levels of cytokine release can be explained by the different levels of autoantibodies 
present in the immune complexes. IL-8 is an important chemokine for neutrophils [45] and 
positively correlated with the amount of infiltrated neutrophils in the inflamed synovium 
of RA patients [43]. IL-8 levels produced by monocytes correlated with both IgA and IgG 
autoantibodies. These results are supported by previous work from our lab demonstrating 
that IL-8 is produced by monocytes after IgA or IgG activation (own unpublished data). 
Interestingly, osteoclasts produced significantly elevated levels of IL-8 after IgA, compared 
to IgG activation. This is likely explained by the fact that mature osteoclasts only expressed 
FcαRI and not the Fc gamma receptors for IgG. However, human CD14+ osteoclasts are 
described to express multiple Fc gamma receptors [46] and autoantibodies can bind 
osteoclasts specifically, thereby promoting osteolytic function in vitro [38]. In this study 
we focused on CD14 negative osteoclasts, as the most mature bone resorbing cells [29].
IgG autoantibodies were described to enhance the production of osteoclastogenic factors, 
including IL-6, IL-8, TNF-α and IL-1β by monocytes and macrophages [13, 47]. However, IgA-
activation of monocytes induced higher levels of pro-inflammatory cytokines compared 
to IgG-activation (own unpublished data). Synovial fluid levels of IL-8 and IL-6 were 
significantly elevated in patients with high ACPA levels in their synovial fluid [43]. ACPA-
induced differentiation of osteoclasts was inhibited in vitro by a neutralizing IL-8 antibody. 
Furthermore, in vivo IL-8 inhibition reversed ACPA-induced bone loss in mice [48], supporting 
the importance of IL-8 in the pathology of RA in ACPA positive patients.
IL-6 production by monocytes only positively correlated with levels of ACPA IgA, but not 
ACPA IgG. These results are in line with previous work showing IL-6 release by monocytes 
upon IgA, but not IgG activation (own unpublished data). Similarly, osteoclasts only produced 
IL-6 after IgA activation. IL-6 significantly increased bone resorption by osteoclasts. In vitro 
IL-6 was shown to enhance osteoclastogenesis through activation of RANKL on osteocytes 
and osteoblasts [49, 50]. In vivo, IL-6 was necessary for inducing osteoclast activity and bone 
resorption [51, 52]. Several clinical trials have shown the potential of the human anti-IL-6 
blocking antibody tocilizumab in treating RA patients [53-55].
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Figure 6. Mechanism of direct and indirect IgA-mediated osteoclast activation. In the inflamed 
joints of RA patients immune complexes consisting of IgA autoantibodies are present. Infiltrated 
neutrophils can form neutrophil extracellular traps (NETs) when activated with IgA-containing immune 
complexes. Monocytes activated with IgA-containing immune complexes produce high levels of IL-6 
and IL-8 and enhance the bone resorptive capacity of osteoclasts. IgA-containing immune complexes 
can also directly target osteoclasts which express the Fc receptor for IgA (FcαRI). After IgA activation 
osteoclasts secrete IL-8 and IL-6, which are osteoclastogenic cytokines known to contribute to the 
formation of osteoclasts. Furthermore, IL-8 contributes to the chemoattraction and infiltration of 
neutrophils thereby enhancing the pro-inflammatory environment in the inflamed synovium of RA 
patients. Osteoclast secreted IL-8 could therefore both lead to auto stimulation and attraction of 
neutrophils to the inflamed area. [Created with BioRender.com].
In conclusion, we propose that IgA-FcαRI interactions on both infiltrated immune cells in 
the synovium and osteoclasts have an essential role in the pathogenesis of RA (figure 6). IL-6 
production after IgA activation of monocytes and osteoclasts can contribute to osteoclast 
formation, activity and their bone resorptive capacity. Elevated IL-8 production after IgA 
stimulation of monocytes and osteoclasts can contribute to the infiltration of neutrophils, 
thereby promoting an inflammatory environment. Furthermore it promotes osteoclast 
activity resulting in increased bone resorption. We anticipate that targeting IgA-FcαRI 
interactions is a promising therapeutic strategy to diminish bone resorption in RA patients.
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Supplementary figure 1. Correlation between NET release after stimulation of neutrophils with 
immune complexes isolated from synovial fluid of RA patients with OD values of (A) ACPA IgA (left) 
or ACPA IgG (right), (B) anti-CarP IgA (left) or anti-CarP IgG (right) and (C) RF IgA measured in synovial 
fluid of RA patients.
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Supplementary figure 2. (A) Correlation between monocyte IL-6 and IL-8 release induced by immune 
complexes of RA SF. (B,C) Correlation between monocyte IL-6 release and (B) (left) anti-CarP IgA levels 
or (right) RF IgA, or (C) (left) ACPA IgG levels and (right) anti-CarP IgG levels. (D) Correlation between 
monocyte IL-8 release and (left) anti-CarP IgA levels and (right) anti-CarP IgG levels.
Supplementary figure 3. Gating strategy to check the purity of sorted OCs. (left) Location of OCs on 
forward-side scatter area with adjusted laser settings to visualize large cells; (middle) viability of the 
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Immunoglobulin A (IgA) is the most prevalent antibody at mucosal surfaces, where it helps to 
maintain homeostasis [1]. It has been viewed traditionally as a silent housekeeping antibody 
without activating properties. This seemingly redundant role of IgA is partly supported 
by the fact that IgA deficiency is relatively common with a prevalence that has been 
reported to range from 1:150 to 1:18.500 in different countries [3]. Most patients suffer 
no major clinical symptoms, although increased susceptibility for gastrointestinal, urinary 
and recurrent respiratory infections, allergies, celiac disease and autoimmune diseases 
have been reported [3]. Most knowledge regarding the functional role of IgA originates 
from in vivo experiments using mice. However, many of these studies have overlooked the 
potential activating properties of IgA as mice lack a structural equivalent of the human 
IgA Fc receptor FcαRI [4]. This has likely contributed to the misapprehension of IgA being 
a non-inflammatory antibody.
Nonetheless, several convincing arguments support the biological relevance and importance 
of IgA. First of all, enormous amounts of IgA are produced by the human body (66mg/
kg/day), representing almost 75% of the total antibody production [5]. This suggests that 
IgA must have important functions in the human body as from an evolutionary point 
of view the amount of energy input in this process would be rather wasteful for a non-
essential molecule. Second, when IgA is lacking other antibody isotypes are described to 
compensate for the loss of IgA. For instance, patients that lack the compensatory action 
of e.g. IgM experience more often pathology in their respiratory tract [6]. One can argue 
that this observation supports the importance of IgA as it is relevant in such a way that 
other antibody classes need to compensate to overcome pathology. Finally, and the most 
convincing evidence for the significance of IgA in protective immunity is emphasized by the 
fact that several bacterial species developed evasion strategies for IgA-mediated elimination 
by FcαRI-expressing immune cells. For instance, many bacterial species produce proteases 
which cleave the exposed hinge region of IgA1. Cleaved IgA1 may compete for functional 
antibodies by binding their fragment antigen-binding (Fab) region thereby preventing 
binding of intact antibodies to their specific antigen [7]. A selective group of bacteria secrete 
proteases, which also cleave IgA2 [8, 9]. Furthermore, anti-IgA proteins including Sir22, Arp4 
and an unrelated β protein from group B streptococci and staphylococcal superantigen-like 
protein 7 from Staphylococcus aureus bind to specific fragment crystallizable (Fc) residues 
of IgA, thereby obstructing binding of IgA to the FcαRI [2, 10, 11]. Thus, multiple bacteria 
have developed escape mechanism to circumvent IgA-FcαRI mediated elimination [2, 11, 12] 
which challenges the dogma of IgA as a non-inflammatory and possibly redundant antibody.
The multifaceted role of IgA and its interaction with the FcαRI has become more clear in the 
past decade. Here I will discuss the functional role of IgA and IgA-FcαRI interactions during 
homeostasis, infection and autoimmunity. I will also elaborate on the potential therapeutic 





The basics of IgA at mucosal surfaces
The intestinal tract is the best studied mucosal surface in relation to the function of IgA. 
The intestinal mucosa has a large surface (400m2), which enables efficient uptake of 
essential dietary components [13]. Maintaining a delicate balance between tolerating 
harmless food particles and commensals and initiating a robust immune response against 
invasive pathogens is a challenging task. Fortunately, the large number of immune cells, 
immunoglobulins and commensal bacteria (1013-1014) cooperatively maintain intestinal 
homeostasis [14].
In the lamina propria of the intestine IgA is produced in a dimeric form by local plasma 
cells. Dimeric IgA (dIgA) can associate with the polymeric Ig receptor (pIgR) present at the 
basolateral side of the epithelium, after which it is transported towards the intestinal lumen. 
After cleavage at the apical side of the epithelial layer, the secretory component (SC) of the 
pIgR remains attached to the IgA molecule, thereby forming secretory IgA (SIgA) [15]. The 
production and secretion of SIgA depends on the rate of antibody production, but is also 
influenced by the expression and activity of the pIgR [16]. The secretory component provides 
stability to SIgA and protects the molecule from proteases produced by the trillions of 
bacterial cells present in the intestinal lumen. Together with the mucus, SIgA forms a barrier 
at the apical side of the epithelium thereby protecting the human body from infiltrating 
pathogens. Bacteria can be entrapped by SIgA and removed from the body by peristaltic 
bowel movements; a process called immune exclusion [17]. Free SC is also described to 
interact with bacteria [18], suggesting that SC as part of SIgA plays an important role in 
microbiota binding to IgA.
Under homeostatic conditions IgA responses are constitutively induced by commensal 
bacteria. M cells are part of the intestinal epithelial layer and facilitate continuous sampling 
of luminal antigens. These commensal antigens are exposed to dendritic cells (DCs) which 
initiate IgA production by B cells. Furthermore, CX3CR1 DCs can extend their dendrites 
through the epithelial layer and sample luminal antigens [19]. The generated IgA may 
be specific towards the sampled commensal components [20], however generation of 
high affinity IgA towards many different antigens is overwhelmingly complex and energy 
demanding. It is therefore anticipated that mucosal IgA is generally polyreactive and able 
to bind and neutralize multiple targets with a low affinity [21].
It has become clear that SIgA plays an important role in the maintenance of a healthy 
intestinal microbiota, which is characterized by a high diversity of bacterial species. On the 
one hand IgA can shape and diversify the intestinal microbiota, while the microbiota on 
the other hand has an important role in regulating SIgA levels [22-24]. Germ free (GF) mice 
have little to no IgA in intestinal secretions. However, exposure to bacteria induced IgA 
secretion [25], supporting the important role of IgA in regulating microbiota. Patients with 
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inflammatory bowel disease (IBD) have a lower bacterial diversity and an altered function 
of their gut microbiota which is referred to as dysbiosis [26]. An increased amount of fecal 
bacteria of inflammatory bowel disease patients was opsonized with IgA compared to those 
obtained from healthy control feces [27-29]. These highly IgA-coated bacteria obtained from 
IBD patients induced colitis in GF mice [28]. It was suggested that leakage of serum IgA or 
dIgA due to a disrupted epithelial layer contributed to enhanced fecal bacteria coating in 
IBD patients [27, 30]. IgA deficient individuals have dysbiotic intestinal and oropharyngeal 
microbiota despite the presence of compensatory IgM levels. These results support the 
critical role for IgA in maintaining a healthy microbiota composition [31, 32].
IgA in the female genital tract
We hypothesized that IgA, similar as in the intestinal tract, has an important role in regulating 
a healthy microbiota composition in the female reproductive tract. In contrast to the 
intestinal microbiota, a healthy vaginal microbiota composition is generally characterized 
by a low diversity of bacterial species, preferentially dominated by Lactobacillus species 
in Caucasian women or (facultative) anaerobic bacteria in African women [33]. L. crispatus 
is associated with anti-inflammatory responses as well as protection from pathogens and 
preserving a stable L. crispatus dominated vaginal microbiota is beneficial for the host’ 
health [34, 35]. We demonstrated that women with a L. crispatus dominant microbiota 
had increased coating of their microbiota with IgA (chapter 2). Furthermore, an additional 
(unidentified) IgA-coated bacterial population was present in L. crispatus dominant 
microbiota, which was not found in non-L. crispatus dominant microbiota.
A possible explanation for lower IgA coating on non-L. crispatus dominant vaginal 
microbiota is enhanced degradation of IgA by bacterial vaginosis-related bacteria [36]. 
Increased diversity of vaginal microbiota is associated with elevated proteolytic activity 
[33]. SIgA was a substrate for bacterial vaginosis-associated degrading enzymes, suggesting 
increased depletion of SIgA in women with bacterial vaginosis [37]. Women with a non-L. 
crispatus dominant microbiota had a higher diversity of bacterial species, which could 
account for the increased IgA degradation and as such lower levels of IgA bound to their 
microbiota. Local pre-existing decreased IgA levels along with impaired immune exclusion 
and subsequent colonization of multiple (pathological) bacterial species should also be 
considered. Decreased IgA levels have also been found in girls with recurrent urinary tract 
infections [38]. It is currently however unknown which factor is initiating a disbalance; i.e. 
it could be either a diversified vaginal microbiota composition, dysregulated IgA levels or 
other currently unidentified factors.
The increased level of IgA present on L. crispatus dominant microbiota might be explained 
by differential glycosylation patterns. Bacterial surface polysaccharides are considered as 
key molecules in host-microbe interactions [39]. But also the abundancy of glycosylated 
sites on IgA is thought to be an important factor for association with microbiota [16]. SIgA 




of glycan structures present on the secretory component of SIgA [40]. It was demonstrated 
that the source of IgA greatly influences the glycosylation of the molecule. Plasma-derived 
IgA has less glycosylated sites compared to SIgA derived from saliva [41]. We demonstrated 
that L. crispatus was more opsonized with SIgA compared to serum IgA (Figure 1). Genomic 
characterization revealed furthermore that L. crispatus has the capacity to encode more 
glycosyltransferases compared to L. iners [42] Glycosyltransferases are enzymes that have 
an important role in protein glycosylation [43]. Determining the contribution of glycan-
dependent binding of IgA to microbiota is challenging as glycans seem to vary between donors, 
with inflammatory status, with rate of IgA production and the site of IgA production [16].
Figure 1. Secretory IgA and serum IgA coating of L. crispatus. Uncoated L. crispatus was included as control.
In sharp contrast to the intestinal mucosa, where IgA is predominantly produced, the female 
genital tract has more IgG producing plasma cells. Relatively higher specific IgG versus total 
IgG levels were found in the female genital tract compared to serum implying that at least 
some of the produced IgG originates from local plasma cells [44]. IgG is transported towards 
the vaginal lumen via the neonatal Fc receptor (FcRn) expressed on vaginal epithelial cells 
[45]. However, vaginal IgG levels and IgG coating of microbiota were not influenced by 
microbiota composition, suggesting that IgG does not play an important role in microbiota 
composition (chapter 2).
Both IgA and IgG levels (either unbound or bound to the vaginal microbiota) were increased 
during menstrual bleeding. As such we expect that there is also a role for systemic 
immunoglobulins in the opsonization of vaginal microbiota. This was supported by other 
studies which demonstrated increased vaginal IgA levels during menstrual bleeding [46, 
47]. Moreover, hormone levels which fluctuate during the menstrual cycle have also been 
described to influence immunoglobulin levels present in the female genital tract. IgA and 
IgG levels in cervical mucus were 10-100 fold lower at midcycle (high level of estrogen) 
compared to the levels present early in the proliferative phase (low level of estrogen) [48]. 
Hormonal regulation of immunoglobulins has also been confirmed in animal models [49, 
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50]. Furthermore, the expression of the pIgR in the uterus, responsible for IgA transport, is 
hormonally regulated and as such related to the stage of the menstrual cycle [51]. Expression 
of pIgR was found to be very low or even absent in vaginal epithelial cells [52]. It is thought 
that IgA in vaginal secretions might originate from the uterus, but it is also possible that 
the vaginal epithelial barrier facilitates passive transport of IgA to the vaginal lumen [53].
A role for immunoglobulins in preterm birth
Since we observed that a healthy vaginal microbiome was associated with increased IgA 
levels, and it has been hypothesized that vaginal dysbiosis is a risk factor for preterm birth, 
we investigated we investigated immunoglobulin and immune mediator levels and their 
association with vaginal microbiota in pregnant women. We did however not find differences 
in vaginal IgA and IgG levels in women with term or preterm birth (PTB). We furthermore 
investigated bacterial immunoglobulin coating and found no differences in IgA or IgG 
coating of vaginal microbiota in women with TB compared to women with PTB. However, 
it was reported that in women with PTB and who had a pathological vaginal microbiota 
composition, cervicovaginal IgA levels were significantly lower compared to women with 
term birth (TB) [54]. These results suggest that the vaginal microbiota composition is an 
essential factor in regulating IgA levels and affects birth outcome either primarily or as a 
consequence of diverging IgA levels. Vaginal microbiota composition is currently under 
investigation in our cohort to check whether microbiota composition is related to the 
level of immunoglobulins found in women with TB or PTB. When we compared White 
European women with non-White European women we found increased IgA coating of 
vaginal microbiota of White European women. Since vaginal microbiota composition differs 
between ethnicities and was shown to affect cervicovaginal IgA levels [54], it is likely that the 
deviation in IgA coating of vaginal microbiota of White European compared to non-White 
European can be linked to a differential microbiota composition.
In line with previous reports we found an increased prevalence of PTB among non-White 
European women. Ethnicity and vaginal microbiota composition are major risk factors for 
PTB. An increased diversity of bacterial species might increase the risk of infections and as 
such also the risk of preterm birth. This can be caused by the fact that anaerobic bacteria 
produce mucus degrading enzymes which affect the protective barrier of the female 
genital tract [55]. Mucus along with SIgA are important to entrap pathogens and remove 
them from the body. When this protective layer is affected pathogens can easily invade 
the underlying tissue. Furthermore, Lactobacillus species produce high levels of D-lactate 
which is important to maintain a low and favorable pH, but it also contributes to entrap 
viruses. Anaerobic bacteria produce low levels of D-lactate thereby making the vaginal 
mucosa more susceptible to viral infections [35]. The above mentioned findings support the 
hypothesis that women with a high diversity vaginal microbiota are more prone for preterm 




Inflammatory mediators to predict preterm birth
During pregnancy a special balance between protecting the host from infections and 
tolerating the allogeneic fetus is required. Normal onset and progression of labor is 
orchestrated by many factors present in the maternal, fetal and placental tissue, including 
inflammatory mediators [56, 57]. Infections along the female genital tract before 37 weeks 
of gestation can increase the risk of preterm birth (PTB) by inducing preterm labor. Other 
risk factors for preterm birth are a disbalanced vaginal microbiota composition, a short 
mid-trimester cervical length and a low pre-pregnancy body mass index [58-61]. To date 
the etiology of spontaneous PTB (sPTB) is considered multifactorial and remains poorly 
understood. In chapter 3 we aimed to define immune predictors for sPTB present in vaginal 
fluid in early stage pregnancy (8-12 weeks of gestation). Recent studies showed increased 
levels of IL-1β, IL-6, eotaxin, Mip-1β and RANTES in vaginal fluid (collected at time of labor 
symptoms) of women with sPTB compared to women with TB [62-64]. In contrast, lower 
levels of IL-8 and IL-1β have been found in cervicovaginal fluid (collected between 22-24 
weeks of gestation) of high PTB risk women with PTB compared to high risk PTB women 
with TB [65]. In one study decreased levels of the anti-inflammatory cytokine IL-10 in plasma 
(collected between 22-24 weeks of gestation) were associated with preterm birth [66], while 
in another study elevated plasma (collected between 23-29 weeks of gestation) levels of 
IL-10 were associated with an increased risk of preterm birth [67]. In our study we did not 
find different levels of IL-1β, IL-6, IL-8 and IL-10 in vaginal fluid (collected between 8-12 weeks 
of gestation) in women with sPTB or TB. Our results are somewhat contradictory with the 
current knowledge on the association between pro-inflammatory mediators and PTB. A 
major difference between our study and the previous studies described is the time point of 
collecting the vaginal fluid. It is likely that levels of pro-inflammatory cytokines present in 
vaginal fluid increase just before onset of labor, as these mediators were described to induce 
and progress labor and no differences may therefore be found in early stage pregnancy.
However, we found lower levels of S100A8/A9 in women with sPTB compared to women 
with TB. The pro-inflammatory peptide S100A8/A9 was described to be responsible for 
neutrophil recruitment in women with vaginal Candida infection [68]. It was furthermore 
shown that expression of S100A8 was increased in placental tissue of women with recurrent 
miscarriages [69]. The level of S100A8/A9 was negatively associated with vaginal IgA levels in 
women with TB, but not sPTB (chapter 3). It might be that IgA is important for the regulation 
of this pro-inflammatory mediator by suppressing its presence. Fewer pro-inflammatory 
mediators present in the vaginal fluid might be beneficial in preventing preterm birth. It is 
clear that much knowledge regarding vaginal immunoglobulins, inflammatory mediators and 
their potential association in relation to preterm birth is still lacking. Further investigation 
on vaginal immune aspects and microbiota composition is needed to clarify the role of 





IgA and FcαRI in mucosal immunity
Antibodies are key mediators of humoral immunity by providing protection against pathogens 
and mediating resolution of infection. IgA can interact with multiple receptors, of which 
FcαRI is the best characterized. FcαRI is expressed by myeloid cells including neutrophils, 
monocytes and some macrophage and DC subsets [70]. When pathogens invade the mucosal 
tissue dimeric IgA, which is produced by local plasma cells, can efficiently opsonize these 
pathogens. The formed IgA-pathogen complexes can potently activate FcαRI after which 
a variety of pro-inflammatory processes can emerge including phagocytosis, antibody 
dependent cellular cytotoxicity, and the production of cytokines and chemokines [71].
Neutrophils are the first cells to be recruited at sites of infection [72]. After activation with 
IgA-complexes neutrophils secrete the chemotactic lipid leukotriene B4 (LTB4) which recruits 
more neutrophils to the site of infection [73]. Knowledge about cellular interactions and 
cellular modulation between (activated) neutrophils and DCs were summarized in chapter 
4. To gain more insight on the influence of an inflammatory environment on DCs we further 
investigated the specific role of IgA-activated neutrophils on residing tolerogenic dendritic 
cells in chapter 5. Neutrophils were activated with serum IgA-coated beads and co-cultured 
with in vitro generated CD103+ DCs. The tolerogenic phenotype of CD103+ DCs was not 
affected by IgA-activated neutrophils. Nevertheless it was demonstrated in another study 
that S. aureus coated with IgA converted tolerogenic CD103+ DCs into a pro-inflammatory 
cell phenotype [74]. Simultaneous activation of Fc receptors and Toll-like receptors (TLRs) 
was shown to result in synergistic release of pro-inflammatory cytokines [75]. Possibly the 
lack of an inflammatory immune response by CD103+ DC after co-culture with IgA-activated 
neutrophils can be explained by the lack of the TLR trigger in our experiments.
We furthermore demonstrated that LTB4 is not only important for neutrophil recruitment, 
but is also relevant for migration of monocytes, which are precursors of moDCs. This process 
is specific for IgA, as crosslinking of Fcγ receptors by IgG did not induced LTB4 release. After 
infection, monocytes are recruited from the circulation and can differentiate into moDCs 
in tissues. DCs are the main antigen presenting cells and responsible for the induction of 
effective adaptive immune responses. We questioned whether freshly recruited moDCs 
are modulated by IgA-activated neutrophils. We found a more mature phenotype and 
enhanced cytokine production by moDC in the presence of IgA-activated neutrophils. We 
propose a model in which tolerogenic CD103+ DCs reside in the lamina propria where they 
contribute in maintaining immune tolerance and homeostasis. However, when pathogens 
are able to breach the protective mucosal barrier invading pathogens can be opsonized with 
dimeric IgA. Neutrophils express the FcαRI which will be cross-linked upon recognition of 
IgA immune complexes resulting in the release of LTB4. This leads to recruitment of more 
neutrophils which will be activated by IgA immune complexes causing higher concentrations 




monocytes can differentiate into moDCs under inflammatory conditions. IgA-activated 
neutrophils can interact with moDCs, modulate their maturation and induce cytokine 
release. The interaction between neutrophils and DCs may furthermore form a bridge 
between innate and adaptive immunity, where neutrophils act fast to clear the infection 
and DCs present antigens towards other cells of the adaptive immune system to support 
with a more specific immune response and build protection.
IgA and FcαRI in systemic immunity
In the circulation IgA is the second most predominant antibody after IgG. Relatively little is 
known about the role of IgA in the circulation as most research on IgA has focused on the 
mucosa. As such a rather traditional view of a supposedly non-inflammatory and possibly 
redundant function of IgA in the circulation has been generally presumed. However, it 
has been demonstrated that when bacteria breach the protective mucosal layers of the 
human body and enter the blood stream IgA can efficiently opsonize these pathogens and 
effectively crosslink the FcαRI [76]. In chapter 6 we furthermore demonstrated increased 
Borrelia antigen C6-peptide specific IgA antibodies levels in serum of Lyme borreliosis 
patients. Approximately one third of early diagnosed Lyme borreliosis patients are IgA 
seropositive [77]. We demonstrated enhanced opsonization capacity of IgA to Borrelia 
strains compared to IgG. IgA has increased neutralizing capacity due to its N-linked 
glycosylation position in the heavy chain [78]. However, antibodies against B. burgdorferi 
are described to ameliorate disease symptoms and are incapable of clearing the infection 
due to multiple immune evasion mechanisms of B. burgdorferi [79, 80]. Antibody responses 
are even thought to play a detrimental role in contributing to disease symptoms through 
their potent immune activation. A correlation between antigen specific serum IgA in early 
Lyme borreliosis patients and disseminated infection and possibly neurologic manifestations 
has been described in one study [77]. However, this association was only present in a small 
study group and currently the harmful role of IgA in infectious diseases is ill understood.
Recently, it was demonstrated that patients with coronavirus disease 2019 (COVID-19) also 
have specific serum IgA titers, which contributed to the neutralization of severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) to a greater extent than IgG [81, 82]. 
However, elevated IgA levels have also been associated with an increased risk of death in 
COVID-19 patients with an age below 70 years [83]. Furthermore, levels of systemic IL-6 
highly correlated with disease severity and mortality in COVID-19 patients [84, 85]. Possibly 
over activation of the immune system caused by elevated IgA levels can result in increased 
levels of systemic IL-6 which initiates an out-of-control release of inflammatory mediators 
also known as a cytokine storm. Cytokine storms may play a role in the pathology of COVID-
19 and other infectious and non-infectious diseases [86, 87].
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Why is there a difference between IgA and IgG?
To further investigate the immune activating potential of serum IgA, we studied the 
differential immune response of monocytes and neutrophils towards serum IgA- and 
IgG-complexes. We showed equal phagocytosis of IgA- and IgG-complexes by both 
neutrophils and monocytes. More in depth analysis of the cellular immune response by 
RNA sequencing revealed increased upregulation of genes involved in immune activation 
when monocytes were activated with complexed serum IgA compared to complexed serum 
IgG (chapter 6). We quantified the amount of pro-inflammatory cytokines produced by 
IgA- versus IgG-activated monocytes and found significantly enhanced production of all the 
measured inflammatory mediators after IgA activation. Most striking was the significant 
upregulated gene expression of IL-6 after monocytes were activated with complexed serum 
IgA compared to complexed serum IgG. These results challenge the current dogma of IgA 
as a non-inflammatory or redundant antibody and by contrast strongly support its pro-
inflammatory function, which can also be of benefit during systemic infection.
One of the reasons why IgA induces a stronger inflammatory response than IgG is that 
cellular signaling pathways differ after stimulation with IgA or IgG complexes. This differential 
response can be explained by several factors. First of all, IgA binds two FcαRI, whereas 
IgG has a 1:1 binding stoichiometry with Fc gamma receptors (FcγRs) [88, 89]. As such, 
one IgA molecule has greater ability for cross-linking Fc receptors than one IgG molecule 
and thereby IgA can initiate more potent cellular responses. Second, to initiate cellular 
signaling the FcαRI induces complex formation with the FcR γ-chain. The FcR γ-chain has 
two immunoreceptor tyrosine-based activation motifs (ITAMs). The tyrosines present in 
the ITAMs phosphorylate upon receptor engagement, which initiates the cellular signaling 
cascade. In contrast, IgG cross-links the FcγRIIA which only has one ITAM. As a result one 
IgA molecule can activate four ITAMs by cross-linking two FcαRI, while one IgG molecule 
can only activate one ITAM via FcγRIIA or two ITAMs via FcγRI (the latter also associates with 
the FcR γ-chain). Cytokine release after stimulation of myeloid cells is presumably induced 
predominantly via the FcR γ-chain ITAMs [90]. However, differences in cytokine release after 
IgA- compared to IgG-stimulation cannot be explained solely by dissimilarities in ITAMs. It 
was shown previously that crosslinking of FcγRIIA resulted in IL-8 release by monocytes 
[91]. We demonstrated that IL-8 is released by monocytes after IgG stimulation as well. In 
addition, monocytes express the high-affinity receptor FcγRI, which signals via the same 
FcR γ-chain as FcαRI [92]. Nonetheless, the lower levels of cytokines, chemokines and lipids 
produced after stimulation of monocytes with IgG suggests that the FcγRI is not equally 
efficient engaged compared to FcαRI. This poor immune cell activation after IgG stimulation 
might be caused by competition for the FcR γ-chain between FcαRI and FcγRI [93]. Another 
explanation might be that FcαRI uses additional signaling routes which enhance cytokine 
release, but are so far unidentified. More research is needed to unravel the distinct cellular 




The level of IgA in the circulation is only 1-3 mg/ml, whereas IgG reaches a concentration 
between 4-12 mg/ml, which has been viewed as evidence for a less important role for serum 
IgA. However, serum levels of IgE, a key pro-inflammatory antibody in mediating allergic 
diseases, are also low. Similarly IgE has a short half-life, which limits unwanted systemic pro-
inflammatory responses [94]. We propose that the lower serum IgA concentration and short 
half-life of IgA in vivo might act as inhibitory mechanisms to prevent prolonged unwanted 
immune activation. This hypothesis is further supported by the fact that both IgA and IgE 
lack the capacity to induce classical complement activation, which additionally may prevent 
excessive immune cell activation through FcαRI and FcεRI respectively [95]. Increased levels 
of complexed IgA can induce high levels of IL-6, which is the main cytokine responsible for 
the initiation of a cytokine storm. We anticipate that the superior potential of IgA to activate 
immune cells is beneficial during infections. But to overcome immune over-activation the 
general low levels of serum IgA and a short half-life are of likely of evolutionary benefit.
Use the potency of IgA in vaccination
Vaccination is one of the most effective contributions to global health resulting in the 
protection against infectious diseases [96]. IgG antibodies are considered the main 
antibody isotype for systemic protection whereas serological changes in vaccine-specific 
IgA antibodies are generally neglected [97]. In chapter 6 we demonstrated that individuals 
vaccinated with the non-live parenteral Vi capsular polysaccharide vaccine (TFV) had 
significantly increased levels of circulating IgA antibodies against Vi antigen up to 12 
weeks post-vaccination. These results are supported by previous studies [98, 99]. It was 
also demonstrated that vaccinated individuals had 2 to 3.5-fold higher levels of Vi-specific 
serum IgA, which correlated with protection against S. typhi after being challenged by oral 
ingestion with S. typhi [100, 101].
Administration of specific IgA (passive immunization) or enhancing IgA production through 
active immunization might be effective strategies to combat all kind of bacterial and viral 
infections [102]. The beneficial role of IgA has been supported by multiple in vivo studies 
performed in mice and rhesus macaques. Oral administration of IgA-coated S. typhimurium 
resulted in reduced intestinal infection rates in mice compared to absence of IgA [103]. Mice 
which received intranasal specific monomeric or polymeric IgA against a mycobacterium 
tuberculosis antigen were shortly, but effectively protected against infection [104]. This 
short protection duration was probably due to degradation of IgA by bacterial proteases 
present in the respiratory tract fluid. To investigate the additional effect of the FcαRI, 
transgenic mice expressing the FcαRI on blood neutrophils and monocytes were used. FcαRI 
transgenic mice which received an IgA monoclonal antibody had reduced mycobacterium 
infection rates compared to wild type mice [105]. These results underline the importance of 
using the appropriate mouse model when investigating both IgA and its interaction with the 
FcαRI. Mice immunized intranasal with hemagglutinin (surface protein on influenza virus) 
produced anti-influenza specific SIgA, which protected mice from infection after intranasal 
administration [106]. Polymeric IgA against influenza virus reached the nasal mucosa after 
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intravenous administration and was 10 times more effective than IgG in reducing viral 
shedding [107, 108]. Mice deficient of IgA, J-chain or pIgR showed compromised immune 
protection [109-111]. WT mice that were immunized and orally challenged with reovirus had 
enhanced serum and intestinal IgA levels and were protected from infection [110, 112]. IgA-/- 
mice were unable to clear reovirus infection [110]. In rhesus macaques passive immunization 
with dimeric IgA showed better protection against HIV transmission. Dimeric IgA directly 
neutralized simian HIV or the virus was trapped by large immune complexes preventing 
entrance in the epithelial barrier [113]. In mice orally and nasally administrated HIV antigens 
bound to SIgA were retro transported through M cells and reached sub-epithelial DCs, 
thereby inducing both mucosal and systemic humoral and cellular immune responses [114]. 
Vaccination with SIgA-HIV antigen protected these mice from infection after challenge with 
a recombinant vaccinia virus expressing the HIV antigen [114, 115]. This demonstrates the 
potential of SIgA to serve as a vaccine carrier for HIV via mucosal administration. In human, 
systemic IgA isolated from serum of HIV survivors and vaccinated HIV patients neutralized 
HIV through occupying the CD4 binding site of the virus. However, by contrast, in another 
study, HIV specific IgA levels in plasma interfered with IgG effector functions in vitro, thereby 
increasing HIV infection risk [116]. In elderly, vaccination with live attenuated polio induced 
intestinal IgA production and induced long-lived memory immune responses in those who 
still had detectable serum and salivary IgA levels [117-119].
PART III autoimmunity
IgA as autoantibody
Prolonged activation of FcαRI can occur when aberrant IgA is present resulting in the 
recruitment of immune cells via the release of multiple chemokines including LTB4 and 
IL-8. Continuous presence of activated immune cells can eventually cause tissue damage 
as observed in a variety of inflammatory autoimmune diseases (Figure 2). In autoimmune 
diseases antibodies are present which recognize a self-antigen. These so-called 
autoantibodies bind to harmless antigens found throughout the body thereby attacking 
the body’s own tissues in which these antigens are found. IgA autoantibodies are found 
in variety of auto-immune diseases and in some conditions IgA autoantibodies have even 




Figure 2. IgA-FcαRI induced pathology in autoimmunity. IgA immune complexes activate neutrophils 
by cross-linking FcαRI, resulting in release of LTB4 and enhanced neutrophil influx, which induces 
tissue damage as seen in the skin (LABD), vessels (IgA vasculitis), joints (RA), and potentially in colon 
(IBD). Additionally, IgA immune complexes activate monocytes which contribute to the inflammatory 
environment in the joint of RA patients.
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a systemic and chronic autoimmune disorder characterized 
by infiltration of inflammatory immune cells in the joints, resulting in swelling and pain. 
Autoantibodies including rheumatoid factor (RF) and anti-citrullinated protein antibodies 
(ACPA) are commonly found, which can be of the IgM, IgG or IgA isotype. High ACPA and 
RF IgA titers correlate with worse disease prognosis and severity, and have been used as 
predictive value for disease progression [120-122]. It was demonstrated that blocking the 
interaction between RF IgA and macrophage FcαRI resulted in reduced levels of TNF-α [123], 
a known pro-osteoclastogenic cytokine. The importance of RF IgA in disease pathology was 
underlined by the fact that RA patients with high pretreatment RF IgA levels had a poor 
clinical response towards TNF-α inhibitors [124, 125]. IgA-immune complexes in patients 
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can induce pro-inflammatory functions by FcαRI expressing neutrophils and macrophages, 
which are prominently present in inflamed joints [126].
We demonstrated that soluble factors produced by IgA-activated monocytes enhanced 
bone resorption by osteoclasts (chapter 7). Synovial fluid levels of IL-8 and IL-6 were 
significantly elevated in patients with high ACPA levels in their synovial fluid [127]. We 
showed that IgA-activated monocytes produced significantly elevated levels of IL-6 and 
IL-8 and both cytokines enhanced bone resorption by osteoclasts in vitro. IL-8 is a known 
chemotactic mediator for neutrophils, which are found in high numbers in the synovial fluid 
of RA patients [128, 129]. Neutrophils stimulated with plasma of RA patients, containing 
IgA immune complexes, formed neutrophil extracellular traps (NETs), which formation was 
inhibited by blocking FcαRI [130]. NETs contribute to the development of carbamylated 
protein antibodies (anti-CarP) thereby enhancing the pro-inflammatory loop in RA patients 
even further. Furthermore, LTB4 levels are increased in synovial fluid and serum of RA 
patients [131-133], contributing to the positive feedback loop of neutrophil and monocyte 
recruitment (Figure 2). Inhibition of IL-8 reversed ACPA-induced bone loss in mice [134], 
supporting the importance of IL-8 in the pathology of RA in ACPA positive patients. We 
demonstrated that osteoclasts expressed FcαRI and were directly activated by IgA resulting 
in increased production of IL-6, which activated RANKL on osteocytes thereby enhancing 
osteoclastogenesis in vitro [135, 136]. In vivo, IL-6 was important for osteoclast activity 
and bone resorption [137, 138]. The potential of the human anti-IL-6 blocking antibody 




Box 1. Problems with IgA isolation
In order to investigate the effect of IgA present in synovial fluid of RA patients in 
chapter 7 we isolated IgA from synovial fluid material using peptide M. Peptide 
M is derived from streptococcal M protein and specifically binds to the Fc region 
of both monomeric and dimeric human IgA [2]. In this way M protein expressing 
streptococcus species escape from IgA-FcαRI mediated pathogen removal by 
FcαRI-expressing immune cells. Streptococcal M protein specifically binds IgA and 
therefore can also be used to extract IgA from synovial fluid. 
We confirmed presence of IgA after its isolation from synovial fluid, although 
significant loss was observed (Figure 3A). Furthermore, we showed that isolated 
IgA coupled to latex beads was able to bind to soluble CD89 (FcαRI) similar to 
commercially available human serum IgA coupled to latex beads (Figure 3B). Isolated 
IgA, either originating from commercial human serum IgA, healthy donor serum, or 
synovial fluid of a RA patient, coupled to latex beads was phagocytosed by human 
monocytes similar to commercially available human serum IgA coupled to latex 
beads (Figure 3C). Interestingly (and unfortunately), isolated IgA coupled to latex 
beads did not induced IL-6 release by monocytes, while commercial available human 
serum IgA coupled to latex beads induced high levels of monocyte IL-6 release (Figure 
3D). Possibly the isolation method with M protein somehow obstructed a specific 
spot on IgA which is essential for effective signaling of the FcαRI. As demonstrated in 
chapter 6, IgA has a much higher potency in inducing cytokine production by human 
monocytes compared to IgG, even though phagocytosis of IgA and IgG beads is 
similar. Cellular signaling pathways after IgA stimulation differ from IgG stimulation 
and could account for the observed effect. Isolated IgA may have been affected 
during the isolation method in such a way that it is still able to partly bind to FcαRI, 
resulting in phagocytosis, but long term effects like cytokine production are lost. 
Potentially, the isolated IgA cannot effectively induce FcαRI signaling via FcR-γ chain 
complexes (and their ITAM motifs) and therefore the cellular response of isolated 
IgA is more similar to IgG. It should be noted that previous studies investigating 
the interaction between isolated IgA and FcαRI might have overlooked the potent 
immune stimulation by IgA due to this problem. Thus, future studies should pay 
attention to the IgA isolation method and should thoroughly test the immune 
activating capacity of isolated IgA.
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Figure 3. Isolated IgA binds to FcαRI but does not induce IL-6 release. (A) IgA was isolated using 
peptide M from commercial IgA (IgA ctrl), serum of a healthy donor (HD serum), serum of a RA patient 
(RA serum) and synovial fluid of a RA patient (RA SF). Black bars represent the IgA input levels, grey 
bars represent the IgA levels after isolation. (B) Binding of beads coated with (left panel) BSA, (middle 
panel) commercial IgA or (left panel) isolated IgA from synovial fluid of RA patients to soluble CD89. 
(C) Phagocytosis of beads coated with BSA or commercial IgA and isolated IgA from commercial 
IgA, healthy donor serum or synovial fluid of a RA patient by monocytes. (D) IL-6 production by 
monocytes stimulated with beads coated with commercial IgA (black bar), or isolated IgA (grey bars) 
from commercial IgA, healthy donor serum or RA patient serum for 24 hours.
IgA nephropathy
IgA nephropathy (IgAN) is the most common form of glomerulonephritis and progresses to 
end-stage kidney failure in 50% of patients. IgA levels are increased in both serum and urine 
of IgAN patients. A link with RA was suggested, as patients can also have enhanced RF IgA 
in their serum. This condition is referred to as rheumatoid nephropathy [142]. Neutrophil 
infiltration in glomeruli of IgA nephropathy patients was demonstrated, however the 
exact contribution of neutrophils to disease pathology is unknown [143] (Figure 2). It was 
hypothesized that galactose-deficient O-glycans in IgA1, produced by plasma cells in the gut, 
can trigger the production of anti-glycan IgG/IgA antibodies, after which formed immune 
complexes deposit in the glomeruli where renal injury is initiated [144, 145]. The enzymes 




amongst others regulated by bacterial products, suggesting that the microbiome regulates 
the specific glycosylation pattern of IgA1 during the initial phase of IgAN [146, 147]. In mice, 
galactose-deficient IgA1 was not cleared from the murine circulation and deposited in the 
kidney [148]. FcαRI+ Kupffer cells were unable to clear circulating IgA of IgAN patients in 
vivo [149]. In transgenic mice expressing the human FcαRI on monocytes and macrophages, 
soluble FcαRI-IgA complexes that were deposited in the mesangium, induced glomerular 
and interstitial macrophage infiltration, hematuria, mesangial matrix expansion and mild 
proteinuria [150, 151]. Moreover, in FcαRI transgenic and human IgA knock-in mice soluble 
FcαRI-IgA complexes induced kidney inflammation by interacting with TfR1 on mesangial 
cells, which induced the release of pro-inflammatory mediators. Additionally, the expression 
of transglutaminase 2 was induced, which subsequently enhanced the expression of TfR1, 
thereby inducing a pathogenic amplification loop [150]. Of note, shedding of FcαRI from 
macrophages of transgenic mice may have aggravated disease, which will likely not occur 
in patients as human macrophages express lower FcαRI levels. Nonetheless, IgA-soluble 
FcαRI complexes have been found in patients with IgAN, and serum IgA immune complexes 
bound more avidly to TfR1 in vitro compared to those from healthy controls [151, 152]. It 
was demonstrated that IgAN and Henoch-Schönlein purpura nephritis patients had reduced 
levels of soluble FcαRI and transglutaminase 2 in their urine [153], which makes it plausible 
that soluble FcαRI immune complexes deposit in the human kidney.
IgA vasculitis
IgA vasculitis, also known as Henoch-Schönlein purpura, is the most common form of 
vasculitis. The condition is characterized by IgA1 immune deposits and neutrophil infiltrates 
affecting the small vessels (Figure 2). As a result, red blood cells can leak into the skin leading 
to typical cutaneous hemorrhages, which leads to diagnosing the disease [154, 155]. The 
pathology of IgA vasculitis remains unclear. However, it is suggested to represent a systemic 
equivalent of IgAN, as IgA vasculitis can be accompanied with nephropathy, resembling 
IgAN [156]. Unlike IgAN, which is characterized by deposits of galactose-deficient IgA1, it 
is unknown which type of IgA accumulates in IgA vasculitis [144, 157].
Increased levels of soluble FcαRI-IgA complexes were found in sera of adult and pediatric 
vasculitis patients with or without co-existing nephritis, which was associated with 
decreased FcαRI expression on monocytes [158, 159]. Furthermore, it was proposed that 
IgA1 anti-endothelial cell antibodies might play a role. Serum IgA from IgA vasculitis patients 
was shown to bind in vitro to human but not bovine glomerular endothelial cells [160]. 
IgA anti-endothelial cell antibodies induced the production of IL-8 by endothelial cells, 
thereby contributing to an inflammatory environment and neutrophil recruitment [161, 
162]. In addition to enhanced levels of serum TNF-α, which promoted anti-endothelial cell 
antibody binding to endothelial cells, IL-8 production increased inflammation in IgA vasculitis 
patients [160, 162, 163]. It was hypothesized that neutrophils become activated by IgA-FcαRI 
mediated cross-linking, resulting in inflammatory processes like reactive oxygen species 
production and NET formation. Moreover, IgA activated neutrophils release LTB4, inducing 
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neutrophil migration, thereby enhancing a positive feedback loop, which may result in 
pathogenesis observed in IgA vasculitis [155].
Inflammatory bowel disease
Inflammatory bowel disease is characterized by chronic inflammation in the intestinal tract 
and is subdivided into ulcerative colitis and Crohn’s disease [164]. The barrier function in 
these patients is disrupted allowing bacteria to invade the subepithelial lamina propria [164]. 
Downregulation of pIgR on intestinal epithelial cells and a disturbed microbiota were observed 
in IBD patients [165]. Furthermore, levels of IgA autoantibodies in serum of IBD patients 
are increased [166], suggesting an involvement of systemic IgA in the pathogenesis of IBD.
It was proposed that intracellular signaling pathways and protein trafficking was altered due 
to damage caused by the inflammatory environment resulting in pIgR regulation defects 
[15]. Mice lacking pIgR have enhanced numbers of IgA-secreting plasma cells, possibly as 
compensation. Increased production, combined with diminished transcytosis of dIgA into the 
lumen may potentially result in accumulation of dIgA in the lamina propria. Invading bacteria 
can become opsonized with dIgA, potentially resulting in activation of neutrophils by cross-
linking of FcαRI, leading to tissue damage. Neutrophils that had taken up IgA were observed 
in the mucosa of ulcerative colitis patients [73]. Cross-talk between Fc receptors and TLRs was 
induced by antibody-coated bacteria, resulting in release of pro-inflammatory mediators (e.g. 
LTB4) by DCs, which may also contribute to inflammation in IBD. LTB4 induces recruitment 
of neutrophils and at higher concentrations also monocytes. Additionally, simultaneous 
triggering of FcαRI and TLR4 on neutrophils resulted in enhanced release of pro-inflammatory 
TNF-α [167]. Furthermore, due to diminished SIgA levels in the lumen, neutralization and 
immune exclusion of microbes is decreased, which may worsen disease in patients [15].
In chapter 5 we found neutrophils in close contact with DCs present in intestinal tissue 
sections of inflammatory bowel disease (IBD) patients. We hypothesize that continuous 
presence of IgA-activated neutrophils and their cellular interactions with DCs contribute 
to aberrant immune activation resulting in pathology as is observed in IBD patients. More 
research is however needed to unravel the role of IgA-FcαRI interactions in IBD.
Celiac disease and dermatitis herpetiformis
Celiac disease is a multifactorial autoimmune disease characterized by a damaged small 
intestinal mucosa and nutrient malabsorption following gluten ingestion. Individuals 
carrying the DQ2 and DQ8 HLA haplotypes have an increased risk to develop celiac disease 
[168]. Gliadin, a glycoprotein of gluten, can complex with specific IgA, after which it can be 
retrotransported across the epithelium via the TfR (Figure 4). Celiac disease patients have 
increased expression of TfR on their epithelial cells, allowing increased retrotransport [169]. 
Intracellular degradation of these peptides is disturbed in patients and after entrance in the 
lamina propria gliadin peptides are deamidated by tissue transglutaminase after which they 




pro-inflammatory mediators, concomitant tissue damage and production of autoantibodies 
[170]. IgA anti-tissue transglutaminase antibodies play a key role in disease pathogenesis 
[171]. Presence of these antibodies serve to diagnose the disease and are furthermore linked 
to other IgA related diseases like dermatitis herpetiformis and IgA nephropathy (Figure 4). 
In dermatitis herpetiformis aberrant IgA antibodies are directed against structural proteins 
maintaining cell-cell adhesion in the epidermis leading to skin tissue damage [172]. It is 
hypothesized that celiac disease patients can develop dermatitis herpetiformis as high 
avidity IgA anti-tissue transglutaminase antibodies form immune complexes and deposit 
in the dermis of these patients, although it is ill understood why some patients develop 
dermatitis herpetiformis, and others do not. Furthermore, small bowel inflammation in 
celiac disease is mostly the result of mononuclear cell infiltration, whereas neutrophils 
accumulate in the skin of dermatitis herpetiformis patients [172]. Patient neutrophils have 
increased ability to bind IgA without FcαRI expression alteration, supporting that FcαRI is 
primed (e.g. by cytokines or differential glycosylation) [173].
Gluten exposure can also lead to glomerular IgA deposition and IgAN [174]. Transgenic human 
IgA and FcαRI knock-in mice developed severe pathology when gluten were present in their 
diet, including intestinal injury, increased IgA1–soluble FcαRI complexes, mesangial IgA1 
deposition, and elevated serum IgA1 anti-gliadin antibodies. IgAN patients also have increased 
IgA1 anti-gliadin antibodies in their serum, suggesting that entrance of gluten can potentially 
result in loss of oral tolerance thereby contributing to IgAN [175]. Consumption of a gluten-
free diet can resolve manifestations of celiac disease, dermatitis herpetiformis and IgAN.
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Figure 4. Celiac disease and gluten-associated diseases (1) IgA-gliadin complexes bind to the 
transferrin receptor (TfR) and are retrotransported across the epithelium. (2) In the lamina propria 
deamidated gliadin is taken up by DCs and after processing (3) presented to T helper (Th) cells. (4) 
Th1 cell activation leads to the release of pro-inflammatory mediators (5) causing tissue damage. 
(6) Activated Th2 cells stimulate autoantibody production directed against gliadin and tissue 
transglutaminase by B cells. (7) Plasma cells produce autoantibodies which (8) can be detected in the 
circulation and form deposits with soluble FcαRI in the kidney resulting in damage (IgA nephropathy). 
(9) IgA anti-tissue transglutaminase forms complexes in the dermis, resulting in neutrophil activation 
and concomitant tissue damage (dermatitis herpetiformis).
Linear IgA Bullous Disease
Linear IgA Bullous Disease (LABD) patients suffer from extensive skin damage and blister 
formation caused by the presence of IgA autoantibodies against collagen XVII, and 
concomitant neutrophil accumulation (Figure 2). Collagen XVII plays a critical role in 
maintaining adhesion between dermis and epidermis in the skin [176]. Neutrophil activation 
is likely the direct result of FcαRI triggering by IgA autoantibodies [177]. Tissue damage was 
induced in the presence of neutrophils and serum of LABD patients (containing IgA anti-
collagen XVII autoantibodies) in an ex vivo skin model, as presence of activated neutrophils 
led to separation of the dermis from the epidermis (reflecting blister formation) [177]. 
Eosinophil influx has been observed in the skin of LABD patients as well, suggesting that 
these cells might also contribute to disease pathology through FcαRI mediated respiratory 
burst activity [176].
PART IV therapeutic strategies
IgA plays an important role in dampening mucosal infections, but can also have detrimental 
effects in inflammatory or autoimmune diseases. Lack of IgA may increase susceptibility 




enhanced activation of the FcαRI may lead to various pathologies. Several therapeutic 
strategies have been proposed that influence the IgA-FcαRI axis (Figure 5). For instance, 
in order to benefit from increased IgA levels during infections it was proposed to increase 
pathogen-specific IgA levels through passive or active vaccination thereby resulting in efficient 
clearance of pathogens (described in part III). Furthermore, IgA might be used as a therapeutic 
antibody to mediate efficient tumor cell killing. Additionally, two different strategies of 
targeting FcαRI have been proposed. First, the induction of ITAMi signaling via FcαRI may 
dampen inflammation that is caused by other pro-inflammatory receptors (e.g. FceRI). 
Second, blocking FcαRI may reduce activation of immune cells in IgA-mediated inflammation.
ITAMi as therapeutic strategy
Binding of mIgA to the FcαRI induces an anti-inflammatory instead of a pro-inflammatory 
signaling cascade (inhibitory ITAM signaling (ITAMi)) which results in the downregulation 
of immune responses [178]. Enhancing ITAMi signaling by monomeric targeting of the 
FcαRI may be a promising strategy to inhibit IgG-induced phagocytosis and IgE-mediated 
allergic diseases [179]. Monovalent targeting of FcαRI with the anti-FcαRI mAb A77 
inhibited degranulation of RBL-2H3 transfected cells and reduced airway inflammation in 
FcαRI transgenic mice after crosslinking FcεRI with IgE immune complexes in an allergic 
asthma model [178, 179]. Furthermore, naturally occurring serum IgA dampened immune 
responses by inducing ITAMi signaling via FcαRI [180]. FcαRI transgenic mice (expression 
on monocytes/macrophages), which developed RA after injection with IgG anti-collagen 
had reduced manifestations or even complete resolution of arthritis after treatment with 
monomeric IgA. IgG-induced ITAM signaling was blocked efficiently, implicating a potential 
role of monomeric IgA in treatment of autoimmune diseases with IgG autoantibodies [181]. 
Moreover, prior targeting of FcαRI by Fab A77 suppressed inflammation in transgenic mice 
with FcαRI-expressing monocytes and macrophages that suffered from IgG immune complex 
glomerulonephritis and obstructive nephropathy [182]. Renal inflammation induced by 
pristane was characterized by enhanced serum IgG levels, pro-inflammatory cytokines and 
immune infiltration in FcαRI transgenic mice with receptor expression on monocytes and 
macrophages. Blocking FcαRI with Fab MIP8a inhibited cytokine production, leukocyte 
recruitment and inflammation [183]. Furthermore, renal inflammation induced by CpG (TLR9 
agonist) in these FcαRI transgenic mice was downregulated by monomeric occupancy of 
FcαRI [184]. Thus, monomeric targeting of FcαRI is suggested to induce anti-inflammatory 
properties, which could be useful in treatment of inflammatory diseases with involvement 
of myeloid cells.
Blocking IgA-FcαRI in IgA mediated diseases
Blocking FcαRI might be effective in IgA-mediated inflammation. In vitro it was shown 
that neutrophils stimulated with IgA immune complexes obtained from RA patients 
released NETs. FcαRI blocking on neutrophils with the anti-FcαRI mAb MIP8a reduced NET 
formation and might alleviate neutrophil induced tissue damage in RA patients [130]. IgA 
autoantibodies in serum of LABD patients induced neutrophil-mediated tissue damage 
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in an ex vivo human skin model. FcαRI blocking with MIP8a prevented IgA induced tissue 
damage [177]. Similarly, peptides targeting the interaction sites of IgA and FcαRI showed 
effective blocking of IgA binding to FcαRI, and reduced IgA-induced neutrophil migration in 
vitro. These peptides were able to penetrate into human skin, supporting that they might 
function as novel therapy in skin autoimmune diseases [185]. As such, blocking FcαRI might 
serve as therapeutic strategy for IgA-associated inflammatory diseases.
IgA as therapeutic antibody in tumor
The potent activation of immune cells through IgA-FcαRI interactions offers opportunities to 
inhibit this interaction in case of autoimmunity. However, enhancement of IgA-FcαRI can be 
beneficial in case the immune system needs to deal with tumor cells. IgA or FcαRI bispecific 
antibodies (BsAb) may represent promising novel drugs to treat cancer by enhancing 
activation of FcαRI-expressing immune cells [186]. For instance, BsAb targeting both tumor 
antigens and FcαRI efficiently recruited neutrophils in vitro, which was not observed after 
targeting Fcγ receptors [187-189]. Moreover, (immature) neutrophils were able to kill tumor 
cells more efficiently due to FcαRI-induced antibody dependent cellular cytotoxicity [190-
192]. Similarly, IgA anti-tumor monoclonal antibodies (mAbs) mediated tumor killing more 
efficient compared to IgG mAbs. In vitro studies demonstrated the superior ability of FcαRI 
to induce neutrophil-mediated tumor cell killing for multiple tumor antigens, including EGFR, 
HER2, EpCAM, HLA-II, CD20, CD30 and carcinoembryonic antigen [187, 191, 193].
Unfortunately, in vivo tumor targeting using IgA anti-tumor mAbs has been difficult as mice 
do not express a homologue of the human FcαRI, and human IgA has a short half-life in 
mice [151]. The utilization of FcαRI transgenic mice [151, 194] can contribute to study IgA 
as therapeutic antibody in vivo. Treatment with IgA anti-HER2 or IgA anti-EGFR anti-tumor 
mAbs resulted in significantly enhanced anti-tumor cytotoxicity in FcαRI transgenic mice 
compared to WT littermates, which was mediated by FcαRI-expressing macrophages [195, 
196]. Furthermore, IgA anti-CD20 mAbs inhibited B cell lymphoma cell proliferation in vitro 
and recruited FcαRI-expressing immune cells in vivo in FcαRI transgenic mice [197, 198].
The short half-life of IgA in serum is a major drawback for use of IgA as therapeutic antibody. 
Compared to IgG, the glycosylation sites of therapeutic IgA mAbs that are produced in non-
human systems (like rodent cells) have higher immunogenic potential (high glycosylation) 
and therapeutic IgA will be likely cleared efficiently from the human (or murine) circulation. 
Increasing the sialylation of glycans on IgA mAbs enhanced their serum half-life due to 
decreased clearance of IgA by the asialoglycoprotein receptor in the liver [195]. Inducing 
sialylation of IgA mAbs was done by using fully human systems thereby augmenting their 
in vivo therapeutic potential [196, 199-201]. Increased sialylation of the N-glycans in IgA 
anti-HER2 mAbs resulted in significantly reduced tumor growth in FcαRI-transgenic SCID 




Addition of an albumin-binding domain to IgA1 (IgA1-albumin) enhanced interaction of 
the antibody with the FcRn, which extended the half-life of IgA1 in vivo. Although ex vivo 
studies showed that IgA1-albumin induced lower maximal tumor cell lysis, enhanced 
tumor cell killing was observed in vivo [196] Another modified IgA molecule against EGFR 
lacking glycosylation and free cysteine’s, and with a stabilized heavy and light chain linkage, 
showed increased efficacy by interacting with FcαRI-expressing myeloid cells in vivo. Some 
therapeutic activity was observed in non-FcαRI transgenic mice demonstrating contribution 
of Fab-mediated effector functions as well [201]. Although IgA antibodies are not used in 
clinical studies yet, engineering IgA with increased half-life represents a promising strategy 
for targeting tumors in patients.
Figure 5. IgA and FcαRI as therapeutic targets (1) Enhanced IgA-FcαRI activation in IgA-associated 
autoimmune diseases is unwanted. Blocking IgA-FcαRI interactions by monoclonal antibodies or 
peptides may reduce tissue damage in these diseases. (2) Treatment with monomeric IgA or anti-FcαRI 
Fabs may induce ITAMi signaling thereby inhibiting IgG-induced phagocytosis and IgE-mediated allergic 
diseases. (3) To combat infections, administration of IgA (passive vaccination) or induction of IgA 
levels via active vaccination may result in enhanced protective immunity. (4) IgA monoclonal antibody 




In conclusion, IgA has important functions in the maintenance of immune homeostasis. 
Containing a healthy microbiota composition at multiple sites in the human body is one 
of the major tasks of SIgA. A misbalanced intestinal microbiota composition and diverged 
opsonization with IgA is associated with inflammatory bowel disease. We demonstrated in this 
thesis that IgA has a potential role in maintaining the vaginal microbiota composition as well. 
L. crispatus dominant vaginal microbiota had increased opsonization with IgA compared to 
non-L. crispatus dominant vaginal microbiota. This increased opsonization might be regulated 
through differential glycosylation patterns on the microbiota and IgA. An unhealthy vaginal 
microbiota composition is related to unwanted pregnancy outcomes including preterm birth. 
We and others demonstrated a higher prevalence of preterm birth in non-White European 
women. Generally African women have a more diversified vaginal microbiota composition, 
while Caucasians have a vaginal microbiota, which is dominated by Lactobacilli. Potentially, 
next to the composition of the vaginal microbiota, diverging IgA levels in the female genital 
tract are involved in preterm birth as well, but were not found in early stage pregnancy.
IgA is an extremely important antibody in neutralizing pathogens. It can efficiently 
opsonize invading bacteria after which FcαRI-expressing immune cells can phagocytose 
and eliminate these pathogens. In order to orchestrate effective immune responses, IgA 
activated neutrophils release LTB4 which recruits both neutrophils and monocytes and 
they have the capacity to mature the phenotype of moDCs. In this way IgA may induce 
both protective immune responses for effective elimination of pathogens and potential 
induction of adaptive immune responses to generate long term protection. We showed 
that vaccinated individuals develop a high specific serum IgA response, which I anticipate 
is important for the protection against pathogens. Although IgG is generally accepted as 
marker for systemic protection, serum IgA induced higher pro-inflammatory responses 
which can help to combat infections. It remains to be discovered why IgA induces higher 
pro-inflammatory responses compared to IgG.
The presence of aberrant or excessive IgA complexes can result in over activation of immune 
responses, eventually resulting in pathology. Autoimmune diseases including rheumatoid 
arthritis are characterized by the presence of IgA autoantibodies. We demonstrated that 
IgA can induce bone resorption indirectly through activation of immune cells which produce 
cytokines that affect osteoclast activity. Moreover, osteoclasts express the FcαRI and were 
directly activated by IgA thereby enhancing bone loss. Our study supports findings in previous 
studies which showed that patients with IgA autoantibodies have worse disease pathology.
It is therefore of major importance that IgA levels are in balance. Strategies that benefit 
from the pro-inflammatory function of IgA are applicable in the fight against cancer and 
infections, while at the same time blocking the interaction between aberrant IgA and 




expressing a homologue of the human FcαRI has previously hampered the interpretation 
of data obtained from mouse models in the context of human diseases. Therefore the 
powerful function of IgA has been overlooked by researchers and physicians for many years. 
It is time to change this view. Using genetically engineered mice which produce human IgA 
and express the human FcαRI will drastically improve future in vivo studies investigating 
the role of IgA and the FcαRI in maintaining homeostasis, inducing protective immunity, 
enhancing anti-tumor immunity and aggravating autoimmune diseases. By understanding 
these mechanisms in more detail therapeutic strategies can be adapted by administrating 
IgA to protect against infectious diseases, or to combat cancer, whereas inhibiting IgA-FcαRI 
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Het menselijk lichaam wordt dagelijks blootgesteld aan mogelijke ziekteverwekkers zoals 
bacteriën, virussen, schimmels en parasieten, maar ook aan essentiële niet-lichaamseigen 
voedingscomponenten. Het immuunsysteem zorgt ervoor dat er een goede balans is 
tussen enerzijds het tolereren van belangrijke stoffen zoals onze voeding, en anderzijds 
het voorkomen en bestrijden van infecties. Dit doet het immuunsysteem op een efficiënte 
wijze samen met de organen, weefsels en cellen in het lichaam.
De slijmvliezen, zoals in de darmen en luchtwegen, vormen gezamenlijk het grootste oppervlak 
van het lichaam. In de darmen bevindt zich de grootste dichtheid aan bacteriën. De grote 
diversiteit aan verschillende soorten bacteriën die aanwezig zijn in de darmen reflecteert 
de gezondheidsstatus van het menselijk lichaam. De compositie van de verschillende 
bacteriën die aanwezig zijn in de darm wordt mede gereguleerd door componenten van 
het immuunsysteem. De verzamelnaam voor de verschillende microben, waaronder 
bacteriën en schimmels, aanwezig in het lichaam is flora, microbiota of microbioom.
Antilichamen zijn belangrijke immunologische moleculen en maken onderdeel uit van de 
beschermende barrière in de slijmvliezen. Antilichamen worden in verschillende vormen 
aangemaakt door ons lichaam, genaamd IgA, IgG, IgE, IgD en IgM. Elk type antilichaam 
heeft een specifieke rol in ons lichaam. In de darm wordt voornamelijk IgA geproduceerd 
dat uit twee IgA moleculen bestaat die aan elkaar zijn verbonden middels de zogenaamde 
J keten. Daarom noemen we dit dimeer (= tweedelig) IgA. Het kan door de darmwand 
getransporteerd worden naar de kant waar zich de bacteriën en voedingscomponenten 
bevinden. Tijdens dit transport wordt er een eiwit toegevoegd aan dimeer IgA waardoor 
secretoir IgA (SIgA) wordt gevormd. SIgA kan binden aan de bacteriën die aanwezig zijn in 
de darm waardoor potentiële ziekteverwekkers niet in de onderliggende weefsels kunnen 
komen. De bacteriën worden vervolgens door de peristaltiek weggevoerd en uitgescheiden 
met de ontlasting. Daarnaast speelt SIgA een belangrijke rol in de instandhouding en het 
herstel van een gezonde darmflora.
Het kan voorkomen dat een ziekteverwekker ondanks deze beschermende barrière toch 
het lichaam binnendringt. Ook dan speelt IgA een belangrijke rol om infectie en ziekte te 
voorkomen. Dimeer IgA in het weefsel herkent de ziekteverwekker en vormt een laagje 
rond de ziekteverwekker. De zijde van IgA dat nu aan de buitenkant op de ziekteverwekker 
uitsteekt kan binden aan de Fc receptor voor IgA (FcαRI) die aanwezig is op verschillende 
soorten immuuncellen (figuur 1). De FcαRI geeft vervolgens verschillende signalen aan de 
immuuncel om tot actie over te gaan en de ziekteverwekker uit te schakelen. Op deze 
manier vormen antilichamen een brug tussen de ziekteverwekker en de immuuncellen.
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Figuur 1. Overzicht van een immuuncel (rood) welke de FcαRI (groen) op het cel oppervlak heeft. Een 
ziekteverwekker (roze) wordt herkend door IgA (paars), waarna dit complex kan binden aan de FcαRI.
Antilichamen komen, naast in de slijmvliezen, ook voor in het bloed. IgG is het voornaamste 
antilichaam in de bloedcirculatie, maar er bevinden zich ook aanzienlijke hoeveelheden 
IgA. In het bloed komt IgA voor als monomeer (mIgA). Wanneer ziekteverwekkers in het 
bloed terechtkomen, vormt mIgA een laagje op de ziekteverwekkers, waardoor FcαRI kan 
worden geactiveerd (figuur 1). Hierdoor worden bacteriën of virussen in het bloed efficiënt 
uitgeschakeld door de immuun cellen die FcαRI op hun celoppervlak hebben.
In dit proefschrift heb ik de rol van IgA in de slijmvliezen en in het bloed nader onderzocht. 
In hoofdstuk 1 introduceer ik IgA en ga ik in op de belangrijke functies op de verschillende 
plekken in het menselijk lichaam. Daarnaast beschrijf ik de interactie van IgA met de FcαRI 
aanwezig op immuuncellen welke belangrijk is voor de eliminatie van ziekteverwekkers. 
In hoofdstuk 2 heb ik de interactie van IgA en IgG met vaginale microbiota onderzocht. 
In tegenstelling tot de andere slijmvliezen bevindt zich meer IgG dan IgA in het vaginale 
slijmvlies. Bovendien wordt een gezonde vaginale microbiota samenstelling gekarakteriseerd 
door een lage diversiteit aan bacteriën, terwijl in gezonde darmen een hoge diversiteit 
aan bacteriën aanwezig is. De Lactobacillus bacteriën domineren de vagina waarbij de 
specifieke L. crispatus stam bekend staat om zijn beschermende immuun dempende effect. 
Vaginale flora met verschillende stammen, waaronder potentiële ziekteverwekkers, en 
waarbij vrouwen klachten ervaren, wordt aangeduid als bacteriële vaginose. In deze studie 
werden vaginale bacteriën verzameld middels zelfafname van een vaginale swab door 
gezonde vrouwen gedurende drie tijdspunten in hun menstruele cyclus. Gedurende de 
menstruatie waren de vaginale concentraties IgA en IgG het hoogste in alle deelneemsters. 
Daarnaast hadden vrouwen met vaginale microbiota gedomineerd door L. crispatus meer 
binding van IgA aan hun vaginale microbiota dan vrouwen die geen L. crispatus dominante 
vaginale microbiota samenstelling hadden. Daarom heb ik de hypothese dat IgA, net zoals 
in de darmen, een belangrijke rol speelt in de tot stand houding van een gezonde vaginale 
microbiota samenstelling welke wordt gedomineerd door L. crispatus.
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In hoofdstuk 3 ga ik verder in op de rol van IgA in de vaginale slijmvliezen gedurende 
zwangerschap. We hebben onderzocht wat de mogelijke rol van IgA en andere immuun 
componenten aanwezig in de vaginale slijmvliezen kan zijn in vroeggeboorte. Vroeggeboorte 
wordt gedefinieerd als geboorte vóór een zwangerschapsduur van 37 weken. We spreken 
van een à terme geboorte wanneer de geboorte plaatsvindt bij een zwangerschapsduur 
tussen de 37-40 weken. Meerdere risicofactoren voor vroeggeboorte, waaronder roken, een 
lage BMI en een afwijkende vaginale microbiota compositie zijn al bekend. Daarnaast spelen 
ontstekingsfactoren een belangrijke rol bij het in gang zetten van de bevalling in het geval 
van zowel een à terme geboorte als een vroeggeboorte. In deze studie hebben zwangere 
vrouwen bij een zwangerschapsduur van 8-12 weken een vaginale swab afgenomen, 
waarna we de concentratie IgA en IgG hebben bepaald. Er is geen verschil in concentratie 
vaginaal IgA en IgG tussen zwangere vrouwen met een uiteindelijke vroeggeboorte of à 
terme geboorte. Bovendien was er geen verschil in de hoeveelheid IgA of IgG gebonden 
aan vaginale microbiota tussen vrouwen met vroeggeboorte of à terme geboorte. Uit 
eerdere studies is bekend dat etniciteit een grote invloed heeft op de samenstelling van 
de vaginale microbiota. Gezonde blanke vrouwen hebben voornamelijk een Lactobacillus 
dominante vaginale microbiota samenstelling, terwijl gezonde niet-blanke vrouwen vaker 
een diverse vaginale microbiota samenstelling hebben. In hoofdstuk 3 hebben we gevonden 
dat blanke vrouwen een hogere binding van IgA aan vaginale microbiota hebben dan niet-
blanke vrouwen. We denken dat dit komt doordat blanke vrouwen een andere vaginale 
microbiota samenstelling hebben waarin meer IgA is gebonden aan bacteriën. Helaas 
hebben we in deze studie de microbiota samenstelling niet kunnen bepalen en daardoor 
blijft deze onderzoeksvraag nog open voor vervolgonderzoek.
Wanneer ziekteverwekkers de weefsels binnendringen kunnen ze een infectie veroorzaken. 
Neutrofielen zijn de meest voorkomende witte bloedcellen van het immuunsysteem en 
zijn de eerste immuuncellen die vanuit het beenmerg en bloed naar de plek van de infectie 
worden aangetrokken. De ziekteverwekkers met daarop een laagje IgA kunnen door de 
neutrofielen, die de FcαRI op hun celoppervlak hebben, worden opgeruimd. IgA-geactiveerde 
neutrofielen produceren signaalstoffen, waaronder de lipide leukotriene B4 (LTB4), die 
ervoor zorgen dat er meer neutrofielen naar de plek van de infectie worden gebracht. 
In de geïnfecteerde weefsels kunnen zogenaamde dendritische cellen een stukje van de 
ziekteverwekker opnemen en presenteren aan cellen van het adaptieve immuunsysteem. 
Hierdoor wordt er een herinnering voor deze specifieke ziekteverwekker ingebouwd 
waardoor bij een herhaling met dezelfde ziekteverwekker het immuunsysteem sneller 
en specifieker de infectie kan verhelpen. In hoofdstuk 4 beschrijven we hoe neutrofielen 
interacties aangaan met dendritische cellen en dat neutrofielen bepaalde acties, zoals 
de productie van ontstekingsstoffen, van de dendritische cellen kunnen beïnvloeden. In 
hoofdstuk 5 gaan we verder in op de specifieke rol van IgA-geactiveerde neutrofielen 
en hun effect op zogenaamde monocyten (een type witte bloedcel), de voorlopers van 
de dendritische cellen, en dendritische cellen zelf. We laten zien dat IgA-geactiveerde 
neutrofielen LTB4 produceren. Neutrofielen die geactiveerd worden met IgG produceren 
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geen LTB4. Een lage concentratie LTB4 zorgt ervoor dat er meer neutrofielen worden 
aangetrokken terwijl er voor de aantrekking van monocyten een hogere concentratie LTB4 
nodig is. Dit duidt erop dat neutrofielen als eerst aanwezige immuuncellen bij een infectie 
gevoeliger reageren op LTB4 en zodra de concentratie van LTB4 hoger is, wordt ook de 
hulp van de monocyten ingeschakeld. Zodra monocyten vanuit het bloed de geïnfecteerde 
weefsels in gaan kunnen ze veranderen in dendritische cellen. In hoofdstuk 5 laten we 
zien dat de interactie tussen IgA-geactiveerde neutrofielen en dendritische cellen zorgt 
voor een verhoogde productie van inflammatoire stoffen door de dendritische cellen die 
bijdragen aan een efficiënte immuunreactie tijdens infectie. Deze respons zien we niet 
wanneer neutrofielen geactiveerd zijn met IgG.
Na een infectie vormt het immuunsysteem geheugencellen en worden er specifieke 
antilichamen geproduceerd die de ziekteverwekker herkennen bij een volgende infectie. 
Personen met de ziekte van Lyme zijn geïnfecteerd met Borrelia-bacteriën die via een 
teek worden overgedragen. In hoofdstuk 6 laten we zien dat Lymepatiënten specifieke 
antilichamen, waaronder die van de IgA-subklasse, in hun bloed hebben tegen deze bacteriën. 
Vaccins dienen ter bescherming tegen infectieziekten. Een vaccin induceert de aanmaak van 
specifieke antilichamen zodat, in het geval van een infectie, het immuunsysteem is voorbereid 
en de ziekteverwekkers sneller kunnen worden uitgeschakeld. We laten zien dat personen 
gevaccineerd met een vaccin tegen buiktyfus, specifieke antilichamen van zowel de IgM-, 
IgG- als de IgA-subklasse hebben aangemaakt in hun bloed. In hoofdstuk 6 hebben we nader 
onderzocht wat de rol is van IgA in het bloed. Zowel monocyten en neutrofielen konden 
serum IgA- en IgG-immuuncomplexen fagocyteren, of wel opeten, en produceerden gelijke 
hoeveelheden van zuurstofradicalen en neutrofiel extracellulaire vallen (vangnetten). Dit zijn 
twee methoden die de neutrofielen gebruiken om ziekteverwekkers te doden. Maar het was 
duidelijk dat serum IgA-immuuncomplexen een ander effect hadden op de neutrofielen en 
monocyten dan de serum IgG-immuuncomplexen. Nadat monocyten of neutrofielen met 
IgA-immuuncomplexen geactiveerd waren produceerden ze meer ontstekingsfactoren en 
stoffen die andere immuuncellen aantrekken. Monocyten geactiveerd met bacteriën met 
een laagje IgA, produceren meer interleukine 6 (ontstekingsstof), dan wanneer er bacteriën 
met een laagje IgG aanwezig zijn. Uit onze studie is gebleken dat IgA in het bloed een 
immuun-activerende rol heeft wat voordelig is in de uitschakeling van ziekteverwekkers.
Het kan helaas ook voorkomen dat IgA niet gericht is tegen een ziekteverwekker, maar tegen 
lichaamseigen moleculen. Zulke varianten van IgA noemen we IgA-autoantilichamen. Dit is 
het geval in personen die een auto-immuunziekte hebben en die grote schade ondervinden 
aan hun lichaamsweefsels. Deze schade ontstaat onder andere doordat neutrofielen 
het lichaamseigen molecuul dat bedekt is met IgA, aanvallen. Hierbij wordt schade aan 
weefsels veroorzaakt, zoals het geval is bij reumapatiënten met IgA-autoantilichamen. In 
hoofdstuk 7 hebben we onderzocht hoe IgA bijdraagt aan botafbraak in reuma-patiënten. 
Osteoclasten zijn grote cellen die bot opeten. We laten zien dat stoffen geproduceerd door 
IgA-geactiveerde monocyten zorgen voor een verhoogde botafbraak door osteoclasten. Dit 
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was niet het geval bij stoffen geproduceerd door IgG-geactiveerde monocyten. Naast deze 
indirecte activatie van osteoclasten door IgA hebben we ook gevonden dat osteoclasten 
de FcαRI op hun celoppervlak hebben. Osteoclasten worden ook direct geactiveerd door 
IgA, waarna de cellen meerdere stoffen produceren die de botafbraak verhogen. Reuma-
patiënten met IgA-autoantilichamen hebben vaker een ernstiger verloop van de ziekte in 
vergelijking tot patiënten die autoantilichamen in een andere vorm, bijvoorbeeld IgG of IgM, 
hebben. Het blokkeren van de interactie tussen IgA en de FcαRI zou kunnen dienen als een 
mogelijke therapie in auto-immuunziekten met IgA-autoantilichamen.
Conclusie
In dit proefschrift heb ik IgA en IgA-FcαRI interacties nader onderzocht. In de slijmvliezen 
heeft IgA een belangrijke rol in de afweer tegen ziekteverwekkers. IgA heeft de capaciteit om 
een interactie aan te gaan met lokale microbiota. Hierdoor wordt het lastig voor mogelijke 
ziekteverwekkers om het lichaam binnen te dringen. De interactie tussen IgA en bacteriën 
is bovendien belangrijk voor de instandhouding van een gezonde microbiota samenstelling. 
Wanneer ziekteverwekkers onverhoopt toch binnendringen kan IgA een laagje vormen 
om de ziekteverwekker, waardoor een complex wordt gevormd. Immuuncellen die FcαRI 
tot expressie brengen, worden geactiveerd met IgA-complexen en produceren meer pro-
inflammatoire stoffen dan na activatie met IgG-complexen. Deze potente stimulatie middels 
IgA is voordelig in het elimineren van de ziekteverwekker. Helaas kan het ook voorkomen 
dat IgA niet is gericht tegen een ziekteverwekker, maar tegen lichaamseigen moleculen. Dit 
zogenoemde auto-IgA kan leiden tot weefselschade, zoals dat voorkomt in verschillende 
auto-immuunziekten. Auto-IgA kan immuuncellen die FcαRI op hun celoppervlak hebben 
activeren en zorgen voor een verslechterde conditie van de patiënt. Het blokkeren van 
interacties tussen IgA en FcαRI is een veelbelovende nieuwe therapie voor IgA-gemedieerde 
ziekten. Om de gezondheid van het menselijk lichaam in stand te houden, is het dus 
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extra keer over. Toen we in januari 2016 verhuisden naar het O2 gebouw was het meteen 
duidelijk dat we samen een kamer wilden delen. Eerst op de 11e verdieping en later zaten 
we tegenover elkaar op de 10e in de open ruimte. We hebben wat met elkaar meegemaakt: 
congressen (inclusief lekkere bedden), borrels, feestjes en natuurlijk hard werken aan 
onze promotie! “Waar zijn we in godsnaam aan begonnen” en “wat doen we hier nog” zijn 
bekende frases die we regelmatig naar elkaar uitspraken. Ik weet nog dat je me vertelde dat 
Reina vond dat je niet meer met me mocht praten. Was ik echt zo’n slechte invloed? Haha. 
Gelukkig is alles goed gekomen! Bedankt voor alle gezelligheid, serieuze gesprekken en hulp!
Melissa, ik was erg blij toen jij onze groep kwam versterken. Eerst was het nog even kat 
uit de boom kijken, maar al gauw merkte ik dat we een goede klik hadden. Gelukkig, want 
zonder jou weet ik niet of ik mijn promotie wel succesvol had afgerond (en dat meen ik!). 
Wat hebben we de afgelopen jaren veel meegemaakt. Lachen tot de tranen over onze 
wangen rolden, en af en toe een traantje van verdriet en frustratie. Ik heb altijd met heel 
226
Appendices
veel plezier met jou samengewerkt. De projecten liepen niet altijd even soepeltjes, maar 
doordat we samen konden sparren en elkaar konden motiveren is het allemaal tot een goed 
eind gekomen! Ondanks de Corona crisis hebben we de essentiële experimenten kunnen 
afronden om zo twee mooie artikelen te kunnen submitten. Bedankt voor de samenwerking, 
de fijne gesprekken en de kopjes thee!
Heleen, we hebben samen vele uren op het lab gespendeerd met als resultaat een mooi 
artikel. Tijdens de Corona crisis hebben we een mooi begin gemaakt aan het Propellor 
cohort en ik hoop dat ook dit een mooi manuscript wordt! Ik heb onze samenwerking altijd 
erg fijn gevonden en heb ervan genoten om te zien hoe jij je steeds meer thuis voelde in het 
lab. Op een gegeven moment deden we samen tientallen ELISA’s per week. Bedankt voor 
alle fijne gesprekken, gezelligheid en natuurlijk voor al jouw kennis over de microbiologie 
en vagina’s waar ik van heb mogen leren!
Amélie, mevrouw Bos. Jouw levendigheid in de groep gaf weer een nieuwe dimensie aan 
mijn promotietraject. Vol interesse luisterde ik naar alle avonturen die je meemaakte die 
niet altijd even makkelijk waren. Bedankt voor alle gezelligheid die jij meebracht. Zet ‘m op 
met de laatste loodjes van je proefschrift!
DuomAb: Alle leden van DuomAb bedankt voor jullie adviezen, hulp en gezelligheid. Kees, 
bedankt voor jouw expertise. Zonder alle kennis die jij hebt over protocollen, het lab etc. 
zijn we nergens! Natuurlijk een extra bedankje voor alle keren dat jij bloed hebt geprikt bij 
de vele donoren die nodig waren voor de totstandkoming van deze thesis. Rens, in de MF 
mocht ik naast je zitten en we verhuisden naar dezelfde kamer in het O2 gebouw. Je stond 
altijd voor me klaar als ik hulp nodig had met het voorbereiden van mijn experimenten. 
Samen FACS-panels maken, nadenken over co-kweken en gewoon gezellig kletsen kon altijd! 
Bedankt voor alles! Niels, wij begonnen onze projecten tegelijkertijd. Jij een post-doc, ik 
een PhD. Samen volgden we een introductiedag in het ziekenhuis, jij toen nog met lang 
haar (mijn haar was toen korter dan het jouwe!). Ik vind je een ambitieuze wetenschapper 
die altijd veel creatieve ideeën heeft en een kritische blik heeft op andermans projecten. 
Bedankt daarvoor. Marieke, jij was al een tijdje bezig met jouw project toen ik in de groep 
kwam werken. Ik kon altijd bij je terecht als ik een vraag had over mijn project. Bedankt! 
Myrthe, bedankt voor alle hulp met experimenten en het analyseren van data. Last but not 
least; Carolien, Dennis, Mandy, Paula, Reinder en Richard. Bedankt voor alle input tijdens 
de DuomAb meetings en de gezelligheid in de groep!
10W01: Iedereen in de open ruimte wil ik bedanken voor alle baksels, lekkernijen en 
gezelligheid. Tanja, bedankt voor alle hulp in de Flow Facility, de vele malen bloed afnemen 




Special thanks to Tom, for all the help and time invested behind the influx. I very much 
appreciated your assistance. Thanks!
De vaste kern van helden van de MCBI: Eelco & Ed! Altijd zullen jullie streven om de afdeling 
weer een stukje beter, mooier en efficiënter te maken. Zeker in tijden van corona perikelen 
was het voor jullie hard werken. Bedankt voor jullie inzet en hulp!
Bloeddonoren: Zonder jullie materiaal was het voor mij onmogelijk geweest om dit 
onderzoek te doen. Bedankt voor de vele donaties!
MCBI: What a great department to work! Thanks to all of you for the scientific input and 
social activities.
Dames van Van-8: Anne, Annelieke, Evelien, Floor, Noor, Sanne en Willemijn. Bedankt 
voor jullie steun en interesse in de onderzoeken die ik de afgelopen jaren heb gedaan. Al 
zal het jullie wel tegenvallen dat er geen muisexperimenten in dit proefschrift staan, haha 
(ik kan het uitleggen ;))! Ik word zo blij van jullie als mijn vriendinnen.
Familie Schaefers-Okkens: Dank voor jullie interesse en support in mijn promotieonderzoek. 
Fijn dat ik altijd bij jullie terecht kan en dat papers met grote belangstelling worden gelezen 
en ook voor een heel groot gedeelte worden begrepen!
Wouter & Waria, dank jullie wel voor alle gezelligheid die we de afgelopen jaren samen, 
voornamelijk in Holten bij mama en papa, hebben gehad. Even een moment van ontspanning 
tussen de drukke werkdagen door deed ons allen goed.
Lieve Mama en Papa, dankzij jullie sta ik waar ik nu ben. Ik heb altijd de mogelijkheid gehad 
om op jullie terug te vallen wanneer dat nodig was en jullie hebben me altijd gesteund in de 
beslissingen die ik heb gemaakt. Studeren was geen probleem, wat niet voor iedereen een 
vanzelfsprekendheid is. Honderd keer verhuizen, een beetje een probleem ;). Maar daardoor 
heb ik wel alle dromen die ik had kunnen naleven in Wageningen, Salamanca, Davos, Brixen 
im Thale, Utrecht en Amsterdam. Nu uiteindelijk gesetteld in Utrecht ga ik mijn toekomst 
lachend tegemoet en dat mede dankzij jullie. Bedankt voor alles!
Lieve Richard, ons avontuur begon toen ik halverwege mijn PhD traject zat. Je was van begin 
af aan geïnteresseerd in wat er zich allemaal op het lab afspeelde (inclusief de roddels). Ik 
hoop nu dan ook dat je een beetje hebt begrepen wat er in dit boekje staat (want je hebt 
natuurlijk eerst de hoofdstukken gelezen voordat je bij dit stukje tekst aankomt). Bedankt 
voor je steun en extra motivatie die je me gaf in tijden dat ik gefrustreerd thuiskwam van 
het lab. We gaan samen een mooie toekomst tegemoet. Ons eerstvolgende avontuur zal zich 
over ruim twee maanden aandienen. Ik kijk er naar uit om samen met jou en onze dochter 
in spé een gezin te vormen! Ik hou heel veel van je!


